---
document_datetime: 2023-09-21 20:22:16
document_pages: 101
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/trimbow-h-c-4257-x-0008-g-epar-assessment-report-extension_en.pdf
document_name: trimbow-h-c-4257-x-0008-g-epar-assessment-report-extension_en.pdf
version: success
processing_time: 73.176688
conversion_datetime: 2025-12-21 11:56:22.774119
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
12 November 2020 EMA/667393/2020

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Trimbow

International non-proprietary name: beclometasone / formoterol / glycopyrronium bromide

Procedure No. EMEA/H/C/004257/X/0008/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                          |
|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................7       |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                          |
| 2. Scientific discussion                                                                                                    | ................................................................................8                        |
| 2.1. Problem statement                                                                                                      | ...............................................................................................8         |
| 2.1.1. Disease or condition...........................................................................................9     |                                                                                                          |
| 2.1.2. Epidemiology                                                                                                         | ....................................................................................................9    |
| 2.1.3. Aetiology and pathogenesis                                                                                           | ................................................................................9                        |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                 | ..............................................9                                                          |
| 2.1.5. Management...................................................................................................10      |                                                                                                          |
| 2.2. About the product                                                                                                      | ..............................................................................................10         |
| 2.3. Type of Application and aspects on development....................................................11                   |                                                                                                          |
| 2.4. Quality aspects                                                                                                        | ..................................................................................................13     |
| 2.4.1. Introduction....................................................................................................13   |                                                                                                          |
| 2.4.2. Active substance                                                                                                     | .............................................................................................13          |
| 2.4.3. Finished medicinal product................................................................................13         |                                                                                                          |
| Description of the product and Pharmaceutical development                                                                   | ..........................................13                                                             |
| Manufacture of the product and process controls ..........................................................14                |                                                                                                          |
| Product specification                                                                                                       | .................................................................................................14      |
| Stability of the product                                                                                                    | ..............................................................................................15         |
| Adventitious agents...................................................................................................15    |                                                                                                          |
| 2.4.4. Discussion on chemical, and pharmaceutical aspects............................................16                     |                                                                                                          |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                   | ......................16                                                                                 |
| 2.4.6. Recommendation for future quality development.................................................16                     |                                                                                                          |
| 2.5. Non-clinical aspects                                                                                                   | ............................................................................................16           |
| 2.5.1. Introduction....................................................................................................16   |                                                                                                          |
| 2.5.2. Pharmacology                                                                                                         | .................................................................................................16      |
| 2.5.3. Pharmacokinetics.............................................................................................16      |                                                                                                          |
| 2.5.4. Toxicology                                                                                                           | ......................................................................................................16 |
| 2.5.5. Ecotoxicity/environmental risk assessment                                                                            | .........................................................17                                              |
| 2.5.6. Discussion on non-clinical aspects......................................................................17           |                                                                                                          |
| 2.5.7. Conclusion on the non-clinical aspects................................................................21             |                                                                                                          |
| 2.6. Clinical aspects                                                                                                       | ..................................................................................................21     |
| 2.6.1. Introduction....................................................................................................21   |                                                                                                          |
| 2.6.2. Pharmacokinetics and Pharmacodynamics                                                                                | ..........................................................26                                             |
| 2.6.3. Discussion on clinical pharmacology...................................................................27             |                                                                                                          |
| 2.6.4. Conclusions on clinical pharmacology.................................................................28              |                                                                                                          |
| 2.7. Clinical efficacy                                                                                                      | ..................................................................................................28     |
| 2.7.1. Dose response studies......................................................................................28        |                                                                                                          |
| 2.7.2. Main studies                                                                                                         | ...................................................................................................29    |
| 2.7.3. Discussion on clinical efficacy............................................................................73        |                                                                                                          |
| 2.7.4. Conclusions on the clinical efficacy.....................................................................78          |                                                                                                          |
| 2.8. Clinical safety ....................................................................................................79 |                                                                                                          |

<div style=\"page-break-after: always\"></div>

2.8.2. Conclusions on the clinical safety  .......................................................................  90

2.9. Risk Management Plan ........................................................................................  90

2.10. Pharmacovigilance  ............................................................................................  91

2.11. Product information ..........................................................................................  91

2.11.1. User consultation  ...........................................................................................  91

3. Benefit-Risk Balance..............................................................................  92

3.1. Therapeutic Context ...........................................................................................  92

3.1.1. Disease or condition  .........................................................................................  92

3.1.2. Available therapies and unmet medical need  .......................................................  92

3.1.3. Main clinical studies .........................................................................................  92

3.2. Favourable effects ..............................................................................................  93

3.3. Uncertainties and limitations about favourable effects  .............................................  94

3.4. Unfavourable effects  ...........................................................................................  95

3.5. Uncertainties and limitations about unfavourable effects .........................................  96

3.6. Effects Table  ......................................................................................................  96

3.7. Benefit-risk assessment and discussion  .................................................................  99

3.7.1. Importance of favourable and unfavourable effects  ..............................................  99

3.7.2. Balance of benefits and risks  ...........................................................................  100

3.8. Conclusions .....................................................................................................  100

4. Recommendations ...............................................................................  100

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ACQ-7

Asthma Control Questionnaire

Adj.

Adjusted

ADR

Adverse drug reaction

AE

Adverse event

AEMPS

Agencia Española de Medicamentos y Productos Sanitarios

AeroChamber Plus

AeroChamber Plus   Flow-Vu antistatic VHC spacer

ALT

Alanine aminotransferase

ATS

American Thoracic Society

AUCx-y

Area under the concentration-time curve calculated between time X and time Y

AUC0-t

Area under the concentration-time curve calculated between time 0 and the last quantifiable time point

AUCtau

Area under the concentration-time curve during a dosing interval

B17MP

Beclometasone-17-monopropionate

BDP

Beclometasone dipropionate

BfArm

Bundesinstitut für Arzneimittel und Medizinprodukte

bid

Twice daily

BMI

Body mass index

bpm

Beat(s) per minute

BTS

British Thoracic Society

CFC

Chlorofluorocarbon

CHF5993 MS

Medium ICS dose formulation of the IMP (CHF5993 100/6/12.5)

CHF5993 HS

High ICS dose formulation of the IMP (CHF5993 200/6/12.5)

CI

Confidence interval

CL

Total clearance

Cmax

Maximum plasma concentration

Cmin

Minimum plasma concentration

COPD

Chronic obstructive pulmonary disease

CRCL

Creatinine clearance

CS

Clinically significant

CSR

Clinical study report

CTP

Clinical trial protocol

CV

Coefficient of variation

DALY

Disability adjusted life year

DBP

Diastolic blood pressure

DD

Delivered dose

DDI

Drug-drug interaction

DPI

Dry powder inhaler

DDR

(Blinded) data review report

DSMB

Data safety monitoring board

ECG

Electrocardiogram

eCRF

Electronic CRF

eDiary

Electronic (patient) diary

EDTA

Ethylenediamine tetra-acetic acid

EMA

European Medicines Agency

EQ-5D-3L

EuroQuality of Life Five-Dimensional Questionnaire Three Level Version

ER

Emergency room

ERS

European Respiratory Society

F1

Fraction of the dose absorbed by a first-order process

FDA

Food and Drug Administration

FDC

Fixed dose combination

FEV1

Forced expiratory volume in 1 second

FF

Formoterol fumarate

FPFV

First visit of the first patient

FPM

Fine particle mass

FVC

Forced vital capacity

γ -GT

Gamma-glutamyltransferase

GB

Glycopyrronium bromide

GCP

Good Clinical Practice

GINA

Global Initiative for Asthma

GOLD

Global Initiative for Chronic Obstructive Lung Disease

HFA-134a

Hydrofluoroalkane-134a

HPA

Hypothalamic-pituitary-adrenal

HR

Heart rate

HRx-y

Average heart rate calculated between time X and time Y

HRQoL

Health-related quality of life

IC

Inspiratory capacity

ICH

International Council on Harmonisation of Technical Requirements

for Pharmaceuticals for Human Use

ICS

Inhaled corticosteroid(s)

ICSR

Individual case safety report

IgE

Immunoglobulin E

IMP

Investigational medicinal product

IRT

Interactive Response Technology (system)

ITT

Intention-to-treat

i.v.

Intravenous

Ka

First-order absorption rate constant

LABA

Long- acting β 2-agonist

LAMA

Long-acting muscarinic antagonist

LC/MS-MS

Liquid chromatography followed by tandem mass spectrometry

LLOQ

Lower limit of quantification

LPLV

Last visit of the last patient

LRTI

Lower respiratory tract infection

MAA

Marketing authorisation application

MACE

Major Adverse Cardiovascular Event

MATE1

Multidrug and toxin extrusion protein 1

MCID

Minimal clinically important dose

MD

Metered dose

MEB

Medicines Evaluation Board

MHRA

Medicines and Healthcare products Regulatory Agency

MITT

Multi-inhaler triple therapy

MMAD

Mass median aerodynamic diameter

NCS

Non-clinically significant

OCT

Organic cationic transporter

od

Once daily

OIP

Orally inhaled products

PAL

Persistent airflow limitation

PD

Pharmacodynamic(s)

Peakx-y FEV1

Peak FEV1 within x to y hours post-dose

PEF

Peak expiratory flow

PEx

Pulmonary exacerbation

PK

Pharmacokinetic(s)

pMDI

Pressurised metered dose inhaler

PP

Per-protocol

PR

PR interval

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| PT   | Preferred term                            |
|------|-------------------------------------------|
| QA   | Quality assurance                         |
| QC   | Quality control                           |
| QRS  | QRS interval                              |
| QTcF | Fridericia-corrected QT interval          |
| RR   | Rate or risk ratio (depending on context) |
| SABA | Short-acting β 2 -agonist                 |
| SAMA | Short-acting muscarinic antagonist        |
| SAP  | Statistical analysis plan                 |
| SBP  | Systolic blood pressure                   |
| SD   | Standard deviation                        |
| SITT | Single-inhaler triple therapy             |
| SmPC | Summary of Product Characteristics        |
| SOC  | System organ class                        |
| TEAE | Treatment-emergent adverse event          |
| TMF  | Trial Master File                         |
| ULOQ | Upper limit of quantification             |
| V 2  | Apparent central volume of distribution   |
| VAS  | Visual Analogue Scale                     |
| VRS  | Verbal Rating Scale                       |
| vs.  | Versus                                    |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Chiesi Farmaceutici S.p.A. submitted on 13 September 2019 a group of variations consisting of an extension of the marketing authorisation and the following variation:

| Variations requested   | Variations requested                                                                                                           | Type   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

The MAH applied for an addition of a new strength (172 μg / 5 μg / 9 μg) . In addition, the MAH proposed to add a new indication (asthma). The RMP (version 6.1) is updated in accordance.

## The legal basis for this application refers to:

Article 7.2 of Commission Regulation (EC) No 1234/2008 - Group of variations

## Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/00365/2019 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/00365/2019 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Additional Marketing protection

The MAH requested consideration of one-year marketing protection in regards of its application for a new indication in accordance with Article 14(11) of Regulation (EC) 726/2004. The MAH withdrew the request during the procedure.

## Scientific advice

The MAH did seek Scientific advice at the CHMP (EMEA/H/SA/026/1/2014/II and EMEA/H/SA/3068/2/FU/1/2015/II).

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Janet Koenig

Co-Rapporteur:  Peter Kiely

| The application was received by the EMA on   | 13 September 2019   |
|----------------------------------------------|---------------------|

<div style=\"page-break-after: always\"></div>

| The procedure started on                                                                                                                                                                | 28 November 2019   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                          | 17 February 2020   |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                       | 17 February 2020   |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                     | 20 February 2020   |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 12 March 2020      |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                                                       | 26 March 2020      |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                           | 10 July 2020       |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                 | 19 August 2020     |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 20 February 2020   |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the MAH on                                                                                                     | 17 September 2020  |
| The MAH submitted the responses to the CHMP List of Outstanding Issues on                                                                                                               | 8 October 2020     |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                        | 19 August 2020     |
| The PRAC Rapporteur's Assessment Report was circulated to all PRAC members on                                                                                                           | 16 October 2020    |
| The Rapporteur's Assessment Report was circulated to all CHMP members on                                                                                                                | 28 October 2020    |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Trimbow on | 12 November 2020   |

## 2. Scientific discussion

## 2.1. Problem statement

The purpose of this application is to extend the initially authorised indication of Trimbow to asthma adult patients. The MAH also applied for a new strength (higher strength) to be used in the asthma indication only.

<div style=\"page-break-after: always\"></div>

## 2.1.1. Disease or condition

Asthma is  a  common  and  potentially  serious  chronic  disease  that  imposes  a  substantial  burden  on patients, their families, and the community. It causes respiratory symptoms, limitation of activity, and exacerbations that sometimes require urgent medical care and may be fatal. The long-term goals of asthma  management  are  therefore  risk  reduction  and  symptom  control.  Treatment  with  inhaled corticosteroid (ICS)-containing medications markedly reduces the risk of flare-ups or dying of asthma. In patients with more severe disease expression, other controller medications such as Longacting β 2agonist (LABA) or tiotropium are added to the therapeutic regimen.

A global committee bringing together clinicians and scientist ( Global Initiative for Asthma , GINA) was established to increase the awareness about asthma and to improve the prevention and management of the  disease  through  a  co-ordinated  worldwide  effort.  Based  on  documentation  published  by  GINA, asthma severity is currently assessed retrospectively from the level of treatment required to control symptoms  and  exacerbations.  Accordingly,  there  are  five  steps  with  step 1  being  the  mildest manifestation of the disease and step 5 the most severe.

The biggest challenge are currently difficult-to-treat asthma patients (i.e. patients with poor symptom control and/or exacerbations despite use of high dose controller treatment) and severe asthma (i.e. patients with poor symptom control and/or exacerbations despite maximal optimised therapy, treatment of contributory factors and acceptable treatment compliance and inhaler technique). GINA estimates that in Europe about 17% of patients have difficult-to-treat asthma and about 3-4% have severe asthma.

## 2.1.2. Epidemiology

Asthma is the most prevalent chronic respiratory disease, affecting an estimated 358 million persons worldwide with 0.40 million annual deaths, according to the 2015 Global Burden of Disease study [GBD, 2015].

Patients with severe persistent asthma comprise only 5-10% of the total asthma population, but account for a large proportion of asthma morbidity and health care expenditures [Lang, 2015].

## 2.1.3. Aetiology and pathogenesis

The pathophysiology of asthma is characterised by inflammation, intermittent obstruction of the airways and bronchial hyper-responsiveness. Inflammation in asthma generally involves the same cells involved in the allergic response in the nasal passages and skin (atopy), and includes mast cells, eosinophils and Th2 lymphocytes.

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

Asthma causes symptoms such as wheezing, shortness of breath, chest tightness and cough that vary over time in their occurrence, frequency and intensity. These symptoms are associated with variable expiratory airflow. Symptoms occur particularly at night or in the early morning. Patients with asthma can experience exacerbations that may be life threatening.

Factors that may trigger or worsen symptoms include viral infections, allergens at home or work (e.g. dust  mite,  pollen),  tobacco  smoke,  exercise,  stress  and  some  drugs  including  beta-blockers  and nonsteroidal anti-inflammatory drugs (NSAIDs).

Diagnosis is based on two key features:

- a history variable respiratory symptom
- variable expiratory airflow limitation and reversibility

<div style=\"page-break-after: always\"></div>

Patient scan be classified as mild, moderate and severe based on symptom control and treatment requirements.

## 2.1.5. Management

The long-term treatment goals are symptom control and risk reduction. Symptom control aims to have only  occasional  daytime  symptoms  without  sleep  disturbance  or  exercise  limitation.  Risk  reduction involves preventing exacerbations, preserving lung function and avoiding asthma deaths.

A stepwise approach is recommended by GINA for adjusting treatment for individual patient needs.

Patients not adequately controlled with ICS / LABA maintenance treatment have the following treatment options (depending on the dose of ICS already prescribed)

- increase in the dose of ICS taken;
- add on treatment with the LAMA tiotropium;
- add on treatment with leukotriene receptor antagonists;
- administration of low doses of oral corticosteroids (at step 5);
- phenotyping for eosinophilic asthma (type 2 inflammation) and considering biological therapy (e.g. anti IgE, anti Il-5, anti Il-4R) if confirmed.

With the 2019 edition of the GINA report, important changes in asthma management and categorisation of  treatment  steps  have  been  implemented.  From  2019,  GINA  no  longer  recommends  starting  with short-acting β 2-agonist (SABA)-only treatment for safety reasons. Instead, GINA recommends that all adult and adolescent patients should receive ICS-containing controller treatment in order to reduce their risk of serious exacerbations and to control symptoms. Important changes were implemented also for patients with more severe asthma disease. While in previous editions, patients on medium to high dose ICS / LABA treatment were allocated to step 4, this classification was revised. Patients on medium dose ICS / LABA maintenance therapy (plus as needed SABA) remain in step 4, whereas those requiring higher doses of ICS have now been moved to step 5.

These modified GINA recommendations have relevant implications for the two pivotal phase III trials included in this application and their interpretation. Whereas at trial start, the patients enrolled in the two trials belonged to the same GINA step (i.e. step 4), they are now categorised in two different steps, i.e. GINA step 4 for TRIMARAN and GINA step 5 for TRIGGER. As a consequence, the basic considerations on which the TRIMARAN and TRIGGER trial design was based are no more fully applicable.

It is recognised that inadequate asthma control due to severity or poor compliance is present in up to 50% of asthma patients and that therapeutic options are limited at GINA step 5.

## 2.2. About the product

Trimbow (CHF 5993) is a fixed dose combination (FDC) of the ICS beclometasone dipropionate (BDP), the LABA formoterol fumarate (FF) and the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (GB).

The medicinal product is formulated as a hydrofluoroalkane-134a (HFA-134a) extrafine solution (i.e. mass median aerodynamic diameter  around  1.1 µm)  and  presented  as  a  pressurised  metered  dose inhaler [pMDI].

In the present application, the MAH seeks to extend the initially authorised indication of Trimbow to asthma. Two dose strengths are proposed:

<div style=\"page-break-after: always\"></div>

- lower  dose  strength  product  containing 100 µg  BDP ,  6 µg  FF,  and  12.5 µg  GB  (CHF 5993 100/6/12.5);  this  medicinal  product  delivers  a  dose  of  87 µg  beclometasone  dipropionate,  5 µg formoterol fumarate dihydrate and 9 µg glycopyrronium (11 µg GB); this product will be referred to as ' medium strength ', abbreviated as CHF 5993 MS in the remainder of this document and is the same as the one already authorised in COPD;
- higher  dose  strength  product  containing 200 µg  BDP ,  6 µg  FF,  and  12.5 µg  GB  (CHF 5993 200/6/12.5); this medicinal product delivers a dose of 172 µg beclometasone dipropionate, 5 µg formoterol fumarate dihydrate and 9 µg glycopyrronium (11 µg GB); this product will be referred to as ' high strength ', abbreviated as CHF 5993 HS in the remainder of this document and is intended for use in the asthma indication exclusively.

## Claimed indication and recommendation for use

The initially proposed indication is as follows:

'Maintenance treatment in adult patients with asthma who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or who are already treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist plus a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).'

The recommended and also maximum dose is two inhalations of CHF 5993 twice daily, corresponding to a total daily dose of 348 µg / 24 µg / 50 µg for CHF 5993 MS and 696 µg / 24 µg / 50 µg for CHF 5993 HS, respectively. Therefore, if breakthrough symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be used for immediate relief.

No dose adj ustment is proposed in elderly patients (≥65 years  of  age)  and  mild  to  moderate  renal impairment. The product should be used in patients with severe renal impairment or end-stage renal disease requiring dialysis (especially if associated with significant body weight reduction) only, if the expected benefit outweighs the potential risk.

Due to the lack of data on the use of the product in patients with severe hepatic impairment, it should be used with caution in these patients.

## Mode of action

Beclometasone is  a  synthetic  corticosteroid  with  high  affinity  for  glucocorticoid  receptors  and  antiinflammatory  properties. Formoterol is  a  long  acting  beta2  agonist  and  used  as  a  bronchodilator. Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) which works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby also dilating the airways.

## 2.3. Type of Application and aspects on development

The MAH has submitted a grouped application consisting of

- a type II variation in order to extend the approved indication of CHF 5993 to asthma patients (type II, C.I.6.a);
- a line extension to seek approval for an additional higher dose strength of the product (twice the amount of ICS per actuation, but the same amounts of LABA and LAMA) to be introduced in the asthma, but not the COPD indication).

<div style=\"page-break-after: always\"></div>

## A. Type II variation, triple combination in asthma as a new indication

From a development perspective, the two strengths of CHF 5993 applied for were considered by the MAH to be fixed dose combination products of the approved dual fixed dose combination products associating BDP and FF (CHF 1535 100/6 [first approval in asthma in 2006] and CHF 1535 200/6 [first approval in asthma  in  2015;  marketed  in  Europe  as Foster and  associated  names)  plus  one  additional  active substance (i.e. glycopyrronium bromide, GB).

In line with the guideline on fixed-dose combination medicinal products, the main objective of the clinical programme  was  therefore  to  demonstrate  and  quantify  the  contribution  of  the  additional  active substance GB to the desired therapeutic effect.

This approach and the resulting clinical development programme were confirmed to be acceptable in scientific advice meetings with three national agencies  (AEMPS,  MHRA,  MEB)  and  the  EMA (EMEA/H/SA/026/1/2014/II  and  EMEA/H/SA/3068/2/FU/1/2015/II).  Two  phase II /  IIb  dose-finding studies  ( TRISKEL and ELITRA )  and  two  pivotal  phase III  trials  ( TRIMARAN and TRIGGER )  were designed and constitute the core of the application.

The objective of the phase II / IIb programme was to identify and confirm the most suitable dose of GB to be used in the triple combination product, from both an efficacy, but also safety point of view. A reassessment of the BDP and FF dose strengths established for the dual combination product CHF 1335 was neither planned nor performed.

The main objective of the two pivotal phase III studies was to demonstrate the superiority of triple fixeddose treatment with CHF 5993 over the approved dual combination product CHF 1535 in terms of the co-primary endpoint associating a spirometry endpoint (the change from baseline in pre-dose FEV1 at week 26) to a clinical outcome parameter (the reduction of moderate and severe asthma exacerbation rate by the end of the 52-week treatment period).

The patient population enrolled in these studies was either uncontrolled on medium dose ICS / LABA (TRIMARAN study) or high dose ICS / LABA (TRIGGER study) and had a documented history of at least one (1) asthma exacerbation in the previous year.

The design of the second pivotal study (TRIGGER) was adjusted after the first LAMA (tiotropium, Spiriva Respimat 2.5 µg inhalation solution) was approved in Europe as add-on maintenance bronchodilator treatment in severely affected asthma patients (GINA steps 4 and 5). Another active comparator was added (CHF1535 200/6 + tiotropium, as open label arm) to provide exploratory data that the new fixed combination  product  CHF 5993  had  comparable  efficacy  and  safety  to  this  extemporaneous  triple combination.

<div style=\"page-break-after: always\"></div>

## B. Line extension, higher ICS dose strength intended to be used in the asthma indication only

Further to the triple fixed-combination product (CHF 5993 100/6/12.5) already approved in the COPD indication, the MAH has developed an additional, higher strength product delivering a higher dose of BDP (CHF 5993 200/6/12.5, i.e. 200 µg per actuation).

Both products have similar formulations and are intended to be administered as two puffs bid in line with the dose regimen in the approved COPD indication.

In addition to assessment of the in vitro inhalation performance, two clinical trials were performed:

- a pharmacokinetic (PK) study in adult healthy volunteers to confirm the dose-proportionality of the corticosteroid  components  at  the  two  dose  strengths  (CHF 5993  100/6/12.5  and  CHF 5993 200/6/12.5) ( dose proportionality study , CCD-05993 AB2-01);
- another PK study in adult subjects with moderate asthma to assess the disposition BDP and its major metabolite  form  CHF 5993  200/6/12.5 if  administered  with  or  without  a  spacer  ( spacer study , CLI-05993AB2-03).

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product subject of this line extension, Trimbow 172/5/9 micrograms (also referred to as CHF 5993 pMDI 200+6+12.5 μg/actuation) is pr esented as pressurised inhalation solution. Each delivered dose (the dose leaving the mouthpiece) contains 172 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms glycopyrronium bromide).

Each metered dose (the dose leaving the valve) contains 200 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium (as 12.5 micrograms glycopyrronium bromide).

Other ingredients are: ethanol anhydrous, hydrochloric acid and norflurane (propellant).

The product is available in a pressurised container (coated aluminium), with a metering valve. The pressurised container is inserted in a polypropylene inhaler which incorporates a mouthpiece and a dose counter (60 actuations or 120 actuations per pressurised container) and is provided with a polypropylene mouthpiece cap, as described in section 6.5 of the SmPC.

## 2.4.2. Active substance

The line extension solely concerns a new strength of the already authorised product (Trimbow 87/5/9 micrograms, EMEA/H/C/004257/) with the same qualitative composition of the proposed finished product. Since no changes have been introduced to the active substances with this procedure, no module 3.2.S has been provided; this is accepted.

## 2.4.3. Finished medicinal product

## Description of the product and Pharmaceutical development

The finished product subject of this line extension, Trimbow 172/5/9, is presented as pressurised inhalation solution containing 172 micrograms of beclometasone dipropionate, 5 micrograms of

<div style=\"page-break-after: always\"></div>

formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms glycopyrronium bromide) per delivered dose (the dose leaving the mouthpiece).

The three active substances are dissolved in the propellant norflurane, ethanol anhydrous, as cosolvent, and hydrochloric acid (HCl), as formulation stabiliser. This is the same qualitative formulation of the already marketed Trimbow 87/5/9.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

For norflurane, in addition to the tests described in the Ph.Eur., a test for volatile related substance has been introduced in the specifications. The methods have been adequately validated.

Sufficient information has been provided on all performance parameters for pressured metered dose inhalers according to the requirements outlined in the Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products.

Equivalence study between the aerosol aerodynamic particle size distribution (APSD) obtained with the actuator used in the clinical studies, the commercial actuator with integrated dose counter and with the commercial actuator used in conjunction with the spacer AeroChamber Plus has been presented. The APSD profile of the clinical and commercial actuator are found to be equivalent.

The packaging material complies with Ph.Eur. and EC requirements, as applicable. The colourants used in the manufacture of the actuator with integrated dose counter may contain additive of animal origin as they are tallow derived; adequate certification for the tallow derived additives has been included demonstrating that they fulfil the requirements in accordance with the Note for Guidance, EMEA/410/01 (Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products). The information provided on the container closure is in line with that which was previously approved for the 60 and 120 actuation/can presentations of the authorised strength Trimbow 87/5/9.

It has been demonstrated that there is no risk concerning extractables/leachables. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

A description of the manufacturing method has been provided. In-process controls were adequate considering the nature of the product. Process validation studies have been conducted on production scale batches and are acceptable. All validation data were within specifications. A holding time has been described, which is supported by data provided in the pharmaceutical development. The Applicant confirms that shelf life of the finished product is calculated in line with the 'Note for Guidance on Start of Shelf-Life of the Finished Dosage Form (CPMP/QWP/082/96)'.It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner.

## Product specification

The  finished  product  specifications,  include  the  following  tests;  description  (product  and  primary packaging), identification of each active substance (HPLC and HPLC/UV), assay of each active substance (HPLC and HPLC/UV), related substances of each active substance (HPLC), moisture content (KF), fine particle mass-beginning of can (new generation impactor (NGI)/HPLC), mean delivered dose intra-can

<div style=\"page-break-after: always\"></div>

and inter-cans (HPLC) and uniformity of delivered dose intra-can and inter-cans (HPLC), microbiological limits (Ph.Eur.), leak rate, number of actuations per container.

The tests included in the specification are appropriate for this kind of dosage form and are in line with the requirements of the 'Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products' (EMEA/CHMP/QWP/49313/2005 Corr).

The specifications for the 60 and 120 actuations presentation differ in terms of number of actuations and content of the active substances in the can.

The potential presence of elemental impurities in the finished product has been assessed on a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data generated using a validated ICP-MS method, were provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

The analytical methods used are the same as those used for the already approved product. The analytical methods have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided for three commercial scale batches of the 60 actuations/can presentation and eight commercial scale batches of the 120 actuations/can presentation confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification. All parameters complied with the proposed specifications.

## Stability of the product

Stability data from three commercial scale batches for each presentation of finished product stored for up to 24 months under long-term conditions (5°C) and 6 months under accelerated conditions (25°C/60 % RH) according to the ICH guidelines were provided. For both presentations the inhalers were stored both in the inverted and upright position using a satisfactory matrix design. The batches of medicinal product  are  identical  to  those  proposed  for  marketing  and  were  packed  in  the  primary  packaging proposed for marketing.

In-use stability data after storing the finished product under long term conditions has also been provided. All the stability results comply with the proposed stability specification. Based on available stability data, the proposed shelf-life of 20 months for the 60 actuations container and 21 months for the 120 actuations container when stored in the refrigerator is supported. As stated in the SmPC (section 6.3), chemical and physical in-use stability has been demonstrated for 2 months at 25°C, for the 60 presentation, and for for 3 months at 25°C, for the 120 presentation. After dispensing, the medicinal product may be stored for a maximum of 2 months (for the 60 presentation) and for 3 months (for the 120 presentation) at a temperature up to 25°C. Other in-use storage times and conditions are under the responsibility of the user. The following special precautions for storage are stated in the SmPC (Section 6.4): do not freeze; do not expose to temperatures higher than 50°C; do not pierce the pressurised container. Prior to dispensing, store in a refrigerator (2°C 8°C).

The stability conditions and precautions are the same as for the approved product and considered acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

<div style=\"page-break-after: always\"></div>

## 2.4.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the finished product has been presented in a satisfactory manner; the development of the additional strength is based on the currently marketed product with the main difference being the increase of the concentration of beclometasone dipropionate, which has been adequately supported. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.4.6. Recommendation for future quality development

Not applicable.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

For the 100+6+12.5 µg strength, the total daily dose and the posology intended for asthmatic patients are the same as the one already authorised for COPD (i.e. 400+24+50 µg BDP/FF/GB per day, two actuations twice daily), therefore no new non-clinical studies have been conducted to support the asthma application, and the MAH referred to the non-clinical contents of the CHF 5993 COPD dossier as the studies are also considered applicable to support the asthma indication.

The only new non-clinical information relevant to the asthma indication is a re-calculation of the safety margins taking into account the systemic exposure of asthmatic patients instead of COPD patients and that the higher BDP dose strength (200+6+12.5 µg/actuation) will expose asthmatic patients to a total daily dose of 800+24+50 µg/day BDP/FF/GB.

## 2.5.2. Pharmacology

No new pharmacology data has been presented. The MAH referred to the CHF 5993 COPD dossier.

## 2.5.3. Pharmacokinetics

No new pharmacokinetics data has been presented. The MAH referred to the CHF 5993 COPD dossier

## 2.5.4. Toxicology

The MAH referred to the CHF 5993 COPD dossier and has not submitted any new experimental data. However, re-evaluations of the safety margin calculations were provided to account for the use of CHF 5993 100+6+12.5 µg BDP/FF/GB per actuation and 200+6+12.5 µg BDP/FF/GB per actuation strengths in asthmatic patients (see Discussion on non-clinical aspects). In addition, safety factor calculations for active  substance  related  impurities  were  presented  on  basis  of  the  available  inhalation  repeat  dose toxicity studies (see Discussion on non-clinical aspects).

<div style=\"page-break-after: always\"></div>

## 2.5.5. Ecotoxicity/environmental risk assessment

The MAH submitted an updated ERA, taking into account the request of the CHMP.

The water-sediment study demonstrating that the transformation product 'Met-L' should be classified as 'very persistent' in water.

Based on the provided data/information a risk to the environment is not to be expected.

## 2.5.6. Discussion on non-clinical aspects

## Pharmacology

The MAH refers to the CHF 5993 COPD dossier and has not submitted any new experimental data.

Reference to the CHF 5993 COPD dossier and the specific justification provided for the extent/absence of  data  available  for  'Secondary  pharmacodynamics'  and  'Pharmacodynamic  drug  interactions'  are considered acceptable by CHMP.

## Pharmacokinetics

The MAH refers to the CHF 5993 COPD dossier and has not submitted any new experimental data, which is considered acceptable by CHMP.

## Toxicology

## Single dose toxicity

The MAH refers to the CHF 5993 COPD dossier and has not submitted any new experimental data, which is considered acceptable by CHMP.

## Repeat-dose toxicity

The systemic effects and the local tolerability of CHF 5993 on the respiratory system were investigated in rats and dogs in 4- and 13-week inhalation toxicity studies (see CHF 5993 COPD dossier for detailed results of these studies).

In the rat studies, a NOAEL for CHF 5993 could not be defined since systemic adverse effects (e.g. a probably glucocorticoid-related significant decrease in thymus weight) were already observed in the lowdose CHF 5993 groups (at a CHF 5993 dose of 95/6/23 respectively 110/6/24 µg/kg/day BDP/FF/GB in the 4- respectively 13-week study; see Trimbow EPAR - Non-clinical aspects).

In the dog studies, a NOAEL could be established for the low dose CHF 5993 groups (at a dose of 31/2/7 respectively 36/2/8 µg/kg/day BDP/FF/GB in the 4- respectively 13-week study). Systemic glucocorticoid effects  and  cardiovascular  effects  were  observed  in  the  mid-  and  high-dose  CHF  5993  groups  (see Trimbow EPAR- Non-clinical aspects).

Safety factors (exposure multiples) for asthma patients have been re-calculated by the MAH based on (i) the exposure (Cmax, AUC) of the animals to BDP (respectively its main metabolite B17MP), FF and GB as measured in the toxicokinetic part of the repeat dose toxicity studies and (ii) the estimated exposure of  asthma  patients  to  B17MP,  FF,  and  GB  following  therapeutic  doses  of  CHF  5993  of  400/24/50 respectively 800/24/50 (maximal clinic dose) BDP/FF/GB.

The safety factors, calculated for asthma patients on basis of Cmax- and AUC0-24h-values, are presented in the following tables:

<div style=\"page-break-after: always\"></div>

Table 1: Cmax-based safety exposure multiples for asthma patients derived from inhalatio repeat dose toxicity studies

| Substance               | Human      | Rat              | Rat              | Dog             | Dog           |
|-------------------------|------------|------------------|------------------|-----------------|---------------|
|                         | daily dose | 4 week           | 13 week          | 4 week          | 13 week       |
| BDP (measured as B17MP) | 400 µg     | 27.0 (16.0-38.0) | 41.5 (30.0-53.0) | 6.4 (6.4-6.4)   | 6.2 (6.3-6.1) |
|                         | 800 µg     | 13.4 (7.8-19.0)  | 20.5 (15.0-26.0) | 3.2 (3.2-3.2)   | 3.1 (3.1-3.0) |
| FF                      | 24 µg      | 8.2 (8.4-7.9)    | 15.5 (18.0-13.0) | 5.4 (4.9-5.8)   | 3.4 (3.4-3.3) |
| GB                      | 50 µg      | 13.0 (13.0-13.0) | 19.5 (24.0-15.0) | 15.4 (7.7-23.0) | 4.8 (5.2-4.4) |

Table 2: AUC0-24h-based safety exposure multiples derived from inhalation repeat dose toxicity studies

| Substance               | Human      | Rat              | Rat             | Dog              | Dog              |
|-------------------------|------------|------------------|-----------------|------------------|------------------|
|                         | daily dose | 4 week           | 13 week         | 4 week           | 13 week          |
| BDP (measured as B17MP) | 400 µg     | 9.6 (3.2-16.0)   | 16.5 (5.0-28.0) | 0.56 (0.49-0.63) | 0.49 (0.51-0.47) |
|                         | 800 µg     | 4.9 (1.6-8.1)    | 8.3 (2.5-14.0)  | 0.28 (0.25-0.31) | 0.25 (0.26-0.24) |
| FF                      | 24 µg      | 0.49 (0.44-0.53) | 1.08 (1.2-0.96) | 0.86 (0.89-0.83) | 0.41 (0.41-0.40) |
| GB                      | 50 µg      | 7.3 (6.6-8.0)    | 14.1 (21.0-7.2) | 7.2 (5.2-9.2)    | 1.8 (1.6-2.0)    |

Values are presented as mean value (male value - female value) and were calculated based on NOAEL values (dog, marked green) respectively LOAEL values (rat, marked blue; a NOAEL for CHF 5993 could not be established in this species).Whereas for Cmax exposure multiple values &gt;1 were obvious for all CHF 5993 components, AUCrelated exposure multiple values  &lt;1 were observed for BDP (calculated on basis of the main metabolite B17MP) and FF on basis of the rat NOAEL values, whereby giving, in principle, cause for concern for the clinical use of CHF 5993 in asthma patients at the doses proposed for FF and BDP, and in particular for the high BDP-dose.

In principle, this signal for concern is further corroborated by the fact that the estimated clinical exposure of asthma patients to (high dose) BDP and FF may be higher (with respect to AUC0-24h) than the exposure of COPD patients at the approved BDP and FF doses, which, in consequence, results in (more than 2fold) lower safety margins (exposure multiples) for FF and high-dose BDP use in asthma patients (see following table:

Table 3: Clinical exposure of asthma and COPD patients to components of CHF 5993

| Substance   | Human daily dose   | C max ng/ml     | C max ng/ml   | Ratio   | AUC 0-24h ng x h/ml   | AUC 0-24h ng x h/ml   | Ratio   |
|-------------|--------------------|-----------------|---------------|---------|-----------------------|-----------------------|---------|
|             |                    | Asthma patients | COPD patients |         | Asthma patients       | COPD patients         |         |
| BDP         | 400 µg             | 0.628           | 0.678         | 0.93    | 5.55                  | 4.65                  | 1.19    |
|             | 800 µg             | 1.260           | -             | (1.86)  | 11.10                 | -                     | (2.38)  |

<div style=\"page-break-after: always\"></div>

| (exposure to B17MP)   |       |       |       |      |      |      |      |
|-----------------------|-------|-------|-------|------|------|------|------|
| FF                    | 24 µg | 0.016 | 0.017 | 0.94 | 0.42 | 0.16 | 2.63 |
| GB                    | 50 µg | 0.042 | 0.046 | 0.91 | 0.37 | 0.32 | 1.16 |

Ratios for BDF 800 µg/day were calculated by comparison with the 400 µg/day values for COPD patients. For data source see current Non-clinical Overview and EMEA/H/4257, Rapporteur´s D80 Critical Assessment Report - Nonclinical aspects.

However, to put these principal non-clinical signals of concern into perspective, it has to be pointed out that  BDP  and  FF,  the  two  active  constituents  of  CHF  5993  for  which  exposure  multiples  &lt;1  and  an increased exposure in asthma patients may be expected, are already approved for treatment of asthma patients in form of a dual fixed dose combination product (e.g. in the EU under the tradename 'Foster' in daily doses of 400/24 µg, since 2006, and 800/24 µg BDP/FF, since 2015, respectively). Since the available pharmacokinetic data do no point to an increased exposure of asthma patients to GB compared with COPD patients, clinical and epidemiological safety data for GB from the Trimbow COPD indication as well as from marketing authorisation of GB as a single agent for COPD treatment (e.g. under the tradename 'Seebri Breezhaler') may be extrapolated to the 'new' asthma indication.

Overall conclusion : No new non-clinical toxicology studies have been performed which is considered to be acceptable by CHMP. The MAH has submitted updated safety margin calculations from LOAELs and NOAELs  defined  in  the  non-clinical  safety  program  to  predict  human  concentrations  in  the  asthma population. This resulted in exposure levels in excess of those observed at defined LOAELS (in rats) and NOAELs for FF and B17MP. Given the clinical experience with the use of these three mono-component classes (when used as single agents or in combination) via this route of administration and the lack of evidence of synergistic toxicity from completed studies, the CHMP considered that additional non-clinical studies/discussion are unlikely to add further to the know safety profile of these agents and therefore considered the justification provided by the MAH acceptable.

## Genotoxicity

The MAH refers to the CHF 5993 COPD dossier and has not submitted any new experimental data, which is considered acceptable by CHMP. GB and CHF 1535 (BDP+FF ratio 200:12) were not considered to be genotoxic in vitro and in vivo in the MAA of Trimbow in the COPD indication. This remains unchanged for the new asthma indication.

## Carcinogenicity

The MAH refers to the CHF 5993 COPD dossier and has not submitted any new experimental data, which is considered acceptable by CHMP.

BDP and FF have not been tested for a carcinogenic potential in the MAA of Trimbow in the COPD indication because for FF and BDP extensive non-clinical and clinical data were available indicating no signs  of  human  relevant  tumorigenesis.  Therefore,  additional  carcinogenicity  studies  for  these compounds were not considered necessary. This remains unchanged for the new asthma indication.

GB was tested in a 104-week carcinogenicity study in rats and a 26-week carcinogenicity in Tg.rasH2 mice in the MAA of Trimbow in the COPD indication. No treatment-related neoplastic findings occurred in neither study. The NOEL for carcinogenicity was set to 447 μg/kg/day (mean AUC t: 43.8 ng*h/mL at week 26) in the rat study. This corresponds to an AUC-based safety margin of 120-fold considering the AUC-based simulated GB exposure of 0.366 ng∙hr/mL in asthma patients using BDP/FF/GB 400/24/50 µg/day or 800/24/50 µg/day.

In conclusion, no human relevant carcinogenic potential of CHF 5993 is expected for the new asthma indication.

## Reproductive and developmental toxicity

<div style=\"page-break-after: always\"></div>

The MAH refers to the CHF 5993 COPD dossier and has not submitted any new experimental data, which is considered acceptable by CHMP.

For  the  MAA  of  Trimbow  in  the  COPD  indication,  the  effects  of  CHF  5993  on  fertility,  reproductive functions and on the pre- and post-natal development as well as embryotoxic and teratogenic effects in rats  were  studied  following  oral  administration  (BDP,  formoterol  and  glycopyrrolate  in  the  ratio  of 100+6+25).  A  dose-range-finding  and  toxicokinetic  study  in  pregnant  rats  was  also  carried  out  to support the embryo-foetal development study.

In addition, embryo-fetal developmental studies in rats and rabbits were performed with glycopyrrolate.

Studies in juvenile animals were not performed and are, according to the MAH, not planned, in line with the Paediatric Investigation Plan agreed with the PDCO for CHF 5993. Trimbow is intended for treatment in  adult  patients  with  COPD  or  asthma.  Trimbow  is  currently  not  recommended  for  children  and adolescents with asthma under 18 years until further data become available. Therefore, the absence of studies in juvenile animals is acceptable by CHMP.

The higher dose of BDP in the 200+6+12.5 μg/actuation formulation of CHF 5993 may result in a higher exposure of the pregnant women and the embryo or fetus to BDP or its metabolite B17MP.

Considering the AUCbased simulated exposure of 11.1 ng∙hr/mL in asthma patients using BDP/FF/GB 400/24/50 µg/day, the exposure margin to the exposure of B17MP in pregnant rats at the dose of 0.2 mg/kg/day CHF 5993 (NOAEL of the EFD studies in rats) is 8.4.

BDP, as a glucocorticoid when used during pregnancy was associated in some studies with an increased risk of cleft palate and impaired fetal growth, primarily with systemic rather than inhalation exposure.

One study showed that an inhalative dose of &gt;1,0 00 μg/day of beclometasone was associated with a small risk of congenital malformation [Blais L, Beauchesne MF, Lemière C, Elftouh N. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. Placenta 2007 Jan;28(1):39-46.]. The highest recommended daily dose of beclometasone would be 800 µg/day when using the 200+6+12.5 µg/actuation formulation of Trimbow. This has been adequately addressed in the SmPC wording, section 4.6.

## Local tolerance

No separate local tolerance studies were conducted with CHF 5993 for the COPD indication; however, its local tolerance was tested during the 4- and 13-week inhalation repeat dose toxicity studies in rats and dogs. Therefore, the absence of specific local tolerance studies with CHF 5993 is considered acceptable by CHMP.

## Other toxicity studies

Antigenicity: There  is  no  specific  antigenic  alert  on  the  well-known  components  of  CHF  5993.  An assessment of the leucocyte populations (immunophenotyping) was nevertheless performed during the 4-week inhalation repeat dose study in rats (Trimbow COPD dossier). The absence of further specific studies on antigenicity for CHF 5993 is considered acceptable by CHMP.

Immunotoxicity: There is no specific immunotoxic alert on the well-known components of CHF 5993. A measure of anti-SRBC IgM titres (primary immune response) was nevertheless performed during the 4week  inhalation  repeat  dose  study  in  rats  (Trimbow  COPD  dossier)  to  assess  immunotoxicity.  The absence of a more detailed immunotoxicological evaluation for CHF 5993 is considered acceptable by CHMP.

Mechanistic studies: As the pharmacological modes of action are well understood for CHF 5993 and any observed toxicity was only related to exaggerated pharmacology, no specific mechanistic studies were

<div style=\"page-break-after: always\"></div>

performed by the MAH. The absence of specific mechanistic studies for CHF 5993 is considered acceptable by CHMP.

Dependence: The components of CHF 5993 are well known not to have any relevant central nervous system activity, belonging to pharmacological classes not related to dependence or causing withdrawal symptoms.  No  specific  studies  were  conducted  by  the  MAH.  The  absence  of  specific  studies  on dependence potential for CHF 5993 is considered acceptable by CHMP.

Metabolites: Monitoring of the metabolites of CHF 5993 was performed by toxicokinetic plasma analysis during the toxicology studies. In addition, specific pharmacokinetic studies on metabolites of GB are reported in the COPD dossier. Based on the CHF 5993 COPD MA dossier, the spectrum of data available for metabolites of the active substances is considered sufficient.

Studies on impurities: The data presented by the MAH for exposure of animals to active substancerelated  impurities  during the  available  inhalation  repeat  dose  toxicity  studies  and  the  safety  factors derived therefrom by a comparison with the expected maximal clinical exposure, provide reassurance that, within the proposed specifications limits, active substance-related impurities do not constitute a safety concern.

Other studies: The propellant HFA-134a (present in both CHF 5993 pMDI strengths in the maximum quantity of 64.81206 mg/actuation) is the HFA that has been developed for all Chiesi pMDI formulations. The dose of propellant for the asthma formulations is in line with the dose already registered for COPD and  is  therefore  considered  safe.  Furthermore,  the  quantities  of  the  ethanol  and  hydrochloric  acid excipients in the CHF 5993 strengths for asthma are identical to those already registered for COPD and are considered safe. Therefore, the absence of toxicological studies concerning the propellant HFA-134a and of the excipients used with CHF 5993 is considered acceptable by CHMP.

## 2.5.7. Conclusion on the non-clinical aspects

With regard to the claimed asthma indication, for this line extension/variation the MAH refers to the CHF 5993 COPD dossier and has not submitted any new experimental non-clinical data, however, a recalculation of safety factors based on the expected clinical exposure of asthma patients to CHF 5993 was provided. This approach is endorsed by CHMP. Based on the provided data/information, a risk to the environment is not to be expected. Overall, the submitted non-clinical summary does not change the benefit risk assessment of Trimbow in the newly proposed asthma indication.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

The clinical development programme in order to obtain regulatory approval for the two strengths of CHF5993 included the following six (6) clinical studies:

- -two PK single-dose studies, a dose proportionality study in healthy subjects and a spacer study in patients with asthma;

<div style=\"page-break-after: always\"></div>

- -two Phase II/IIb studies in patients with asthma (TRISKEL and ELITRA);
- -two pivotal Phase III studies in patients with asthma (TRIMARAN and TRIGGER).

<div style=\"page-break-after: always\"></div>

Table 4: Overview of the clinical development - phase I studies

|                                        | DoseProportionality study CCD-05993AB2-01                                                                                                                                                                                                     | Spacer study CLI-05993AB2-03                                                                                                                                                                                                                                                                                                                          |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Narrativeslocation                     | M 2.7.1.2.2                                                                                                                                                                                                                                   | M 2.7.1.2.1                                                                                                                                                                                                                                                                                                                                           |
| CSR location                           | M 5.3.3.2.1                                                                                                                                                                                                                                   | M 5.3.1.2.3                                                                                                                                                                                                                                                                                                                                           |
| Study type                             | PK                                                                                                                                                                                                                                            | PK                                                                                                                                                                                                                                                                                                                                                    |
| Design                                 | Phase I, randomised, open-label, single-dose, placebo-controlled, 5-way cross-over study                                                                                                                                                      | Phase I, randomised, open-label, single-dose, placebo-controlled, 3-way cross-over study                                                                                                                                                                                                                                                              |
| Primary objective                      | To evaluate the lung exposure (with charcoal block) and total systemic exposure (without charcoal block) to B17MP, FF and GB as AUCo-t and Cmax across two different dose strengths of CHF 5993 (100/6/25 and 200/6/25) administered via pMDI | To investigate the effect of the spacer on the PK of CHF 5993 pMD1 200/6/12.5 active ingredients, by comparing the systemic exposure (AUCo-t and Cmax) of B17MP, FF and GB after a single dose of CHF5993 200/6/12.5 administered viapMDI using the standard actuator plus AeroChamber Plus? spacer (Test) or the standard actuator alone (Reference) |
| Studymedication andtotal dose          | CHF 5993 pMDI 200/6/25 with or without charcoal block, 4 puffs (total dose: 800 μg BDP, 24 μg FF, 100 μg GB)                                                                                                                                  | CHF 5993 pMDI 200/6/12.5 with AeroChamber? Plus, 4 puffs (total dose: 800 μg BDP, 24 μug FF, 50 μug GB)                                                                                                                                                                                                                                               |
| Subjects/patients                      | Healthy adults                                                                                                                                                                                                                                | Adults with moderate asthma                                                                                                                                                                                                                                                                                                                           |
| Number of randomised subjects/patients | 50                                                                                                                                                                                                                                            | 36                                                                                                                                                                                                                                                                                                                                                    |
|                                        | CHF 5993 pMD1 100/6/25 with or without charcoal block, 4 puffs (total dose: 400 μg BDP, 24 μug FF, 100 μg GB); CHF 5993 pMDI placebo, 4 puffs                                                                                                 | CHF 5993 pMD1 200/6/12.5 with standard actuator,4 puffs Comparators and totaldose (total dose: 800 μg BDP, 24 μg FF, 50 μg GB); CHF 5993 pMDI placebo, 4 puffs                                                                                                                                                                                        |
| Treatmentduration                      | Single dose                                                                                                                                                                                                                                   | Single dose                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

Table 5: Overview of the clinical development - phase II studies

|                                                                                                                                                            | TRISKEL study (CCD-1206-CSR-0100)                                                                                                                                                   | ELITRA study (CCD-05993AB1-02)                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Design                                                                                                                                                     | Phase II, randomised, double-blind, active-controlled, 3-way incomplete-block cross-over study Phase IIb, randomised, double-blind, placebo-controlled, 2-way cross-over study      |                                                       |
| N=211 adults with moderate to severe asthma                                                                                                                | N=98 adults with mild to severe asthma so far uncontrolled on ICS alone                                                                                                             | Patients                                              |
| To evaluate the effects of GB, if administered at three levels on top of CHF 1535 100/6                                                                    | dose To demonstrate that the selected dose of GB is superior to placebo if administered on top of low to medium alone                                                               | Objective                                             |
| CHF 1535 100/6, two puffs bid plus (total daily dose: 400 µg BDP/24 µg FF ) (total daily GB ) b 2)GB 25, one (total daily GB ) b 3)GB 25, two (total daily | puff bid dose: 25 µg puff bid dose: 50 µg puffs bid dose: GB 12.5 µg per actuation, two puffs bid (total daily dose 50 µg GB ) administered on top of low to medium ICS doses alone | Study medication and total daily doses 1)GB 12.5, one |
| Comparator(s) and total daily dose CHF 1535 100/6, two puffs BDP/24                                                                                        | 400 µg matched placebo of GB, 2 puffs bid                                                                                                                                           | bid (total daily dose: µg FF) b                       |
| duration 3                                                                                                                                                 | 6 weeks /treatment period; treatment periods separated by a 1-week wash-out period 6 weeks /treatment period; 2 treatment periods separated by a 1-week wash-out period             | Treatment                                             |
| Primary variable                                                                                                                                           | FEV 1 AUC0-12h normalised by time on Day 42                                                                                                                                         | FEV 1 AUC0-12h normalised by time on Day 42           |
| Key secondary variables                                                                                                                                    | peak 0-12h FEV 1 on Day 42                                                                                                                                                          | peak 0-12h FEV 1 on Day 42                            |

a All patients received Qvar at a dose which was equipotent to that of their previous ICS treatment, i.e. 50 µg or 100 µg, one to two puffs bid (total daily dose: 100-400 µg) at screening, which was maintained as a background medication throughout the study.

b The double-blind design was ensured by adding 1 puff of GB placebo bid for the study medication and 2 puffs of GB placebo for the comparator.

<div style=\"page-break-after: always\"></div>

Table 6: Overview of the clinical development - phase III studies

|                                       | TRIMARAN study a (CCD-05993AB1-03)                                                                                                                                                                                                                                                                                                                                                                                                                  | TRIGGER study (CCD-05993AB2-02)                                                                                        |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Design                                | Phase III, randomised, double-blind, active-controlled, 2-arm parallel group study                                                                                                                                                                                                                                                                                                                                                                  | Phase III, randomised, double-blind, with an open-label arm, active-controlled, 3-arm parallel group study             |
| Patients                              | N= 1155 adult patients with asthma uncontrolled on medium doses of ICS / LABA N=1437 adult patients with asthma on high doses of ICS / LABA                                                                                                                                                                                                                                                                                                         | uncontrolled                                                                                                           |
| Objective(s)                          | • to investigate the long-term efficacy and safety CHF 5993 MS (100/6/12.5) for up to 52 weeks of treatment; • to demonstrate the superiority of triple treatment with CHF 5993 MS (100/6/12.5) as compared to dual treatment (CHF 1535 100/6) • to investigate the long-term efficacy and safety (200/6/12.5) for up to 52 weeks of treatment; • to demonstrate the superiority of triple treatment (200/6/12.5 as compared to dual treatment (CHF | CHF 5993 HS with CHF 5993 HS 1535 200/6)                                                                               |
| Study medication and total daily dose | CHF 5993 100/6/12.5, two puffs bid (total daily dose: 400 µg BDP , 24 µg FF, 50 µg GB) CHF 5993 200/6/12.5, two puffs (total daily dose: 800 µg BDP , 24 µg                                                                                                                                                                                                                                                                                         | bid FF, 50 µg GB)                                                                                                      |
| Comparators and total daily dose      | CHF 1535 100/6, two puffs bid (total daily dose: 400 µg BDP , 24 µg FF) • CHF 1535 200/6, two puffs bid (total daily dose: 800 µg BDP , 24 µg FF) • CHF 1535 200 /6, two puffs bid + tiotropium 2.5 (total daily dose: 800 µg BDP , 24 µg FF + 5 µg                                                                                                                                                                                                 | µg, two inhalations od tiotropium ) b                                                                                  |
| Treatment duration                    | in both trials: 52 weeks                                                                                                                                                                                                                                                                                                                                                                                                                            | in both trials: 52 weeks                                                                                               |
| Primary variables                     | FEV1 (L) at Week 26;                                                                                                                                                                                                                                                                                                                                                                                                                                | FEV1 (L) at Week 26;                                                                                                   |
| Key secondary variables               | PEF averaged over the 26-week treatment period the TRIMARAN and TRIGGER results was pre-planned to evaluate the effect                                                                                                                                                                                                                                                                                                                              | PEF averaged over the 26-week treatment period the TRIMARAN and TRIGGER results was pre-planned to evaluate the effect |

a  PK data from this study were used for population PK analyses discussed in Section 2.5.3 of Module 2.5.

b  Open-label arm for benchmarking purposes; the number of patients randomised to this arm was half those randomised to each of the other two arms (i.e. randomisation ratio of 2:2:1).

<div style=\"page-break-after: always\"></div>

## 2.6.2. Pharmacokinetics and Pharmacodynamics

The clinical  programme of CHF 5993 pMDI 100 /6/12.5 and CHF 5993 pMDI 200 /6/12.5 in asthma includes  evaluating  the  PK  profiles  in  order  to  confirm  the  dose  proportionality  for  BDP  and beclometasone-17-monopropionate (B17MP; the active metabolite of BDP) in healthy subjects ( Dose Proportionality study ) and to investigate the effect of a spacer in asthmatic patients ( Spacer study ).

In the Dose Proportionality study, B17MP systemic and lung exposure resulted to be dose-proportional between CHF 5993 pMDI 100 /6/25 μg and CHF 5993 pMDI 200 /6/25 μg. Although the CHF 5993 pMDI 100/6/25 μg and CHF 5993 pMDI 200/6/25 µg  (test)  formulations are not the object of the current application, these were selected and used as treatments in the study, to allow a better and more reliable estimation of GB plasma concentration vs. time. GB exposure was not bioequivalent when comparing CHF 5993 pMDI 100/6/25 μg and CHF 5993 pMDI 200/6/25 μg. GB Cmax was higher after inhalation of CHF 5993 pMDI 200/6/25µg compared to inhalation of CHF 5993 pMDI 100/6/25µg with and without activated  charcoal,  with  point  estimates  (90%  CI)  of  the  ratios  of  122.0%  (103.9%-143.3%),  and 113.0%  (96.4%-132.5%),  respectively.  Notable,  results  of in  vitro comparison  between  the  to-bemarketed formulations (reference formulations) and the ones with enriched GB (test formulations) show that the ratio for some stages, particularly those ones where the deposition of drug substances is lower, are not fully within the acceptance criteria of ±15% (0.85-1.18). Thus, extrapolation of in vivo (PK) data from the test formulations to the intended to-bemarketed formulations (BDP/FF/GB 100/6/12.5 μg and BDP/FF/GB 200/6/12.5 μg per actuation) is formally not possible.

In the Spacer study, inhalation of CHF 5993 pMDI 200/6/12.5µg with the spacer AeroChamber Plus resulted in an increase in GB lung exposure (Cmax and AUC0-30min) and total exposure (AUC0-t). GB Cmax, AUC 0-30min and AUC0-t were higher after inhalation of CHF 5993 pMDI 200/6/12.5 µg with spacer compared to inhalation without spacer, with point estimates (90% CI) of the ratios of 134.3% (106.5-169.3%), 137.6% (109.2-173.3%) and 135.8% (107.2-171.83%), respectively. An additional analysis was performed by stratifying subjects into two groups on the basis of their FF AUC0-30min values with pMDI alone. GB Cmax and AUC0-t in patients with good coordination after administration of CHF  5993  pMDI  200/6/12.5  without  spacer  were  higher  compared  to  poor  coordinators  after administration  of  CHF  5993  pMDI  200/6/12.5  with  spacer.  Nevertheless,  the  higher  total  exposure (AUC0-t) of GB when CHF 5993 is administered with a spacer is expected to reflect on the systemic safety profile of CHF 5993. Notable, for GB, no safety signals have been observed in studies GLYCO 2 and CARSAF in which GB was administered at supra-therapeutic doses (i.e. up to 200 µg in study GLYCO 2 and at 100 µg in study CARSAF) in COPD patients, suggesting that a 2-fold increase in GB exposure is unlikely to result in (cardiovascular) safety concerns. In addition, in both pivotal studies TRIMARAN and TRIGGER,  patients  who  were  used  to  inhaling  their  medication  with  a  spacer  continued  using AeroChamber Plus during the studies. Stratified analyses by using a spacer in the studies TRIMARAN and TRIGGER are discussed in the Safety Section. Overall, the trends observed in this spacer study are similar to those trends observed for the spacer study performed in COPD patients.

In addition, using data from the TRIMARAN study, a population PK analysis was conducted in order to obtain estimates of typical PK parameters, quantify the intra- and inter-individual variability and provide a quantitative assessment of the potential effect of intrinsic and extrinsic covariates on PK parameters of B17MP, FF and GB.

All bioanalytical method validation reports, and associated data analysis reports, were assessed in the context of the EMA guidelines (EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**). Sufficient data were presented  to  confirm  CC  performance,  selectivity  and  the  absence  of  carry-over  between  sample injections. There was no significant matrix effect interfering with the determination of each analyte.

<div style=\"page-break-after: always\"></div>

Intra- and inter-assay performance was demonstrated using appropriate QC samples that sufficiently covered  the  entire  CC.  Long-term  stability  data  was  also  provided.  There  was  sufficient  partial  revalidation data provided for each amendment.

## 2.6.3. Discussion on clinical pharmacology

All bioanalytical method validation reports, and associated data analysis reports, were assessed in the context of the EMA guidelines (EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**).

The dose proportionality of systemic and lung exposure to beclometasone dipropionate has been investigated in a pharmacokinetic study conducted in healthy subjects with non-marketed Trimbow formulations, containing twice the approved strength of glycopyrronium (given as metered dose). The study compared data obtained after treatment with a single dose (4 inhalations) of Trimbow 200/6/25 micrograms or a single dose (4 inhalations) of Trimbow 100/6/25 micrograms (both are non-marketed formulations containing twice the approved strength of glycopyrronium). Trimbow 200/6/25 micrograms treatment resulted in a two times higher systemic and lung exposure to beclometasone dipropionate and to its main active metabolite (beclometasone 17 monopropionate) in comparison to Trimbow 100/6/25 micrograms, which is consistent with the different strengths of the two formulations. The systemic and lung exposure to glycopyrronium and formoterol was similar after the two treatments although a high variability was observed for glycopyrronium bromide Cmax. Results of the dose proportionality have been reflected in section 5.2 of the SmPC.

The trends observed in the spacer study were similar to those trends observed for the spacer study performed in COPD patients. Consequently, section 5.2 of the SmPC has been updated to reflect that in patients with asthma, the use of Trimbow with the AeroChamber Plus spacer increased the lung delivery of beclometasone 17 monopropionate, formoterol and glycopyrronium (maximum plasma concentration increased by 7%, 23% and 34% respectively). The total systemic exposure (as measured by AUC0 t) was slightly reduced for beclometasone 17 monopropionate (by 34%) and formoterol (by 30%), while it was increased for glycopyrronium (by 36%).

In addition, using data from the TRIMARAN study, a population PK analysis was conducted in order to obtain estimates of typical PK parameters, quantify the intra- and inter-individual variability and provide a quantitative assessment of the potential effect of intrinsic and extrinsic covariates on PK parameters of B17MP, FF and GB. Appropriate methods were used for model development and evaluation. Data exclusions  were  well  documented  and  are  acceptable.  Covariate  analyses  showed  that  intrinsic  and extrinsic factors had a limited effect on B17MP, FF and GB exposure (AUCtau) and therefore, it is agreed that no requirement for a dose adjustment is needed.

As already mentioned above, from a development perspective, CHF5993 MS and CHF5993 HS were considered by the MAH to be FDC products of the already in asthma approved dual combination products associating BDP and FF (CHF1535 100/6 [first approval in asthma in 2006] and CHF1535 200/6 [first approval in asthma in 2015; marketed in Europe as Foster and associated names) plus one additional active substance (i.e. GB).

The pharmacodynamics of GB was previously characterised in COPD population. Thus, in principle, the pharmacodynamics properties of GB are adequately explored. In addition, two phase II dose-response studies (ELITRA and TRISKEL) in the asthma population have been conducted (see below).

It is well accepted that in moderate-to-severe asthma, adding a LABA to an ICS provides better disease control by enhancing the clinical efficacy of ICSs. In vitro , LABAs synergistically enhance the maximal expression of glucocorticoid-induced genes. Other genes (e.g. dual-specificity phosphatase 1 [DUSP1] in human airways smooth muscle and epithelial cells) are up-regulated additively by both drug classes. Synergy may also occur for LABA-induced genes, as shown by the bronchoprotective gene, regulator of

<div style=\"page-break-after: always\"></div>

G-protein signalling 2 in airways smooth muscle. Such effects cannot be produced by either drug alone; and may explain the therapeutic efficacy of ICS/LABA combination therapies. LAMAs are well established in  guidelines  for  COPD  but  tiotropium  only  is  currently  licensed  for  use  in  asthma.  Data  suggest  a potential protective effect of tiotropium against bronchoconstriction and airway remodelling when added to ICS/LABA [Hoshino et al, 2016].

For further details on safety endpoints related to the PK studies please see the safety section of this report.

## 2.6.4. Conclusions on clinical pharmacology

The pharmacokinetics of GB as single monotherapy and of the triple combination CHF 5993 has been sufficiently investigated by the MAH. The design and methodology of these studies are appropriate for the objectives. The observed increase in GB exposure when CHF 5993 pMDI is inhaled with the spacer AeroChamber Plus has been adequately reflected in section 5.2 of the SmPC.

## 2.7. Clinical efficacy

The  core  of  this  application  consists  of  four  clinical  trials,  i.e.  two  phases  II  dose-response  studies (ELITRA and TRISKEL) and two pivotal studies (TRIMARAN and TRIGGER) supporting the use of the triple combination product CHF 5993 in asthmatic patients. The main objective of the phase II studies was to confirm the dose strength of GB to be used in asthma in association with the dual fixed-dose combination associating an ICS and a LABA. Both studies were designed and performed after scientific input had been received  from  EMA  (EMA/CHMP/SAWP/441847/2014). Once the dose of GB to be used in the triple combination product had been confirmed, two pivotal studies of 52-weeks duration have been designed to  assess  the  long-term  efficacy  and  safety  of  CHF  5993  in  asthma  patients  uncontrolled  on  dual ICS/LABA treatment.

## 2.7.1. Dose response studies

The  MAH  conducted  two  phase  II  studies  (TRISKEL  &amp;  ELITRA)  to  provide  information  on  the  dose response to GB in asthma patients.

The TRISKEL study was a key dose-finding study, which led to selection of the dose of GB for CHF 5993 pMDI. A dose range of 25/50/100 µg GB daily on top of medium-dose Foster has been tested against medium-dose Foster alone for a variety of spirometry outcomes. The selected dose range for GB relies mainly on data obtained during the COPD development programme for Trimbow which is supported. In this study, all doses of GB (25, 50, and 100 μg) in combination with Foster were superior versus Foster alone in terms of the primary efficacy variable, FEV1 AUC0-12h normalised by time after 6 weeks of treatment in adult patients with uncontrolled asthma on medium-dose ICS/LABA, and also for the key secondary efficacy variable change from baseline in peak FEV1 evaluated after 6 weeks of treatment. The two highest doses of GB (50 and 100 μg) generally showed a similar improvement in lung function, which was consistently numerically greater than that observed with the GB 25 μg dose. Overall, there was no efficacy advanta ge seen with the GB 100 μg dose over the GB 50 μg dose. Thus, the proposed daily dosing for the LAMA component (i.e. 50 µg GB) seems to be the optimal dose when combined with medium-dose BDP and FF in a fixed triple combination. Notable, no formal dose finding for the GB component of CHF-5993-HS has been conducted.

Of note, the proposed dose of GB has been chosen based on the two dose-finding studies of 6 weeks duration. Treatment durations of 6-12 weeks are recommended by the COPD guideline (EMA/CHMP/483572/2012-corr1).  The  use  of  GB  in  asthma  is  as  a  controller  medication,  although

<div style=\"page-break-after: always\"></div>

bronchodilation appears to be its primary pharmacodynamic action. It is possible that similarly to other controllers the maximum effect of GB in asthma occurs only after 3-4 months of treatment. Therefore, the proposed 6 weeks treatment duration runs the risk of under-estimating the effects of GB. However, it is agreed that to balance practical feasibility of a cross-over study and taking into consideration the primary endpoint is lung function, the proposed 6-week duration can be accepted in a dose-selection study.

The  ELITRA  study  was  carried  out  to  assess  the  efficacy  and  safety  of  GB  as  the  only  long-acting bronchodilator added to background ICS therapy compared with placebo. This study investigated the bronchodilator efficacy of GB at a daily dose of 50 μg (selected from the TRISKEL study) vs. placebo i n patients with uncontrolled asthma on a background of low/medium-dose ICS treatment with BDP (Qvar 100400 μg/day) over 6 -week treatment periods in a 2-way cross-over design. The results of this study characterised the bronchodilator effect of GB in the absence of concomitant exposure to other longacting bronchodilators (e.g. LABA) and provided additional supportive evidence of the clinical efficacy of the selected 50 μg total daily dose.

## 2.7.2. Main studies

The MAH submitted two pivotal studies supporting the use of the triple combination product CHF 5993 in asthmatic patients, one performed with the medium dose strength (CHF 5993 100/6/12.5; TRIMARAN) and another with the high dose strength (CHF 5993 200/6/12.5; TRIGGER).

Based on the requirements defined in the fixed-dose combination guideline, the main objective of these two studies was to assess and confirm the contribution of the additional component (glycopyrronium bromide, LAMA) to the efficacy of the already approved dual fixed-dose combination product (ICS / LABA;  CHF  1535).  Therefore,  it  had  to  be  demonstrated  in  the  studies  that  the  triple  fixed-dose combination (CHF 5993) had superior efficacy in asthma patients uncontrolled on the approved dual fixed-dose treatment (CHF1535).

Overall,  the  design  of  both  studies  was  essentially  similar  in  terms  of  design  (double-blind,  parallel treatment groups), primary and key secondary response variables, treatment duration, and objectives. Both studies enrolled patients who had asthma uncontrolled by current dual ICS / LABA treatment and who remained at potential risk of asthma exacerbations despite that treatment (≥ 1 documented asthma exacerbation in the year prior to enrolment).

The remaining differences between the two studies related to:

- the patient population enrolled (TRIMARAN: adult patients with asthma uncontrolled on medium doses of ICS/LABA; TRIGGER: adult patients with asthma uncontrolled on high doses of ICS/LABA);
- the doses of ICS administered  during  the  52-week  double-blind  treatment  period  (TRIMARAN: 100 µg BDP two puffs bid, total daily BDP dose 400 µg; TRIGGER: 200 µg BDP two puffs bid, total daily BDP dose 800 µg);
- the number / type of control groups (TRIMARAN: comparison vs. the corresponding ICS/LABA dual treatment group; TRIGGER: comparison vs. the corresponding ICS/LABA dual treatment group vs. an extemporaneous triple treatment group [tiotropium add-on as reference]).

<div style=\"page-break-after: always\"></div>

Table 7: Overview on the two pivotal studies (TRIMARAN, TRIGGER)

| Study ID                 | no. of countries (recruit- ting sites)   | Posology CHF5993 (BDP/FF/ GB)   | subjects rand. total (N=); by arm (compl.)    | Treatment duration   | Gender M/F (%) median age (range)   |
|--------------------------|------------------------------------------|---------------------------------|-----------------------------------------------|----------------------|-------------------------------------|
| TRIMARAN CCD-05993AB1-03 | 16 (171)                                 | 100/6/12.5                      | N=1155 T: 579 (542) R: 576 (539)              | 52 wks               | 38.4% / 61.6% 54 years (18-75)      |
| TRIGGER CCD-05993AB2-02  | 17 (221)                                 | 200/6/12.5                      | N=1437 T: 573 (534) R: 576 (533) C: 288 (262) | 52 wks               | 39.1% / 60.9% 54 years (18-75)      |

It is noted that - based on GINA applicable at the time of trial start - patients of both studies were allocated to the same GINA group (step 4), while with the changes implemented by GINA 2019, they now belong to different groups (step 4 for TRIMARAN and step 5 for TRIGGER).

## Study CCD-05993AB1-03 - TRIMARAN (Eudra-CT 2015-000716-18)

## Trial title

A 52 week, randomized, double-blind, multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate) in patients with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long-acting ß2-agonists.

## Methods

This was a randomized, double-blind multicenter trial with two parallel treatment groups and a total treatment duration of 52 weeks. The study comprised the following:

- a screening visit (visit V1);
- a run-in period of two weeks where all eligible patients received dual treatment with CHF 1535 100/6 (two puffs bid) in order to ' standardise ' and/or ' stabilise ' the intended study population on the same treatment;
- a 52-week treatment period with a total of five return visits (weeks 4, 12, 26, 40 and 52, visits V3 to V7), whereby the last visit corresponded to the end-of-trial visit (i.e. no follow-up period after discontinuation of study treatment).

<div style=\"page-break-after: always\"></div>

Figure 1: Study design and schedule of visits (TRIMARAN study)

<!-- image -->

BDP=Beclometasone dipropionate;BID=Twice daily;FF=Formoterol fumarate;GB=Glycopyrronium bromide;pMDI=Pressurisedmetered doseinhaler;R=Randomisation;V=Visit;Wk=Week.

## Study Participants

Main inclusion and exclusion criteria were:

- -both gender, aged ≥18 and ≤75 years;
- -asthma onset before the age of 40 and documented history for at least one year;
- -uncontrolled  asthma  on  double  therapy  (medium  dose  ICS  in  combination  with  LABA  [i.e. 500-1'000 µg non-extrafine BDP per day or equivalent dose], stable dose for at least four weeks prior to screening) as evidenced by a ACQ7 score of ≥1.5 (criterion met a t screening and the end of run-in);
- -positive reversibility test at screening (ΔFEV1 &gt;12% and &gt;200 mL over baseline 10-15 minutes after inhaling 400μg of salbutamol pMDI; one repeat test possible prior to randomization);
- -pre-bronchodilator FEV1 &lt;80% of predicted normal value;
- -documented  history  of  one  or  more  asthma  exacerbations  requiring  treatment  with  systemic corticosteroids  or  emergency  department  visit  or  in-patient  hospitalisation  in  the  previous 12 months;
- -patients with a recent exacerbation (&lt;4 weeks prior to screening), having a diagnosis of COPD or a clinically significant cardiovascular condition (as based on investigator judgement) were excluded;
- -current smokers or exsmokers (cumulative exposure ≥10 pack-years or having stopped smoking less than one year prior to screening) were also excluded.

## Treatments

Independent of the medium dose ICS/LABA combination used before, all eligible patients were switched to  CHF 1535 100/6 and administered 2 puffs bid during the run-in period of two weeks in order to ' standardise ' and/or ' stabilise ' the intended study population on the same treatment.

At the end of the run-in period, patients were then randomly assigned to receive one of the following study treatments for a total of 52 weeks (randomization in a ratio of 1:1).

- fixed triple dose combination CHF 5993 100/6/12.5, two puffs bid, total daily dose of BDP/FF/GB 400/24/50µg;
- fixed dual dose combination CHF 1535 100/6, two puffs bid, total daily dose of BDP/FF 400/24µg.

## Outcomes/endpoints

<div style=\"page-break-after: always\"></div>

A co-primary endpoint combining a lung-function parameter (i.e. pre-dose FEV1 at week 26) and another clinically  more  relevant  parameter  (i.e.  rate  of  moderate  to  severe  exacerbations  over  52 weeks  of treatment) was chosen by the MAH to assess the effects of CHF 5993 in line with the guideline on the clinical investigation of medicinal products for the treatment of asthma (CHMP/EWP/2922/01 rev.01).

## Co-primary endpoint

- -change from baseline in pre-dose FEV1 at Week 26 (from visits V2 to V7, FEV1 was measured twice at -45min and -15min pre-dose);
- -rate of moderate to severe exacerbations over 52 weeks of treatment.

## Key secondary endpoints

- -change from baseline in post-dose peak FEV1 (0-3h) at Week 26;
- -change from baseline in the average morning PEF measured by patients at home over the 26-week treatment period (patients were instructed to perform three consecutive manoeuvres; the derived variable for statistical analysis was the highest PEF result out of a minimum of two measurements which were of 'good' quality; baseline was calculated as the average of all available PEF values measured by the patient during the run-in period [minimum number required: N=7]);
- -rate of severe asthma exacerbations over 52 weeks of treatment (pre-specified pooled analysis of data gathered in the two pivotal studies).

<div style=\"page-break-after: always\"></div>

The criteria for what is a ' severe ' asthma exacerbation episode were based on the current definitions recommended by EMA guidance, however the MAH did not exactly follow this definition. In both studies, patients having a visit to the emergency room but not requiring systemic corticosteroids for at least 3 days were classified as having a ' moderate '  exacerbation only. The MAH was therefore requested to calculate  results  of  the  primary  analysis  by  applying  the  definitions  made  in  the  CHMP  guidance document.

The definition used for ' moderate ' asthma exacerbation episodes was sufficiently detailed to allow their consistent identification in both treatment groups, based on diary data. An arbitrary numerical criterion of 7 days was defined in the SAP to decide whether an event met the study criteria for a new exacerbation rather than being a relapse or continuation of a previously recorded exacerbation. This was considered acceptable.

To mitigate the consequences of a small sample size per pivotal trial and low background incidence of exacerbations, it was pre-defined by the MAH (and agreed upon in the SAWP) to pool the rate of «severe exacerbations over 52 weeks» across studies and to define this as a key secondary endpoint.

A central adjudication committee was in charge of evaluating all MACE.

Data in relation with asthma symptom / control and compliance with the investigational treatment were to be recorded by patients in an electronic diary (eDiary).

## Randomisation and blinding (masking)

A balanced block randomisation scheme stratified by country was prepared. Patients were centrally assigned to one of the two treatment arms in a 1:1 ratio, using an Interactive Response Technology (IRT) system.

All IMPs (test and comparator) were administered via an identical fixed dose combination inhaler combining all individual components. Thereby, the blinding was guaranteed and no double dummy design for GB component was required.

## Statistical methods

The Intention-to-Treat (ITT) population was the primary population for analysis and - in accordance with standard criteria - defined as all randomised patients who received at least one dose of IMP and who had at least one post-baseline assessment of efficacy (primary or secondary efficacy variables).

A hierarchical testing procedure was pre-defined for the comparisons between CHF5993 and CHF1535 and the following variables (by hierarchical order of assessment):

1. change from baseline in pre-dose FEV1 at Week 26 and moderate and severe exacerbation rate over 52 weeks (co-primary endpoint);
2. change from baseline in peak0-3h FEV1 at Week 26 (key secondary endpoint 1);
3. change from baseline in morning PEF over 26 weeks (key secondary endpoint 2);
4. severe exacerbation rate over 52 weeks in the pooled analysis (key secondary endpoint 3).

<div style=\"page-break-after: always\"></div>

## Results

The study was performed at 171 recruiting sites in 16 countries; N=23 sites (11.9%) did not enroll any patient. FPFV was on 17 February2016, LPLV on 17 May 2018.

Out of 1628 patients screened, N=1155 (70.9%) were randomly allocated to one of the two treatment groups.  Five  of  these  patients  did  not  start  treatment  as  they  were  randomised  in  error.  A  high percentage of patients in both groups completed the study (CHF 5993: N=542, 93.6% ; CHF 1535: N=539, 93.6% ).

## Numbers analysed, Baseline data

The disposition of subjects is graphically displayed in the Figure below.

Overall, demographic characteristics and a sthma disease characteristics were balanced between the two treatment groups. At study entry, about 90% of patients already used a ICS/LABA fixed combination product, and only about 10% an extemporary combination. Only a small percentage of patients (around 13%) used a spacer device for administration of their orally inhaled products prior to study entry.

Spirometry . Upon screening, parameters of lung function were comparable between treatment groups. Median pre-bronchodilator FEV1 (in % of predicted normal value) was 56.0% and highly variable (min: 17%; max: 79%). Median FVC was 2.74 L and also exhibited a high variability (min: 0.92 L; max: 6.12 L).

In line with the inclusion criteria, FEV1 reversibility had to be confirmed in all eligible patients. Following salbutamol, median FEV1 reversibility was 420.0 mL (min: 210 mL; max: 2410 mL) or 31.7% (min: 12.1%; max: 419.2%) with no relevant between-group differences.

<div style=\"page-break-after: always\"></div>

Figure 2: Disposition of patients

<!-- image -->

Excl. = Exclusion; Incl. = Inclusion; pMDI = Pressurised metered dose inhaler. N=Number of patients.

Note:Re-screenedpatients arecounted more than once.

<div style=\"page-break-after: always\"></div>

Table 8: Patient demography (extract) - safety population

|                 | CHF5993pMDI 100/6/12.5 μg N=576   | CHF1535pMDI 100/6 μg N=574   | Overall N=1150   |
|-----------------|-----------------------------------|------------------------------|------------------|
| Age (years)     |                                   |                              |                  |
| n               | 576                               | 574                          | 1150             |
| Mean (SD)       | 52.6 (12.4)                       | 52.5 (12.2)                  | 52.5 (12.3)      |
| Median(min;max) | 54.0 (18 ; 75)                    | 54.0 (18 ;74)                | 54.0 (18 ; 75)   |
| Agegroup,n(%)   |                                   |                              |                  |
| <65years        | 470 (81.6)                        | 476 (82.9)                   | 946 (82.3)       |
| ≥65 years       | 106 (18.4)                        | 98 (17.1)                    | 204 (17.7)       |
| Gender,n (%)    |                                   |                              |                  |
| Male            | 221 (38.4)                        | 221 (38.5)                   | 442 (38.4)       |
| Female          | 355 (61.6)                        | 353 (61.5)                   | 708 (61.6)       |

Table 9: Asthma disease characteristics - safety population

|                                                     | CHF 5993pMDI 100/6/12.5 μg N=576                    | CHF 1535 pMDI 100/6μg N=574                         | Overall N=1150                                      |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Duration of asthma disease (years)                  | Duration of asthma disease (years)                  | Duration of asthma disease (years)                  | Duration of asthma disease (years)                  |
| n                                                   | 576                                                 | 574                                                 | 1150                                                |
| Mean (SD)                                           | 24.8 (12.9)                                         | 25.2 (12.8)                                         | 25.0 (12.8)                                         |
| Median (min ; max)                                  | 24.4 (1 ; 67)                                       | 25.2 (1 ; 67)                                       | 24.6 (1 ; 67)                                       |
| Duration by group, n (%)                            | Duration by group, n (%)                            | Duration by group, n (%)                            | Duration by group, n (%)                            |
| <5 years                                            | 32 (5.6)                                            | 29 (5.1)                                            | 61 (5.3)                                            |
| 5-20 years                                          | 176 (30.6)                                          | 182 (31.7)                                          | 358 (31.1)                                          |
| ≥20 years                                           | 368 (63.9)                                          | 363 (63.2)                                          | 731 (63.6)                                          |
| Numberof asthma exacerbationsin thepreviousyear     | Numberof asthma exacerbationsin thepreviousyear     | Numberof asthma exacerbationsin thepreviousyear     | Numberof asthma exacerbationsin thepreviousyear     |
| n                                                   | 576                                                 | 574                                                 | 1150                                                |
| Mean (SD)                                           | 1.2 (0.4)                                           | 1.2 (0.4)                                           | 1.2 (0.4)                                           |
| Median (min ; max)                                  | 1.0 (1 ; 2)                                         | 1.0 (1 ; 2)                                         | 1.0 (1 ; 2)                                         |
| 1, n (%)                                            | 474 (82.3)                                          | 473 (82.4)                                          | 947 (82.3)                                          |
| > 1, n (%)                                          | 102 (17.7)                                          | 101 (17.6)                                          | 203 (17.7)                                          |
| Time sincelastdocumentedasthma exacerbation(months) | Time sincelastdocumentedasthma exacerbation(months) | Time sincelastdocumentedasthma exacerbation(months) | Time sincelastdocumentedasthma exacerbation(months) |
| n                                                   | 576                                                 | 574                                                 | 1150                                                |
| Mean (SD)                                           | 5.78 (2.60)                                         | 5.83 (2.54)                                         | 5.81 (2.57)                                         |
| Median (min ; max)                                  | 5.40 (1.0 ; 12.3)                                   | 5.68 (1.0 ; 12.0)                                   | 5.54 (1.0 ; 12.3)                                   |
| Asthma medication at study entry, n (%)             | Asthma medication at study entry, n (%)             | Asthma medication at study entry, n (%)             | Asthma medication at study entry, n (%)             |
| ICS/LABA (fixed combination)                        | 522 (90.6)                                          | 511 (89.0)                                          | 1033 (89.8)                                         |
| ICS + LABA (free combination)                       | 54 (9.4)                                            | 63 (11.0)                                           | 117 (10.2)                                          |
| Use of spacer device before study entry, n (%)      | Use of spacer device before study entry, n (%)      | Use of spacer device before study entry, n (%)      | Use of spacer device before study entry, n (%)      |
| Yes                                                 | 76 (13.2)                                           | 75 (13.1)                                           | 151 (13.1)                                          |
| No                                                  | 500 (86.8)                                          | 499 (86.9)                                          | 999 (86.9)                                          |
| Use of spacer device during study, n (%)            | Use of spacer device during study, n (%)            | Use of spacer device during study, n (%)            | Use of spacer device during study, n (%)            |
| Yes                                                 | 92 (16.0)                                           | 93 (16.2)                                           | 185 (16.1)                                          |
| No                                                  | 484 (84.0)                                          | 481 (83.8)                                          | 965 (83.9)                                          |

<div style=\"page-break-after: always\"></div>

Table 10: Lung function, spirometry results (extract) - safety population

upper part: pre-bronchodilator results at screening and baseline; lower part: FEV1 reversibility after bronchodilator at screening

|                                                            | CHF 5993 pMDI 100/6/12.5 μg N=576                          | CHF 1535 pMDI 100/6μg N=574                                | Overall N=1150                                             |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Pre-salbutamol lung function parameters at screening (V1)  | Pre-salbutamol lung function parameters at screening (V1)  | Pre-salbutamol lung function parameters at screening (V1)  | Pre-salbutamol lung function parameters at screening (V1)  |
| FEV (L)                                                    |                                                            |                                                            |                                                            |
| n                                                          | 576                                                        | 574                                                        | 1150                                                       |
| Mean (SD)                                                  | 1.715 (0.562)                                              | 1.743 (0.562)                                              | 1.729 (0.562)                                              |
| Median (min ; max)                                         | 1.655 (0.52 ; 3.61)                                        | 1.685 (0.53 ; 4.12)                                        | 1.670 (0.52 ; 4.12)                                        |
| FEV1 (%predicted normalvalue)                              | FEV1 (%predicted normalvalue)                              | FEV1 (%predicted normalvalue)                              | FEV1 (%predicted normalvalue)                              |
| n                                                          | 576                                                        | 574                                                        | 1150                                                       |
| Mean (SD)                                                  | 55.2 (12.3)                                                | 55.7 (12.0)                                                | 55.5 (12.1)                                                |
| Median (min ; max)                                         | 56.0 (17 ; 79)                                             | 57.0 (20 ; 79)                                             | 56.0 (17 ; 79)                                             |
| Lungfunctionparameters atbaseline (pre-doseV2)             | Lungfunctionparameters atbaseline (pre-doseV2)             | Lungfunctionparameters atbaseline (pre-doseV2)             | Lungfunctionparameters atbaseline (pre-doseV2)             |
| FEV1 (L)                                                   |                                                            |                                                            |                                                            |
| n                                                          | 576                                                        | 574                                                        | 1150                                                       |
| Mean (SD)                                                  | 1.869 (0.582)                                              | 1.869 (0.594)                                              | 1.869 (0.588)                                              |
| Median (min ; max)                                         | 1.803 (0.65 ; 3.76)                                        | 1.795 (0.67 ;4.53)                                         | 1.795 (0.65 ; 4.53)                                        |
| FEV (% predicted normal value)                             | FEV (% predicted normal value)                             | FEV (% predicted normal value)                             | FEV (% predicted normal value)                             |
| n                                                          | 576                                                        | 574                                                        | 1150                                                       |
| Mean (SD)                                                  | 60.2 (11.9)                                                | 59.6 (12.0)                                                | 59.9 (11.9)                                                |
| Median (min ; max)                                         | 62.0 (25 ; 83)                                             | 61.5 (21 ; 86)                                             | 62.0 (21 ; 86)                                             |
| Post-salbutamol lung function parameters at screening (V1) | Post-salbutamol lung function parameters at screening (V1) | Post-salbutamol lung function parameters at screening (V1) | Post-salbutamol lung function parameters at screening (V1) |
| n                                                          | 576                                                        | 574                                                        | 1150                                                       |
| Mean (SD)                                                  | 506.9 (265.1)                                              | 498.7 (300.0)                                              | 502.8 (283.0)                                              |
| Median (min ; max)                                         | 430.0 (210 ; 2180)                                         | 410.0 (210 ; 2410)                                         | 420.0 (210 ; 2410)                                         |
| △FEV: (200-400 mL], n (%)                                  | 259 (45.0)                                                 | 279 (48.6)                                                 | 538 (46.8)                                                 |
| △FEV: > 400 mL, n (%)                                      | 317 (55.0)                                                 | 295 (51.4)                                                 | 612 (53.2)                                                 |
| Reversibility (%)                                          | Reversibility (%)                                          | Reversibility (%)                                          | Reversibility (%)                                          |
| n                                                          | 576                                                        | 574                                                        | 1150                                                       |
| Mean (SD)                                                  | 32.53 (24.72)                                              | 30.80 (20.53)                                              | 31.66 (22.73)                                              |
| Median (min ; max)                                         | 26.25 (12.1 ; 419.2)                                       | 25.15 (12.1 ; 163.0)                                       | 25.65 (12.1 ; 419.2)                                       |

## Co-primary variable

The  primary  efficacy  objective  of  this  clinical  trial  was  met.  CHF 5993  was  found  to  be  superior  to CHF 1535 for the two pre-defined co-primary endpoints as outlined below.

- -change form baseline in pre-dose FEV1 at week 26

Compared with  baseline  (visit  V2),  a  statistically  significant  increase  in  FEV1  was  observed  in  both treatment groups of the ITT population. The adjusted mean difference (95%CI) between treatments was +0.057 L ([0.015; 0.099], p=0.008) , thus formally confirming the superiority of triple treatment with CHF 5993 over dual treatment with CHF 1535.

From a clinical point of view, the effect size was modest and did not achieve the MCID of ≥100 mL (though this threshold has not been rigorously established in asthma patients). It is noted, however, that in both trials, randomised trial medication was given after the standardisation / stabilisation during the two-week run-in period with ICS/LABA maintenance therapy. Reportedly, a relevant improvement in pre-dose FEV1 of about +140 mL was already achieved during these two weeks in both groups. This may serve as an explanation why the room for further improvement during subsequent randomised treatment period was limited.

<div style=\"page-break-after: always\"></div>

On  the  other  hand,  this  effect  size  was  not  consistently  maintained  over  the  52-week  randomized treatment period. Upon visit V7 ( week 52 ), the adjusted mean difference in pre-dose FEV1 amounted to +38 mL [95%CI: -7 mL; 82 mL] only and no longer achieved statistical significance.

Table 11: Change form baseline in pre-dose FEV1 (L) at week 26 - ITT population

|                           |                                                        |                               | CHF 5993 pMDI 100/6/12.5 μg N=575   | CHF 1535 pMDI 100/6 μg N=574   |
|---------------------------|--------------------------------------------------------|-------------------------------|-------------------------------------|--------------------------------|
| Baseline (Week Opre-dose) | Baseline (Week Opre-dose)                              | n                             | 575                                 | 574                            |
|                           |                                                        | Mean (SD)                     | 1.869 (0.582)                       | 1.869 (0.594)                  |
| Week 26                   | Actual values                                          | n                             | 557                                 | 553                            |
| Week 26                   | Change from Baseline                                   | Mean (SD)                     | 2.059 (0.662)                       | 1.984 (0.679)                  |
|                           |                                                        |                               | 557                                 | 553                            |
|                           |                                                        | Mean (SD)                     | 0.186 (0.357)                       | 0.129 (0.369)                  |
|                           |                                                        | Adj. mean (95% CI)            | 0.185 (0.155; 0.214)                | 0.127 (0.098; 0.157)           |
|                           |                                                        | p-value                       | <0.001                              | <0.001                         |
|                           | CHF 5993 pMDI 100/6/12.5 μg vs. CHF 1535 pMDI 100/6 μg | Adj. mean difference (95% CI) | 0.057 (0.015; 0.099)                | 0.057 (0.015; 0.099)           |
|                           |                                                        | p-value                       | 0.008                               | 0.008                          |

Adj. = Adjusted; CI = Confidence interval; FEV1 = Forced expiratory volume in the 1st second; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; SD = Standard deviation; vs. = Versus.

N = Number of patients in the ITT population; n = Number of patients with available data.

Figure 3: Adjusted mean change from baseline in pre-dose FEV1 (L), CHF 5993 vs. CHF 1535, ITT population

<!-- image -->

<div style=\"page-break-after: always\"></div>

## -moderate to severe asthma exacerbation rate at week 52

The total number of moderate to severe asthma exacerbations during the study treatment period was 1'044 events in group CHF 5993 and 1'215 events in group CHF 1535.

About three-fifths of patients (CHF 5993: 58.6% ;  CHF 1535: 66.5% )  had experienced at least one moderate  to  severe  exacerbation  during  the  52-week  treatment  period,  resulting  in  an  adjusted annualized rate of moderate to severe exacerbations per patient of 1.825 (CHF5993; 95%CI [1.634; 2.037]) and 2.157 (CHF1535; 95%CI [1.937; 2.402]). Based on these figures, a statistically significant 15.4%  reduction in  the  adjusted  rate  ratio  of  these  events  was  calculated  (p=0.033),  thereby confirming the superiority of CHF 5993 over CHF 1535 for this parameter.

Similar results were achieved for this parameter in the PP population where the adjusted rate ratio (point estimator 0.849, 95%CI [0.724; 0.995]) was indicative of a statistically significant 15.1% reduction in exacerbation rate with CHF 5993.

Table 12: Moderate to severe asthma exacerbations - ITT population

|                                             |                                                        |                                                     | CHF5993pMDI 100/6/12.5 μg N=575   | CHF 1535 pMDI 100/6 μg N=574   |
|---------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|-----------------------------------|--------------------------------|
| Total followup time (year's)                | Total followup time (year's)                           | Total followup time (year's)                        | 559.83                            | 554.97                         |
| Allmoderate and severe asthma exacerbations | Number of patients with exacerbations (%)              | Number of patients with exacerbations (%)           | 337 (58.6)                        | 379 (66.0)                     |
| Allmoderate and severe asthma exacerbations | Number of exacerbations                                | Number of exacerbations                             | 1044                              | 1215                           |
| Allmoderate and severe asthma exacerbations | Exacerbation rate per patient per year                 | Exacerbation rate per patient per year              | 1.865                             | 2.189                          |
| Allmoderate and severe asthma exacerbations | Adj.exacerbation rate per patient per year (95% CI)    | Adj.exacerbation rate per patient per year (95% CI) | 1.825 (1.634; 2.037)              | 2.157 (1.937; 2.402)           |
| Allmoderate and severe asthma exacerbations | CHF 5993 pMDI 100/6/12.5 μg vs. CHF 1535 pMDI 100/6 μg | Adj.rate ratio (95% CI)                             | 0.846 (0.725; 0.987)              | 0.846 (0.725; 0.987)           |
| Allmoderate and severe asthma exacerbations | CHF 5993 pMDI 100/6/12.5 μg vs. CHF 1535 pMDI 100/6 μg | p-value                                             | 0.033                             | 0.033                          |

Adj. = Adjusted; CI = Confidence interval; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; vs. = Versus. N = Number of patients in the ITT population.

## Key secondary variables

From a statistical point of view, CHF 5993 was shown to be superior to CHF 1535 in terms of two out of three key secondary efficacy variables (post-dose peak FEV1 [0-3h]) and average morning PEF, both assessed at week W26). Although results for both key secondary variables were statistically significantly in favour of CHF 5993, their clinical relevance is questionable.

A relative reduction in the adjusted rate of severe asthma exacerbations over the 52 weeks of 23.0% was calculated for CHF5993 in the pre-defined, pooled analysis of both pivotal trials. However, since a hierarchical testing or 'gatekeeping' procedure was pre-defined by the MAH and since the second pivotal trial failed to achieve its primary objective, no confirmatory claims and formal conclusions about the efficacy of CHF 5993 can be based on this variable.

## -change from baseline in post-dose peak FEV1 (0-3h) at week 26

Compared with baseline (visit V2), statistically significant increases in adjusted means of post-dose peak FEV1 (0-3h) were observed in groups CHF 5993 (point estimate: +0.485 L, 95%CI [0.453; 0.516]) and CHF 1535 (point estimate: +0.401 L, 95%CI [0.369; 0.432]) (results of ITT population). The adjusted mean  difference  (95%CI)  between  treatments  was +0.084 L ([0.040;  0.129],  p&lt;0.001) ,  thus confirming the superiority of triple treatment with CHF 5993 over dual treatment with CHF 1535 (Figure below).

<div style=\"page-break-after: always\"></div>

Sensitivity analyses (ITT population) and analyses based on the PP population had similar result than what is described above for the ITT population.

Figure 4: adjusted mean change from baseline in post-dose peak FEV1 (0-3h) (L) over 52 weeks of treatment (ITT population)

<!-- image -->

## -change from baseline in average morning PEF at week 26

The average morning PEF at baseline (calculated as average over the run-in period) was comparable for the two treatment groups and about 300 L/min.

Compared with baseline (visit V2), a small, but statistically significant increase in adjusted means of PEF (L/min) was observed in treatment group CHF 5993 at week W26 (point estimate: +5.325 L/min , 95%CI  [1.921;  8.729])  while  for  the  comparator  CHF 1535,  a  minor  and  non-significant  decrease occurred  (point  estimate: -3.131 L/min ,  95%CI  [-6.533;  0.271])  (results  of  ITT  population).  The adjusted  mean  difference  between  treatments  was  small  (point  estimate: +8.456 L/min ,  95%CI [3.643; 13.269]), in favour of CHF 5993, and statistically significant (Figure below).

<div style=\"page-break-after: always\"></div>

Figure 5: Adjusted mean change from baseline in average morning PEF (L/min) over 52 weeks of treatment (ITT population)

<!-- image -->

- -severe asthma exacerbation rate over 52 weeks of treatment in the pooled analysis of the two pivotal trials

The co-primary endpoint in the second pivotal study (TRIGGER) in terms of the rate of moderate to severe asthma exacerbations over the 52-week treatment period missed its target and did not achieve a statistically significant result.

Therefore, results of this pooled analysis are presented for descriptive purposes only with nominal p-values .

Both the proportion of patients with severe exacerbations, and the number of these events were lower for CHF 5993 MS+HS (18.2% and 303 events, respectively) as compared with CHF 1535 MS+HS (22.4% and 389 events, respectively) (Table below).

This  difference  did  result  in  a  lower  adjusted  annual  exacerbation  rate  per  patient  with  CHF 5993 (adjusted rate ratio of 0.239) as compared with CHF 1535 (adjusted rate ratio of 0.310), equivalent to a reduction in the rate of severe asthma exacerbations of 23.0% (point estimator of adjusted rate ratio between treatments of 0.770, 95%CI 0.6360.933 , p=0.008).

Sensitivity analyses and the analysis in the PP population exhibited overall comparable results. In the PP analysis, the adjusted rate ratio was 0.757 (95%CI 0.622-0.921), corresponding to a reduction in the rate of severe asthma exacerbations of 24.3%.

<div style=\"page-break-after: always\"></div>

Table 13: Severe asthma exacerbations, pooled analysis of TRIMARAN &amp; TRIGGER - ITT population

|                                 |                                                                                       |                                                          | CHF5993pMDI 100/6/12.5 μg and 200/6/12.5 μg N=1146   | CHF1535pMDI 100/6 μg and 200/6 μg N=1145   |
|---------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|--------------------------------------------|
| Total followup time (year's)    | Total followup time (year's)                                                          | Total followup time (year's)                             | 1114.45                                              | 1106.66                                    |
| All severe asthma exacerbations | Number of patients with exacerbations (%)                                             | Number of patients with exacerbations (%)                | 209 (18.2)                                           | 257 (22.4)                                 |
| All severe asthma exacerbations | Number of exacerbations                                                               | Number of exacerbations                                  | 303                                                  | 389                                        |
| All severe asthma exacerbations | Exacerbation rate per patient per year                                                | Exacerbation rate per patient per year                   | 0.272                                                | 0.352                                      |
| All severe asthma exacerbations | Adjusted exacerbation rate per patient per year (95% CI)                              | Adjusted exacerbation rate per patient per year (95% CI) | 0.239 (0.206; 0.276)                                 | 0.310 (0.271; 0.354)                       |
| All severe asthma exacerbations | CHF 5993 pMDI 100/6/12.5 μg and 200/6/12.5 μg vs. CHF 1535 pMDI 100/6 μg and 200/6 μg | Adj. rate ratio (95% CI)                                 | 0.770 (0.636; 0.933)                                 | 0.770 (0.636; 0.933)                       |
| All severe asthma exacerbations |                                                                                       | p-value                                                  | 0.008                                                | 0.008                                      |

Adj. = Adjusted; CI = Confidence interval; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; vs. = Versus.

N = Number of patients in the pooled ITT population.

## Other secondary variables

In  both  treatment  groups,  significant  improvements  in  a  number  of secondary  spirometric measurements were observed. The effect was evident at week W4 already and overall sustained over the entire treatment period. Numerically, increases were consistently greater in group CHF 5993 than in group CHF 1535. Though the between-group differences were statistically significant in favour of triple treatment at all measurement times (change from baseline in post-dose peak FEV1 [0-3h]) or isolated measurement times only (change from baseline in pre-dose FEV1, percentage of FEV1 responders), improvements from baseline were relatively small (10% or less) and of debatable clinical relevance.

For neither of the variables of patient-reported asthma control, an added benefit was demonstrable when a second controller medication (i.e. glycopyrronium bromide, LAMA) was added to the dual fixed-dose combination regimen (CHF1535 100/6).

<div style=\"page-break-after: always\"></div>

A relevant proportion of patients in both groups reported a symptomatic improvement exceeding the minimal clinically important difference (MCID) for ACQ-7 . However, no added benefit on symptomatic asthma control was detectable with CHF 5993. This result was independent of the type of analysis:

- -change from baseline in ACQ-7 score at consecutive site visit (Figure below);
- -percentage of ACQ-7 response at weeks 26 and 52 (i.e. change from baseline in ACQ7 score ≤ -0.5)

Though  numerically  higher  in  group  CHF 5993  at  isolated  measurement  times,  the  percentage  of 'responders' was comparable between treatment groups, and the between-group difference did not reach statistical significance (CHF 5993 vs. CHF 1535: week W26 55.1% vs. 50.7%; week W52 60.9% vs. 59.2%).

Figure 6: Adjusted mean change from baseline in the ACQ-7 score (points) at each visit, CHF 5993 vs. CHF 1535, ITT population

<!-- image -->

Several analyses for exacerbation-related secondary endpoints go in the same direction and appear to confirm an advantage in favour of treatment with CHF 5993. Depending on the variable, the effect size is, however, moderately low.

- -time to first moderate to severe asthma exacerbation

The time to the first moderate to severe asthma exacerbation was statistically significantly prolonged with CHF 5993 as compared with CHF 1535 (hazard ratio of 0.842 at week W52, 95%CI [0.727; 0.975 ], p=0.022).

- -pooled analysis of the rate of moderate to severe asthma exacerbations over the 52-week treatment period

After  pooling  the  results of  both  pivotal  studies,  the  proportion of  patients with  moderate  to  severe asthma exacerbations and the adjusted yearly exacerbation rate at week W52 were lower in group CHF 5993 as reflected by the 13.8% reduction in adjusted between-group rate ratio (point estimator: 0.862, 95%CI [0.772; 0.963 ], p=0.008).

<div style=\"page-break-after: always\"></div>

- -pooled analysis of the time to first severe asthma exacerbation

In the pooled analysis of data up to 52 weeks of treatment (Cox proportional hazards analysis), CHF 5993 prolonged the time to first severe exacerbation in a statistically significant manner (hazard ratio of 0.788, 95%CI [0.656; 0. 946 ], p=0.011 ).

In  comparison  with  dual  treatment  (CHF1535  199/6),  add-on  therapy  with  glycopyrronium  bromide (CHF5993  100/6/12.5)  had  no  relevant  influence  on  the use  of  rescue  medication in  the  study population enrolled.

Similarly, comparable improvements from baseline in daily asthma symptoms (cough, wheeze, chest tightness, breathlessness) and calculated scores were observed in the two treatment groups with no statistically significant between-group differences (Figure below).

The same applies to the change in baseline in the percentage of asthma symptom-free days and asthma control days in each inter-visit period over the 26- and 52-week treatment periods.

Figure 7: Adjusted mean change (95%CI) from baseline in average daily symptom score of chest tightness (left) and breathlessness (right) during run-in and over the 52 weeks of treatment (ITT population)

<!-- image -->

I nt er-vi sit Period

## Exploratory variables

Patients in both treatment groups self-reported comparable improvements in both index and VAS values of HRQoL (based on EQ-5D-3L as a standardized, validated instrument for measuring generic health status and health-related quality of life). The addition of a second controller medication (i.e. GB) did not result in a measurable between-group difference.

## Ancillary analyses

Post hoc statistical analyses were performed by the MAH in order to assess the rates of severe asthma exacerbations in the individual pivotal studies (TRIMARAN and TRIGGER).

In the TRIMARAN study, the adjusted, annual exacerbation rate in groups CHF 5993 and CHF 1535 was 0.204 (95%CI 0.164-0.255) and 0.277 (95%CI 0.226-0.339), respectively (analysis based on a negative binomial model including treatment, country and number of asthma exacerbations in the previous year

I nt er-vi sit Peri od

<div style=\"page-break-after: always\"></div>

as fixed effects, and log-time on study as an offset). This resulted in an adjusted rate ratio of 0.737 (95%CI 0.5510.987 , p=0.04) or a 26.3% reduction in the rate of severe asthma exacerbations.

## Study CCD-05993AB2-02 - TRIGGER (Eudra-CT 2015-000717-40)

## Trial title

A 52 week, randomized, double-blind, multinational, multicenter, active controlled, 3-arm parallel group trial comparing  CHF 5993  200/6/12.5 µg  pMDI  (fixed  combination  of  extrafine  beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate) alone or on top of openlabel  tiotropium  2.5 µg  Respimat  in  patients  with  asthma  uncontrolled  on  high  doses  of  inhaled corticosteroids in combination with long-acting ß2-agonists.

## Methods

This was a randomized, double-blind multicenter trial with three parallel treatment groups and a total treatment duration of 52 weeks. The study comprised the following (Figure 9):

- a screening visit (visit V1);
- a run-in period of two weeks where all eligible patients received dual treatment with CHF 1535 200/6 (two puffs bid) in order to ' standardise ' and/or ' stabilise ' the intended study population on the same treatment;
- a 52-week treatment period with a total of five return visits (weeks 4, 12, 26, 40 and 52, visits V3 to V7), whereby the last visit corresponded to the end-of-trial visit (i.e. no follow-up period after discontinuation of study treatment).

## Study Participants

With one exception, main inclusion and exclusion criteria corresponded to those applied in the parallel trial (TRIMARAN) and were:

- -both gender, aged ≥18 and ≤75 years;
- -asthma onset before the age of 40 and documented history for at least one (1) year;
- -uncontrolled asthma on double therapy ( high dose ICS in combination with LABA [i.e. &gt;1'000 µg non-extrafine BDP per day or equivalent dose], stable dose for at least four weeks prior to screening) as evidenced by a ACQ7 score of ≥1.5 (criterion met at screening and the end of run-in);
- -positive reversibility test at screening (ΔFEV1 &gt;12% and &gt;200 mL over baseline 10-15 minutes after inhaling 400μg of salbutamol pMDI; one repeat test possible prior to randomization);
- -pre-bronchodilator FEV1 &lt;80% of predicted normal value;
- -documented  history  of  one  or  more  asthma  exacerbations  requiring  treatment  with  systemic corticosteroids  or  emergency  department  visit  or  in-patient  hospitalisation  in  the  previous 12 months;
- -patients with a recent exacerbation (&lt;4 weeks prior to screening), having a diagnosis of COPD or a clinically significant cardiovascular condition (as based on investigator judgement) were excluded;
- -current smokers or exsmokers (cumulative exposure ≥10 pack-years or having stopped smoking less than one year prior to screening) were also excluded.

<div style=\"page-break-after: always\"></div>

Figure 8: Study design and schedule of visits (TRIGGER study)

<!-- image -->

BDP = Beclometasone dipropionate; BID = Twice daily; FF = Formoterol fumarate; GB = Glycopyrronium bromide; Max =Maximum;OD = Once daily;pMDI =Pressurised metered dose inhaler;R = Randomisation;Tio=Tiotropium; Wk(s) = Week(s).

Note: only the Treatment C (CHF 1535 pMDI 200/6 μg + tiotropium 2.5 μg) is an open-label arm.

## Treatments

Independent of the high dose ICS/LABA combination used before, all eligible patients were switched to CHF 1535  200/6  and  administered  2 puffs  bid  during  the  run-in  period  of  two  weeks  in  order  to ' standardise ' and/or ' stabilise ' the intended study population on the same treatment.

At the end of the run-in period, patients were then randomly assigned to receive one of three following study treatments for a total of 52 weeks (randomization in a ratio of 2:2:1 ).

- fixed triple dose combination CHF 5993 200/6/12.5, two puffs bid, total daily dose of BDP/FF/GB 400/24/50µg;
- fixed dual dose combination CHF 1535 200/6, two puffs bid, total daily dose of BDP/FF 400/24µg;
- fixed dual dose combination CHF 1535 200/6 + tiotropium 2.5 (open label arm; added to the study design for 'benchmarking' purposes with no formal hypothesis testing), two puffs bid for ICS/LABA and two puffs once daily (morning) for LAMA, total daily dose of BDP/FF 800/24µg and tiotropium 5µg (Respimat).

## Outcomes/endpoints

The same co-primary and key secondary endpoints as those used in the parallel TRIMARAN trial were defined.

The  co-primary  endpoint  combined  a  lung-function  parameter  (i.e.  pre-dose  FEV1  at  week 26)  and another clinically more relevant parameter (i.e. rate of moderate to severe exacerbations over 52 weeks of treatment). As mentioned above, the choice of these parameters is in line with the guideline on the clinical investigation of medicinal products for the treatment of asthma (CHMP/EWP/2922/01 rev.01).

<div style=\"page-break-after: always\"></div>

## Co-primary endpoint

- -change from baseline in pre-dose FEV1 at Week 26 (from visits V2 to V7, FEV1 was measured twice at -45min and -15min pre-dose);
- -rate of moderate to severe exacerbations over 52 weeks of treatment.

## Key secondary endpoints

- -change from baseline in post-dose peak FEV1 (0-3h) at Week 26;
- -change from baseline in the average morning PEF measured by patients at home over the 26-week treatment period (patients were instructed to perform to perform three (3) consecutive manoeuvres; the derived variable for statistical analysis was the highest PEF result out of a minimum of two measurements which were of 'good' quality; baseline was calculated as the average of all available PEF values measured by the patient during the run-in period [minimum number required: N=7]);
- -rate of severe asthma exacerbations over 52 weeks of treatment (pre-specified pooled analysis of data gathered in the two pivotal studies).

The criteria for what is a 'severe' asthma exacerbation episode were not exactly in line with current definitions recommended by EMA guidance (refer to TRIMARAN study for details). The definition used for 'moderate' asthma exacerbation episodes was sufficiently detailed to allow their consistent identification in both treatment groups, based on diary data. An arbitrary numerical criterion of 7 days was defined in the SAP to decide whether an event met the study criteria for a new exacerbation rather than being a relapse or continuation of a previously recorded exacerbation. This was considered acceptable.

To mitigate the consequences of a small sample size per pivotal trial and low background incidence of exacerbations, it was pre-defined by the MAH (and agreed upon in the SAWP) to pool the rate of «severe exacerbations over 52 weeks» across studies and to define this as a key secondary endpoint.

A central adjudication committee was in charge of evaluating all MACE.

Data in relation with asthma symptom / control and compliance with the investigational treatment were to be recorded by patients in an electronic diary (eDiary).

## Randomisation and blinding (masking)

A  balanced  block  randomisation  scheme  stratified  by  country  was  prepared.  Patients  were  centrally assigned to one of the three treatment arms in a 2:2:1 ratio, using an Interactive Response Technology (IRT) system. Patient numbers were centrally assigned via the IRT, starting with the pre-screening visit (visit V0).

The main test (CHF 5993) and comparator (CHF 1535) were administered via an identical fixed dose combination inhaler combining all individual components. Thereby, the blinding was guaranteed and no double dummy design for GB component was required. The group assigned to extemporaneous triple treatment (CHF1535 + tiotropium) was included in an open-label arm and used two inhalers.

## Statistical methods

Same as in the parallel trial, the Intention-to-Treat (ITT) population was the primary population for analysis and - in accordance with standard criteria - defined as all randomised patients who received at least  one  dose  of  IMP  and  who  had  at  least  one  post-baseline  assessment  of  efficacy  (primary  or secondary efficacy variables).

A hierarchical testing procedure was pre-defined for the comparisons between CHF 5993 and CHF 1535 and the following variables (by hierarchical order of assessment):

<div style=\"page-break-after: always\"></div>

1. change from baseline in pre-dose FEV1 at Week 26 and moderate and severe exacerbation rate over 52 weeks (co-primary endpoint);
2. change from baseline in peak0-3h FEV1 at Week 26 (key secondary endpoint 1);
3. change from baseline in morning PEF over 26 weeks (key secondary endpoint 2);
4. severe exacerbation rate over 52 weeks in the pooled analysis (key secondary endpoint 3).

Additional  descriptive  comparisons  (including  calculation  of  adjusted  mean  difference)  were  made between CHF5993 200/6/12.5 and the extemporaneous combination consisting of CHF 1535 200/6 and the recently approved LABA tiotropium 2.5.

## Results

The study was performed at 221 recruiting sites in 17 countries. Out of 2'100 patients screened, N=1437 (68.4%) were randomly allocated to one of the three treatment groups. FPFV was on 06 April 2016, LPLV on 28 May 2018.

As in the parallel clinical trial (TRIMARAN), the rate of premature discontinuation remained significantly below the prospected rate in both groups; the percentage of patients completing the 52-week treatment period was high and comparable between groups:

- CHF 5993

N=543/573, 93.2%

- CHF 1535

N=533/576, 92.5%

- CHF1535+tiotropium

N=262/288, 91.0%

## Numbers analysed, Baseline data

The disposition of subjects is graphically displayed in Figure below.

Overall, demographic characteristics and a sthma disease characteristics were balanced between the two treatment groups (Tables below). At study entry, about 88% of patients already used an ICS/LABA fixed combination  product,  and  only  about  12%  an  extemporary  combination.  Only  a  low  percentage  of patients (about 18-20% depending on the treatment arm) used a spacer device for administration of their orally inhaled products prior to study entry.

Spirometry . Upon screening, parameters of lung function were comparable between treatment groups. Median pre-bronchodilator FEV1 (in % of predicted normal value) was 53.0% and highly variable (min: 15%; max: 79%). Median FVC was 2.61 L and also exhibited a high variability (min: 0.67 L; max: 7.00 L).

In line with the inclusion criteria, FEV1 reversibility had to be confirmed in all eligible patients Following salbutamol, median FEV1 reversibility was 400.0 mL (min: 210 mL; max: 3140 mL) or 33.8% (min: 12.0%; max: 234.5%) with no relevant between-group differences.

<div style=\"page-break-after: always\"></div>

Figure 9: Disposition of patients

Excl. = Exclusion; Incl. = Inclusion; pMDI = Pressurised metered dose inhaler.

<!-- image -->

N =Number of patients.

Note:Re-screened patients are counted more than once.

<div style=\"page-break-after: always\"></div>

Table 14: Patient demography (extract) - safety population

|                 | CHF5993pMDI 200/6/12.5μg N=571   | CHF 1535 pMDI 200/6μg N=573   | CHF1535pMDI 200/6 μg + tiotropium 2.5 pg N=287   | Overall N=1431   |
|-----------------|----------------------------------|-------------------------------|--------------------------------------------------|------------------|
| Age (years)     |                                  |                               |                                                  |                  |
| n               | 571                              | 573                           | 287                                              | 1431             |
| Mean (SD)       | 53.1 (12.2)                      | 54.0 (11.9)                   | 51.6 (12.3)                                      | 53.2 (12.1)      |
| Median(min;max) | 55.0 (18;75)                     | 55.0 (18 ; 75)                | 53.0 (19 ;75)                                    | 54.0 (18 ; 75)   |
| Agegroup,n(%)   |                                  |                               |                                                  |                  |
| <65years        | 473 (82.8)                       | 450 (78.5)                    | 246 (85.7)                                       | 1169 (81.7)      |
| ≥65 years       | 98 (17.2)                        | 123 (21.5)                    | 41 (14.3)                                        | 262 (18.3)       |
| Gender,n (%)    |                                  |                               |                                                  |                  |
| Male            | 212 (37.1)                       | 245 (42.8)                    | 103 (35.9)                                       | 560 (39.1)       |
| Female          | 359 (62.9)                       | 328 (57.2)                    | 184 (64.1)                                       | 871 (60.9)       |

Table 15: Asthma disease characteristics - safety population

|                        | CHF 5993 pMDI 200/6/12.5 μg N=571   | CHF 1535 pMDI 200/6 μg N=573   | CHF 1535 pMDI 200/6 μg + tiotropium 2.5 pg N=287   | Overall N=1431      |
|------------------------|-------------------------------------|--------------------------------|----------------------------------------------------|---------------------|
| Age (years)            |                                     |                                |                                                    |                     |
| 11                     | 571                                 | 573                            | 287                                                | 1431                |
| Mean (SD)              | 53.1 (12.2)                         | 54.0 (11.9)                    | 51.6 (12.3)                                        | 53.2 (12.1)         |
| Median (min ; max)     | 55.0 (18 ; 75)                      | 55.0 (18 ; 75)                 | 53.0 (19 ; 75)                                     | 54.0 (18 ; 75)      |
| Age group, n (%)       |                                     |                                |                                                    |                     |
| < 65 years             | 473 (82.8)                          | 450 (78.5)                     | 246 (85.7)                                         | 1169 (81.7)         |
| ≥ 65 years             | 98 (17.2)                           | 123 (21.5)                     | 41 (14.3)                                          | 262 (18.3)          |
| Gender, n (%)          |                                     |                                |                                                    |                     |
| Male                   | 212 (37.1)                          | 245 (42.8)                     | 103 (35.9)                                         | 560 (39.1)          |
| Female                 | 359 (62.9)                          | 328 (57.2)                     | 184 (64.1)                                         | 871 (60.9)          |
| Race, n (%)            |                                     |                                |                                                    |                     |
| Asian                  | 2 (0.4)                             | 0 (0.0)                        | 0 (0.0)                                            | 2 (0.1)             |
| Black/African American | 0 (0.0)                             | 0 (0.0)                        | 0 (0.0)                                            | 0 (0.0)             |
| White                  | 569 (99.6)                          | 573 (100.0)                    | 286 (99.7)                                         | 1428 (99.8)         |
| Other                  | 0 (0.0)                             | 0 (0.0)                        | 1 (0.3)                                            | 1 (0.1)             |
| Weight (kg)            |                                     |                                |                                                    |                     |
| 11                     | 571                                 | 573                            | 287                                                | 1431                |
| Mean (SD)              | 79.9 (15.4)                         | 81.2 (17.2)                    | 79.4 (14.6)                                        | 80.3 (16.0)         |
| Median (min ; max)     | 80.0 (47 ; 130)                     | 81.0 (45 ; 165)                | 80.0 (46 ; 129)                                    | 80.0 (45 ; 165)     |
| Height (cm)            |                                     |                                |                                                    |                     |
| 11                     | 571                                 | 573                            | 287                                                | 1431                |
| Mean (SD)              | 167.9 (9.3)                         | 168.3 (9.1)                    | 167.3 (9.7)                                        | 167.9 (9.3)         |
| Median (min ; max)     | 167.0 (143 ; 198)                   | 168.0 (146 ; 196)              | 167.0 (144 ; 210)                                  | 167.0 (143 ; 210)   |
| BMI (kg/m²)            |                                     |                                |                                                    |                     |
| 11                     | 571                                 | 573                            | 287                                                | 1431                |
| Mean (SD)              | 28.36 (5.14)                        | 28.67 (5.87)                   | 28.46 (5.21)                                       | 28.50 (5.46)        |
| Median (min ; max)     | 27.90 (17.9 ; 49.3)                 | 27.90 (15.9 ; 55.1)            | 28.10 (15.0 ; 45.2)                                | 28.00 (15.0 ; 55.1) |

BMI = Body mass index; Max = Maximum; Min = Minimum; pMDI = Pressurised metered dose inhaler; SD = Standard deviation.

N = Number of patients in the Safety population; n = Number of patients with available data.

<div style=\"page-break-after: always\"></div>

Table 16: Lung function, spirometry results (extract) - safety population

upper part: pre-bronchodilator results at screening and baseline; lower part: FEV1 reversibility after bronchodilator at screening

|                                                            | CHF 5993 pMDI 200/6/12.5 μg N=571                          | CHF 1535 pMDI 200/6 μg N=573                               | CHF 1535 pMDI 200/6 μg + tiotropium 2.5 pg N=287           | Overall N=1431                                             |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Pre-salbutamol lung function parameters at screening (V1)  | Pre-salbutamol lung function parameters at screening (V1)  | Pre-salbutamol lung function parameters at screening (V1)  | Pre-salbutamol lung function parameters at screening (V1)  | Pre-salbutamol lung function parameters at screening (V1)  |
| FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   |
| n                                                          | 571                                                        | 573                                                        | 287                                                        | 1431                                                       |
| Mean (SD)                                                  | 1.586 (0.559)                                              | 1.600 (0.567)                                              | 1.611 (0.591)                                              | 1.597 (0.568)                                              |
| Median (min ; max)                                         | 1.510 (0.38 ; 3.55)                                        | 1.550 (0.54 ; 3.61)                                        | 1.550 (0.48 ; 3.89)                                        | 1.540 (0.38 ; 3.89)                                        |
| FEV1 (%predicted normal value)                             | FEV1 (%predicted normal value)                             | FEV1 (%predicted normal value)                             | FEV1 (%predicted normal value)                             | FEV1 (%predicted normal value)                             |
| n                                                          | 571                                                        | 573                                                        | 287                                                        | 1431                                                       |
| Mean (SD)                                                  | 51.9 (13.5)                                                | 51.8 (13.5)                                                | 52.1 (13.2)                                                | 51.9 (13.4)                                                |
| Median (min ; max)                                         | 53.0 (15 ;79)                                              | 52.0 (16 ; 79)                                             | 53.0 (22 ; 79)                                             | 53.0 (15 ;79)                                              |
| Lung function parameters at baseline (pre-dose V2)         | Lung function parameters at baseline (pre-dose V2)         | Lung function parameters at baseline (pre-dose V2)         | Lung function parameters at baseline (pre-dose V2)         | Lung function parameters at baseline (pre-dose V2)         |
| FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   |
| n                                                          | 570                                                        | 570                                                        | 287                                                        | 1427                                                       |
| Mean (SD)                                                  | 1.746 (0.551)                                              | 1.750 (0.567)                                              | 1.743 (0.570)                                              | 1.747 (0.561)                                              |
| Median (min ; max)                                         | 1.673 (0.57 ; 3.69)                                        | 1.705 (0.59 ; 4.00)                                        | 1.685 (0.52 ; 3.60)                                        | 1.685 (0.52 ; 4.00)                                        |
| FEV1 (% predicted normal value)                            | FEV1 (% predicted normal value)                            | FEV1 (% predicted normal value)                            | FEV1 (% predicted normal value)                            | FEV1 (% predicted normal value)                            |
| n                                                          | 570                                                        | 570                                                        | 287                                                        | 1427                                                       |
| Mean (SD)                                                  | 57.2 (12.6)                                                | 56.9 (13.1)                                                | 56.7 (12.5)                                                | 57.0 (12.8)                                                |
| Median (min ; max)                                         | 58.5 (16 ; 82)                                             | 59.0 (19 ; 82)                                             | 58.0 (25 ; 78)                                             | 58.5 (16 ; 82)                                             |
| Post-salbutamol lung function parameters at screening (V1) | Post-salbutamol lung function parameters at screening (V1) | Post-salbutamol lung function parameters at screening (V1) | Post-salbutamol lung function parameters at screening (V1) | Post-salbutamol lung function parameters at screening (V1) |
| FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   | FEV1 (L)                                                   |
| n                                                          | 570                                                        | 573                                                        | 287                                                        | 1430                                                       |
| Mean (SD)                                                  | 2.073 (0.686)                                              | 2.092 (0.671)                                              | 2.119 (0.730)                                              | 2.090 (0.689)                                              |
| Median (min ; max)                                         | 2.005 (0.60 ; 5.13)                                        | 2.020 (0.85 ; 5.46)                                        | 2.030 (0.70 ; 4.85)                                        | 2.020 (0.60 ; 5.46)                                        |
| FEV1 (% of predicted normal value)                         | FEV1 (% of predicted normal value)                         | FEV1 (% of predicted normal value)                         | FEV1 (% of predicted normal value)                         | FEV1 (% of predicted normal value)                         |
| n                                                          | 570                                                        | 573                                                        | 287                                                        | 1430                                                       |
| Mean (SD)                                                  | 67.9 (16.1)                                                | 68.0 (15.6)                                                | 68.7 (15.8)                                                | 68.1 (15.8)                                                |
| Median (min ; max)                                         | 69.0 (21 ; 120)                                            | 69.0 (23 ; 113)                                            | 69.0 (32 ; 114)                                            | 69.0 (21 ; 120)                                            |
| Reversibility (%)                                          | Reversibility (%)                                          | Reversibility (%)                                          | Reversibility (%)                                          | Reversibility (%)                                          |
| n                                                          | 570                                                        | 573                                                        | 287                                                        | 1430                                                       |
| Mean (SD)                                                  | 33.23 (20.21)                                              | 33.87 (21.87)                                              | 34.89 (26.99)                                              | 33.82 (22.37)                                              |
| Median (min ; max)                                         | 26.75 (12.1 ; 147.9)                                       | 27.50 (12.0 ; 152.5)                                       | 27.00 (12.2 ;234.5)                                        | 27.10 (12.0 ; 234.5)                                       |

## Co-primary variable

The  primary  efficacy  objective  of  this  clinical  trial  was  not  met,  since  the  superiority  test  of  the exacerbation co-primary endpoint did not achieve statistical significance. Therefore, the statistical testing hierarchy was broken early and overall type-I error was no more preserved when testing lower-ranking key  secondary  endpoints.  As  a  consequence,  analysis  results  of  the  co-primary  endpoints  and  key secondary endpoints needed to be considered descriptive only and resulting p-values as nominal. Thus, the benefit of adding GB to high dose CHF1535 200/6 was not demonstrated in accordance with the 'Guideline on clinical development of fixed combination medicinal products' (EMA/CHMP/158268/2017).

## -change form baseline in pre-dose FEV1 at week 26

Compared with baseline (visit V2), statistically significant increases in FEV1 were observed in all three treatment  groups  of  the  ITT  population,  with  the  highest  numerical  change  being  observed  for  the extemporaneous open-label triple combination CHF1535 + tiotropium:

CHF5993 200/6/12.5

+0.229L (95%CI [0.196; 0.263]);

CHF1535 200/6

+0.157L (95%CI [0.123; 0.190]);

CHF1535 200/6 + tiotropium 2.5

+0.274L (95%CI [0.227; 0.321]).

<div style=\"page-break-after: always\"></div>

The  adjusted  mean  difference  (95%CI)  for  the  primary  comparison  (CHF  5993  vs.  CHF  1535)  was statistically significant (adjusted mean difference +0.073L (95% CI [0.026; 0.120], p=0.003), thereby confirming the superiority of triple treatment with CHF 5993 over dual treatment with CHF 1535.

Comparison of the two triple combinations numerically was in favour of the extemporaneous product, but this did not achieve statistical significance (adjusted mean difference -0.045L (95% CI [-0.103; 0.013], p=0.125).

Analysis based on the PP population overall confirmed this result. Though the adjusted mean difference was smaller ( +0.064L (95% CI [0.016; 0.112], p=0.009), it still achieved statistical significance.

The effect size between the two treatments was maintained over the entire 52-week treatment period; upon the last visit (week 52), the adjusted mean difference in pre-dose FEV1 between CHF5993 and CHF1535 was +0.086 L ([95%CI [0.038; 0.134], p&lt;0.001) (Figure 11).  Similarly, results numerically favoured  the  extemporaneous triple  combination,  though this  did  not  achieve  statistical  significance (adjusted mean difference -0.028L (95% CI [-0.087; 0.030], p=0.347).

Table 17: Change form baseline in pre-dose FEV1 (L) at week 26 - ITT population

|                   |                                                                          |                               | CHF 5993 pMDI 200/6/12.5 μg N=571   | CHF 1535 pMDI 200/6 μg N=571   | CHF 1535 pMDI 200/6 μg + tiotropium 2.5 μg N=287   |
|-------------------|--------------------------------------------------------------------------|-------------------------------|-------------------------------------|--------------------------------|----------------------------------------------------|
| Baseline          | Baseline                                                                 | 1n                            | 570                                 | 568                            | 287                                                |
| (Week 0 pre-dose) | (Week 0 pre-dose)                                                        | Mean (SD)                     | 1.746 (0.551)                       | 1.748 (0.567)                  | 1.743 (0.570)                                      |
| Week 26           | Actual values                                                            | n                             | 552                                 | 549                            | 275                                                |
| Week 26           |                                                                          | Mean (SD)                     | 1.979 (0.682)                       | 1.912 (0.687)                  | 2.023 (0.741)                                      |
| Week 26           | Change from Baseline                                                     | n1                            | 551                                 | 547                            | 275                                                |
| Week 26           |                                                                          | Mean (SD)                     | 0.227 (0.405)                       | 0.157 (0.387)                  | 0.276 (0.436)                                      |
| Week 26           |                                                                          | Adj. mean (95% CI)            | 0.229 (0.196; 0.263)                | 0.157 (0.123; 0.190)           | 0.274 (0.227; 0.321)                               |
| Week 26           |                                                                          | p-value                       | <0.001                              | <0.001                         | <0.001                                             |
| Week 26           | CHF 5993 pMDI 200/6/12.5 pg vs. CHF 1535 pMDI                            | Adj. mean difference (95% CI) | 0.073 (0.026; 0.120)                | 0.073 (0.026; 0.120)           | 0.073 (0.026; 0.120)                               |
| Week 26           | 200/6 μg                                                                 | p-value                       | 0.003                               | 0.003                          | 0.003                                              |
| Week 26           | CHF 5993 pMDI 200/6/12.5 pg vs. CHF 1535 pMDI 200/6 μg + tiotropium2.5ug | Adj. mean difference (95% CI) | -0.045 (-0.103; 0.013)              | -0.045 (-0.103; 0.013)         | -0.045 (-0.103; 0.013)                             |
| Week 26           |                                                                          | p-value                       | 0.125                               | 0.125                          | 0.125                                              |

Adj. = Adjusted; CI = Confidence interval; FEV1 = Forced expiratory volume in the 1t second; ITT = Intention-to-treat, pMDI = Pressurised metered dose inhaler; SD =Standard deviation; vs. =Versus.

N = Number of patients in the ITT population; n = Number of patients with available data.

<div style=\"page-break-after: always\"></div>

Table 18: Adjusted mean change from baseline in pre-dose FEV1 (L), CHF 5993 (A, in red) vs. CHF 1535 (B, in blue) vs. CHF1535 + tiotropium (C, in green), ITT population

<!-- image -->

## -moderate to severe asthma exacerbation rate at week 52

The total number of moderate to severe asthma exacerbations during the study treatment period was N=990 events  in  group  CHF 5993,  N=1'091  in  group  CHF 1535,  and  N=440  in  group  CHF1535  + tiotropium. Thus, the adjusted rate ratio of moderate to severe exacerbation per patient and year was in each of the three groups:

CHF5993 200/6/12.5

1.726 (95%CI [1.543; 1.932]);

CHF1535 200/6

1.963 (95%CI [1.757; 2.192]);

CHF1535 200/6 + tiotropium 2.5

1.613 (95%CI [1.373; 1.897]).

The  adjusted  rate  ratio  for  the  primary  comparison  was  indicative  of  a 12.0%  reduction in  the occurrence  of  these  events  in  favour  of  CHF  5993.  This  result,  however,  did  not  achieve  statistical significance  ( adjusted RR 0.880 ,  95%CI [0.751; 1.030], p=0.110 ),  and  thus  did  not  confirm  the superiority of CHF 5993 over CHF 1535 for this variable.

The proportion of patients with moderate to severe exacerbations was comparable in the two triple combination  groups  (CHF5993:  56.6%;  CHF1535  +  tiotropium:  56.4%)  though  adjusted  results numerically favoured the extemporaneous triple combination (CHF1535 200/6 + tiotropium).

Similar results were obtained for this parameter in the analysis of the PP population where the adjusted rate ratio was 0.878 (95%CI [0.749; 1.029]) and indicative of a 12.2% reduction in exacerbation rate with CHF 5993. However, as for the analysis based on the ITT population, the result did not achieve statistical significance.

<div style=\"page-break-after: always\"></div>

Table 19: Moderate to severe asthma exacerbations - ITT population

|                                             |                                                          |                                                          | CHF 5993pMDI 200/6/12.5 μg N=571   | CHF 1535 pMDI 200/6 μg N=571   | CHF 1535 pMDI 200/6 μg + tiotropium 2.5 g N=287   |
|---------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------|--------------------------------|---------------------------------------------------|
| Total follow up time (years)                | Total follow up time (years)                             | Total follow up time (years)                             | 554.62                             | 551.69                         | 274.21                                            |
| Allmoderate and severe asthma exacerbations | Number of patients with exacerbations (%)                | Number of patients with exacerbations (%)                | 323 (56.6)                         | 364 (63.7)                     | 162 (56.4)                                        |
| Allmoderate and severe asthma exacerbations | Number of exacerbations                                  | Number of exacerbations                                  | 990                                | 1091                           | 440                                               |
| Allmoderate and severe asthma exacerbations | Exacerbation rateper patient per year                    | Exacerbation rateper patient per year                    | 1.785                              | 1.978                          | 1.605                                             |
| Allmoderate and severe asthma exacerbations | Adjusted exacerbation rate per patient per year (95% CI) | Adjusted exacerbation rate per patient per year (95% CI) | 1.726 (1.543; 1.932)               | 1.963 (1.757; 2.192)           | 1.613 (1.373; 1.897)                              |
| Allmoderate and severe asthma exacerbations | CHF 5993 pMDI 200/6/12.5 pg vs. CHF 1535 pMDI            | Adj. rate ratio (95% CI)                                 | 0.880 (0.751; 1.030)               | 0.880 (0.751; 1.030)           | 0.880 (0.751; 1.030)                              |
| Allmoderate and severe asthma exacerbations | 200/6 μg                                                 | p-value                                                  | 0.110                              | 0.110                          | 0.110                                             |
| Allmoderate and severe asthma exacerbations | CHF 5993 pMDI 200/6/12.5 μg vs. CHF 1535 pMDI 200/6 μg + | Adj. rate ratio (95% CI)                                 | 1.070 (0.878; 1.303)               | 1.070 (0.878; 1.303)           | 1.070 (0.878; 1.303)                              |
| Allmoderate and severe asthma exacerbations | tiotropium 2.5 pg                                        | p-value                                                  | 0.502                              | 0.502                          | 0.502                                             |

Adj. = Adjusted; CI = Confidence interval; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler, vs. = Versus. N = Number of patients in the ITT population.

In order to put the failed demonstration of a significant effect of CHF 5993 HS on the rate of moderate to  severe  exacerbations  into  perspective,  the  MAH  submitted  additional  ( post  hoc )  analyses  of  the TRIGGER study and discussed their clinical relevance.

A central element of the MAH's response were analyses focussing on a patient subpopulation of the TRIGGER  study,  i.e.,  patients  with persistent  airflow  limitation ( PAL ),  defined  as  a  postbronchodilator (400 mcg salbutamol pMDI) FEV1 ≤80% and a Tiffeneau index (FEV1/FVC ratio) ≤0.7. A little less than two thirds of patients in the ITT dataset (62.5% and 60.6% in groups CHF 5993 and CHF 1535, respectively) met these post  hoc selection  criteria.  According  to  the  MAH,  this  TRIGGER subgroup was more comparable to asthma patients included in the PrimoTinA studies assessing the effects if tiotropium was added to double treatment with high dose ICS / LABA (external control).

In this post hoc PAL subpopulation, (nominally) statistically significant and clinically relevant effect sizes in  terms of the exacerbation rates were achieved by CHF 5993 200/6/12.5. Accordingly, the rate of moderate to severe exacerbations was reduced by -25.9% , and that of severe exacerbations by -31.8% (Table 4 below). The effect size in terms of severe exacerbations was numerically larger than what was reported in the pooled analysis of the replicate PrimoTinA trials (risk reduction of -21% for the pooled results).

It was however noted that results from this exploratory subgroup analysis needed to be interpreted with caution, as the focus on patients with PAL and the marked improvement observed might be suggestive of a relevant selection bias.

In addition to the cross-study comparison (TRIGGER vs. PrimoTinA studies), within-study comparisons were performed with the open-label, active comparator arm of the TRIGGER study (CHF 1535 200/6 plus tiotropium) which was added to the study for ' benchmarking '  purposes, i.e. to verify that CHF 5993 200/6/12.5 had a « similar effect on key endpoints ».

The extemporaneous triple group (CHF 1535 200/6 plus tiotropium 2.5) also outperformed dual therapy, thereby demonstrating assay sensitivity, i.e. the ability of the study to detect between-group differences.

<div style=\"page-break-after: always\"></div>

Numerically, the reduction in the rate of moderate to severe exacerbations was highest in this group. This was even more obvious when considering the rate of severe exacerbations. Compared with the dual treatment arm, the risk reduction in the entire group (i.e., group not limited to patients with PAL) was in the same order of magnitude (adjusted rate ratio 0.640, 95%CI [0.458;0.895], p=0.009) as for the PAL subgroup of CHF1535 200/6/12.5.

Table 20: TRIGGER study - Rate of Asthma exacerbation analysis - PAL subset

|                                         |                    | BDP/FF/GB 200/6/12.5 N=357   | BDP/FF 200/6 N=346   | Adjusted RateRatio           |
|-----------------------------------------|--------------------|------------------------------|----------------------|------------------------------|
| Moderate/severeasthma exacerbationsrate | Adj. rate (95% CI) | 1.651 (1.436, 1.896)         | 2.226 (1.946, 2.547) | 0.741 (0.611, 0.900) p=0.002 |
| Moderateasthma exacerbationsrate        | Adj. rate (95% CI) | 1.369 (1.174, 1.598)         | 1.812 (1.560, 2.106) | 0.756 (0.609, 0.937) p=0.011 |
| Severeasthma exacerbationsrate          | Adj. rate (95% CI) | 0.262 (0.205; 0.334)         | 0.384 (0.309; 0.478) | 0.682 (0.494; 0.940) p=0.019 |

N=Number of patients in the ITT population in the PAL subset

## Key secondary variables

As mentioned above, p-values reported in this trial for all three key secondary efficacy variables need to be considered nominal values as the hierarchical testing strategy was broken at the level of the coprimary efficacy variable.

CHF 5993 was shown to be superior to CHF 1535 in terms of post-dose peak FEV1 (0-3h) and average morning PEF, both assessed at week W26. The clinical relevance of the observed effect size is however questionable. As mentioned above, according to the pre-defined, pooled analysis (including results of both pivotal trials) the relative reduction in the adjusted rate of severe asthma exacerbations over the 52 weeks was calculated to be 23.0% .

- -change from baseline in post-dose peak FEV1 (0-3h) at week 26

Compared with baseline (visit V2), statistically significant increases in adjusted means of post-dose peak FEV1 (0-3h) were observed in all three treatment groups (results of the ITT analysis):

- -CHF 5993: +0.522 L, 95%CI [0.488; 0.556];
- -CHF 1535: +0.417 L, 95%CI [0.383; 0.451];
- -CHF1535 + tiotropium: +0.555 L, 95%CI [0.507; 0.603].

The adjusted mean difference (95%CI) between the two primary treatments was +0.105 L ([0.057; 0.153],  p&lt;0.001),  thereby  confirming  the  superiority  of  triple  treatment  with  CHF 5993  over  dual treatment with CHF 1535 (Figure below).

Sensitivity analyses (ITT population) and analyses based on the PP population showed similar result than what is described above for the ITT population.

<div style=\"page-break-after: always\"></div>

Figure 10: Adjusted mean change from baseline in post-dose peak FEV1 (0-3h) (L) over 52 weeks of

## treatment (ITT population)

<!-- image -->

Week

<div style=\"page-break-after: always\"></div>

## -change from baseline in average morning PEF at week 26

The average morning PEF at baseline (calculated as average over the run-in period) was comparable for the two treatment groups and about 280 L/min.

Compared with baseline (visit V2), a small, but statistically significant increase in adjusted means of PEF (L/min)  was  observed  in  the  two  triple  treatment  groups  by  week  W26  (CHF 5993:  point  estimate +10.102 L/min ,  95%CI  [6.717;  13.487];  CHF1535+tiotropium: +10.286 L/min ,  95%CI  [5.540; 15.032]).  A  smaller  effect  was  seen  for  the  dual  treatment  comparator  CHF 1535  (point  estimate: 2.297 L/min ,  95%CI  [-1.091;  5.684])  (results  of  ITT  population).  The  adjusted  mean  difference between  the  two  primary  treatments  was  small  (point  estimate: +7.805 L/min ,  95%CI  [3.016; 12.594]), in favour of CHF 5993, and statistically significant (Figure below).

## -severe asthma exacerbation rate over 52 weeks of treatment in the pooled analysis of the two pivotal trials

Results of the pre-defined pooled analysis for the rate of severe asthma exacerbations have already been presented above. Compared with CHF 1535, treatment with CHF 5993 resulted in a reduction in the rate of these events by 23.0% (point estimator of adjusted rate ratio between treatments of 0.770, 95%CI 0.6360.933 , p=0.008). It is reminded that results need to be considered nominal only.

Figure 11: Adjusted mean change from baseline in average morning PEF (L/min) over 52 weeks of treatment (ITT population)

<!-- image -->

Inter-visitPeriod

<div style=\"page-break-after: always\"></div>

In relation with the pooled analysis of severe exacerbations, effort was spent on the demonstration that  pooled  results  (TRIMARAN  and  TRIGGER  exacerbation  data  pooled  across  the  arms  receiving different background doses of ICS) were not confounded to a relevant degree by the ICS doses received as ICS are known to markedly influence the exacerbation endpoint.

Further statistical analyses presented by the MAH supported the admissibility of the pooled analysis . Though patients enrolled in the TRIGGER study differed in some baseline characteristics (e.g. more severe airflow obstruction, greater proportion of patients with BMI &gt;30kg/m2), comparative statistical calculations suggested the overall homogeneity of the patient populations enrolled in TRIMARAN and TRIGGER. More importantly, results of the sensitivity analyses produced no evidence that the addition of  the  LAMA  glycopyrronium  bromide  to  either  medium  dose  ICS  (TRIMARAN)  or  high  dose  ICS (TRIGGER) did have statistically significant, differential effects on the exacerbation endpoint, though, as could be expected, the effect of add-on treatment with GB was numerically smaller in the high dose CHF5993 arm (-20% reduction) as compared the medium dose CHF5993 arm (-26% reduction).

This  result  was  endorsed  by  the  study  results  published  for  another  fixed-dose  triple  combination product 1  where  the  background  ICS  dose  level  appeared  to  not  impact /  reduce  the  effect  (size) achievable by add-on treatment with a LAMA. However, conflicting results were obtained in another pivotal study 2  where high dose ICS / LABA treatment left almost no room for further improvement when the  LAMA was added to high-dose ICS. These facts suggested that there is no generally applicable scientific evidence for add-on treatment with a LAMA, but that each individual case must be analysed.

## Other secondary variables

In  all  three  treatment  groups,  significant  improvements  in  a  number  of secondary  spirometric measurements were observed. The effect was evident at week W4 already and overall sustained over the entire treatment period. Numerically, increases were consistently greater in the two triple treatment groups (CHF 5993 and CHF 1535 + tiotropium). Overall, improvements from baseline were small (10% or less) and of debatable clinical relevance. Solely in the responder analysis, the percentage of patients with a change from baseline in predose FEV1 of ≥100 mL was somewhat higher with CHF 5993 (odds ratios of 1.660 and 1.831 at week W26 and W52, respectively).

For neither of the variables of patient-reported asthma control, an added benefit was demonstrable when a second controller medication (i.e. glycopyrronium bromide, LAMA) was added to the dual fixed-dose combination regimen (CHF 1535 200/6).

A relevant proportion of patients in all three groups reported a symptomatic improvement exceeding the minimal clinically important difference (MCID) for ACQ-7 . However, no clinically relevant added benefit on  symptomatic  asthma  control  was  detectable  when  adding  a  second  controller.  This  result  was independent of the type of added controller medication (glycopyrronium bromide or tiotropium) or the type of analysis (change from baseline in ACQ-7 score or responder analysis).

- -change from baseline in ACQ-7 score at consecutive site visit: refer to Figure below;
- -percentage of ACQ-7 response at weeks 26 and 52 (i.e. change from baseline in ACQ7 score ≤ -0.5)

1 Kerstjens et  al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasoneindacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. The Lancet - Respiratory Medicine, available online 09JUL2020

2 Kerstjens et al . Captain Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, A Pre-Specified Subgroup Analysis. Am J Respir Crit Care Med 2020;201:A4209

<div style=\"page-break-after: always\"></div>

The percentage of patients classified as ACQ-7 responders was comparable at both measurement times (weeks W26 and W52) with no significant between-group differences:

|    |                      | week W26 (N%)   | week W52 (N%)   |
|----|----------------------|-----------------|-----------------|
| -  | CHF 5993             | 61.3%           | 62.3%           |
| -  | CHF 1535             | 55.9%           | 58.1%           |
| -  | CHF1535 + tiotropium | 62.7%           | 58.5%           |

Figure 12: Adjusted mean change from baseline in the ACQ-7 score (points) at each visit, CHF 5993 vs. CHF 1535, ITT population

<!-- image -->

<div style=\"page-break-after: always\"></div>

Analyses  for exacerbation-related  secondary  endpoints consistently  confirmed  treatment  with CHF 5993  to  result  in  more  favourable  effects  than  dual  treatment  (CHF  1535).  Depending  on  the variable, the effect size was, however, modest and of borderline clinical relevance. At the same time, post hoc analyses suggested that the extemporaneous triple combination performed markedly better for some of these variables.

- -time to first moderate to severe asthma exacerbation

The time to the first moderate to severe asthma exacerbation was statistically significantly prolonged with CHF 5993 as compared with CHF 1535 (hazard ratio of 0.799 at week W52, 95%CI [0.688; 0.929], p=0.003).

- -pooled analysis of the rate of moderate to severe asthma exacerbations over the 52-week treatment period

[ Same results as already included in the assessment of the TRIMARAN study ] After pooling the results of both pivotal studies, the proportion of patients with moderate to severe asthma exacerbations and the adjusted yearly exacerbation rate at week W52 were lower in group CHF 5993 as reflected by the 13.8% reduction in adjusted between-group rate ratio (point estimator: 0.862, 95%CI [0.772; 0.963 ], p=0.008).

- -pooled analysis of the time to first severe asthma exacerbation

[ Same results as already included in the assessment of the TRIMARAN study ] In the pooled analysis of data up to 52 weeks of treatment (Cox proportional hazards analysis), CHF 5993 prolonged the time to first  severe  exacerbation  in  a  statistically  significant  manner  (hazard  ratio  of  0.788,  95%CI  [0.656; 0. 946 ], p=0.011 ).

In comparison with dual treatment (CHF 1535 199/6), add-on therapy with glycopyrronium bromide (CHF  5993  100/6/12.5)  had  no  relevant  influence  on  the use  of  rescue  medication in  the  study population enrolled (Figure below).

Figure 13: Adjusted mean change (95%CI) from baseline in average rescue medication use (puffs/day) during run-in and over the 52 weeks of treatment (ITT population)

<!-- image -->

Inter-visit Period

<div style=\"page-break-after: always\"></div>

Similarly, comparable improvements from baseline in daily asthma symptoms (cough, wheeze, chest tightness, breathlessness) and calculated scores were observed in the two treatment groups with no statistically  significant  between-group  differences.  For  an  important  individual  symptom  (breathlessness), both triple combinations numerically performed better than CHF 1535, but this did not achieve statistical significance (Figure below).

For two variables (change in baseline in the percentage of asthma symptom-free days and asthma control days ), CHF 5993 on average performed better than either CHF1535 and the extemporaneous triple combination. This difference did neither achieve statistical significance nor was it clinically relevant.

Figure 14: Adjusted mean change (95%CI) from baseline in average daily symptom score of chest tightness (left) and breathlessness (right) during run-in and over the 52 weeks of treatment (ITT population)

<!-- image -->

Inter-visit Period

## Exploratory variables

Patients in all three treatment groups self-reported comparable improvements in both index and VAS values of HRQoL (based on EQ-5D-3L as a standardized, validated instrument for measuring generic health status and health-related quality of life). The addition of a second controller medication (i.e. GB) did not result in a measurable between-group difference

Utilisation of health care resources was very low in patients of all three treatment groups (in terms of number of hospital admissions, days spent in hospital, emergency room visits, unscheduled physician contacts or unplanned diagnostic/instrumental tests). Therefore, no group statistics were calculated and no health economic evaluation or economical modelling performed by the MAH.

## Ancillary analyses

Post hoc statistical analyses were performed by the MAH in order to assess the rates of severe asthma exacerbations in the individual pivotal studies (TRIMARAN and TRIGGER).

In  the  TRIGGER  study,  the  adjusted,  annual  exacerbation  rate  in  groups  CHF 5993  200/6/12.5  and CHF 1535  200/6  was 0.270 (95%CI  0.223-0.326)  and 0.339 (95%CI  0.284-0.404),  respectively (analysis  based  on  a  negative  binomial  model  including  treatment,  country  and  number  of  asthma exacerbations in the previous year as fixed effects, and log-time on study as an offset). This resulted in an adjusted rate ratio of 0.797 (95%CI 0.6191.027 , p=0.079 ) or a 20.3% reduction in the rate of severe asthma exacerbations. The extemporaneous triple combination (CHF1535 200/6 + tiotropium,

Inter-visit Period

<div style=\"page-break-after: always\"></div>

open  label)  numerically  performed  best  (adjusted  rate  ratio  vs.  CHF1535  200/6  of 0.640 ,  95%CI [0.458;0.895], p=0.009 ).

Table 21: Efficacy endpoints used in the two pivotal trials (CCD-05993AB1-03, TRIMARAN and CCD-05993AB2-02, TRIGGER)

| Endpoints and definitions   | Co-primary efficacy endpoint                                         | • Change from baseline in pre-dose FEV1 at Week 26; • Rate of moderate to severe exacerbations over 52 weeks of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions   | Key secondary efficacy endpoints                                     | • Change from baseline in peak0-3h FEV1 at Week 26; • Change from baseline in the average morning PEF measured by patients at home over the 26-week treatment period; • Severe asthma exacerbation rate over 52 weeks of treatment in a pre-specified pooled analysis of the two pivotal studies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Endpoints and definitions   | Secondary efficacy endpoints for which results are presen- ted below | • Change from baseline in pre-dose FEV1 at week W52; • Time to first severe asthma exacerbation in the pooled analysis of the two pivotal studies; • ACQ-7 response at Week 26 and Week 52 • Change from baseline in the percentage of asthma symptom-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions   | Secondary end- points with no results included in the below table    | free days the 52-week treatment period. • Change from baseline in peak0-3h FEV1 at all clinical visits; • Change from baseline in pre-dose FEV1 at all clinical visits; • FEV1 response+ at Week 26 and Week 52; • Change from baseline in FEV1 area under the curve between 0 and 3 hours (AUC0 3h) normalised by time at all clinical visits; • Change from baseline in ACQ-7 score at all clinical visits; • Change from baseline in average morning and evening PEF in each inter-visit period, and over the 26-week (evening PEF) as well as 52-week treatment period; • Time to first moderate or severe asthma exacerbation; • Moderate asthma exacerbation rate over 52 weeks of treatment (pooled analysis); • Time to first moderate asthma exacerbation (pooled analysis); • Moderate and severe exacerbation rate over the 52-week treatment period (pooled analysis); • Time to first moderate or severe asthma exacerbation (pooled analysis); • Moderate asthma exacerbation rate over the 52-week treatment period; • Time to first moderate asthma exacerbation; • Change from baseline in the average use of rescue medication (number of puffs/day) in each inter-visit period, over the 26-week as well as 52-week treatment period; • Change from baseline in the percentage of rescue medication-free days in each inter-visit period, over the 26- week as well as 52-week treatment period; • Change from baseline in the average daily asthma symptoms score in each inter-visit period, over the 26-week as well as 52-week treatment period; • Change from baseline in the percentage of asthma symptom- free days in each inter-visit period and over the 26-week treatment period; • Change from baseline in the percentage of asthma control days in each inter-visit period. |

<div style=\"page-break-after: always\"></div>

## Summary of main studies

Table 22: Summary of efficacy for trial CCD-05993AB1-03 -- TRIMARAN

| Title: A 52 week, randomized, double-blind, multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide to CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) in patients with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long-acting ß2-agonists.   | Title: A 52 week, randomized, double-blind, multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide to CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) in patients with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long-acting ß2-agonists.   | Title: A 52 week, randomized, double-blind, multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide to CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) in patients with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long-acting ß2-agonists.   | Title: A 52 week, randomized, double-blind, multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide to CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) in patients with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long-acting ß2-agonists.   | Title: A 52 week, randomized, double-blind, multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide to CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) in patients with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long-acting ß2-agonists.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | CCD-05993AB1-03 -- TRIMARAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | CCD-05993AB1-03 -- TRIMARAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | CCD-05993AB1-03 -- TRIMARAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | CCD-05993AB1-03 -- TRIMARAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Randomized, double-blind, two parallel groups, active controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Randomized, double-blind, two parallel groups, active controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Randomized, double-blind, two parallel groups, active controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Randomized, double-blind, two parallel groups, active controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 52 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 52 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Superiority in terms of efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Superiority in terms of efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Superiority in terms of efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Superiority in terms of efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Treatment groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | CHF 5993 100/6/12.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | CHF 5993 100/6/12.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | CHF5993 (BDP/FF/GB) 100/6/12.5, two puffs bid for 52 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | CHF5993 (BDP/FF/GB) 100/6/12.5, two puffs bid for 52 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Treatment groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | CHF 1535 100/6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CHF 1535 100/6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CHF1535 (BDP/FF) 100/6 two puffs bid for 52 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | CHF1535 (BDP/FF) 100/6 two puffs bid for 52 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Database lock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 31JUL2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 31JUL2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 31JUL2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 31JUL2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Database lock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (Note : a number of changes from the protocol-defined analyses and also additional efficacy variables were introduced in the final SAP dated 27JUL2018; for details reference is made to the respective section of this assessment report)                                                                                                                                                                                                                                                                                  | (Note : a number of changes from the protocol-defined analyses and also additional efficacy variables were introduced in the final SAP dated 27JUL2018; for details reference is made to the respective section of this assessment report)                                                                                                                                                                                                                                                                                  | (Note : a number of changes from the protocol-defined analyses and also additional efficacy variables were introduced in the final SAP dated 27JUL2018; for details reference is made to the respective section of this assessment report)                                                                                                                                                                                                                                                                                  | (Note : a number of changes from the protocol-defined analyses and also additional efficacy variables were introduced in the final SAP dated 27JUL2018; for details reference is made to the respective section of this assessment report)                                                                                                                                                                                                                                                                                  |
| Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Co-primary analysis (two parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Co-primary analysis (two parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Co-primary analysis (two parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Co-primary analysis (two parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis population / time point                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | ITT population / Week W26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis population / time point                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | CHF5993 100/6/12.5 (TEST)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | CHF5993 100/6/12.5 (TEST)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | CHF1535 100/6 (COMPARATOR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| • Change from baseline in pre-dose (trough) FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                             | • Change from baseline in pre-dose (trough) FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                             | • Change from baseline in pre-dose (trough) FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                             | • Change from baseline in pre-dose (trough) FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                             | • Change from baseline in pre-dose (trough) FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | N=557                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=557                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=553                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Adj. mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.185 (0.155; 0.214)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.185 (0.155; 0.214)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.127 (0.098; 0.157)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Adj. mean difference (95% CI), p-value 0.057                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.015; 0.099), p=0.008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | (0.015; 0.099), p=0.008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | (0.015; 0.099), p=0.008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Analysis population / time point                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | ITT population / Week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                          | • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                          | • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                          | • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                          | • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Number of subjects with PEx / all (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=337/575 (58.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | N=337/575 (58.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | N=379/574 (66.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Adj. mean PEx rate (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.825 (1.634; 2.037)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1.825 (1.634; 2.037)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2.157 (1.937; 2.402)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.846 (0.725; 0.987), p=0.033                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.846 (0.725; 0.987), p=0.033                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.846 (0.725; 0.987), p=0.033                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Key secondary efficacy analysis (three parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Key secondary efficacy analysis (three parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Key secondary efficacy analysis (three parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Key secondary efficacy analysis (three parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Analysis population / time point                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | ITT population / Week W26 (peak0-3h FEV1 and morning PEF); Week W52 analysis]                                                                                                                                                                                                                                                                                                                                                                                                                                               | ITT population / Week W26 (peak0-3h FEV1 and morning PEF); Week W52 analysis]                                                                                                                                                                                                                                                                                                                                                                                                                                               | ITT population / Week W26 (peak0-3h FEV1 and morning PEF); Week W52 analysis]                                                                                                                                                                                                                                                                                                                                                                                                                                               | ITT population / Week W26 (peak0-3h FEV1 and morning PEF); Week W52 analysis]                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Treatment group (TEST)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (severe asthma exacerbations [pooled CHF5993 100/6/12.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | (severe asthma exacerbations [pooled CHF5993 100/6/12.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | CHF1535 100/6 (COMPARATOR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | N=553                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=553                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=553                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adj.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.485 (0.453; 0.516) 0.401 (0.369;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.485 (0.453; 0.516) 0.401 (0.369;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.432)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability; effect estimate   | Adj. mean difference (95% CI), p-value   | 0.084 (0.040; 0.129), p<0.001   |
|--------------------------------------------------------------------|------------------------------------------|---------------------------------|

<div style=\"page-break-after: always\"></div>

| Analysis description                                                                                                                                 | Key secondary efficacy analysis ( continued )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Key secondary efficacy analysis ( continued )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Key secondary efficacy analysis ( continued )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                      | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | CHF5993 100/6/12.5 (TEST)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | CHF1535 100/6 (COMPARATOR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                          | • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | N=566                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N=569                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Adj. mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 5.325 (1.921; 8.729)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | -3.131 (-6.533; 0.271)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 8.456 (3.643; 13.269), p<0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 8.456 (3.643; 13.269), p<0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)           | • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                                                                                                                                                                                                                                                                                                                       | • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                                                                                                                                                                                                                                                                                                                       | • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects with PEx / all (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 209/1146 (18.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 257/1145 (22.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Adj. mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.239 (0.206; 0.276)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.310 (0.271; 0.354)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.770 (0.636; 0.933), p=0.008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.770 (0.636; 0.933), p=0.008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Notes                                                                                                                                                | A hierarchical testing procedure was pre-specified in the CTP, meaning that no adjust- ment for multiplicity of testing was required. In the parallel TRIGGER study, the superiority testing of one of the co-primary endpoints did not achieve statistical significance. Thus, the hierarchy was broken early and the results of the pooled analysis for the rate of severe asthma exacerbations over the 52-week treatment period (23% reduction with CHF5993 as compared with CHF1535) are not confirmatory and resulting p-values need to be considered nominal values only. | A hierarchical testing procedure was pre-specified in the CTP, meaning that no adjust- ment for multiplicity of testing was required. In the parallel TRIGGER study, the superiority testing of one of the co-primary endpoints did not achieve statistical significance. Thus, the hierarchy was broken early and the results of the pooled analysis for the rate of severe asthma exacerbations over the 52-week treatment period (23% reduction with CHF5993 as compared with CHF1535) are not confirmatory and resulting p-values need to be considered nominal values only. | A hierarchical testing procedure was pre-specified in the CTP, meaning that no adjust- ment for multiplicity of testing was required. In the parallel TRIGGER study, the superiority testing of one of the co-primary endpoints did not achieve statistical significance. Thus, the hierarchy was broken early and the results of the pooled analysis for the rate of severe asthma exacerbations over the 52-week treatment period (23% reduction with CHF5993 as compared with CHF1535) are not confirmatory and resulting p-values need to be considered nominal values only. |
| Analysis description                                                                                                                                 | Selected secondary efficacy analysis (five parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Selected secondary efficacy analysis (five parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Selected secondary efficacy analysis (five parameters)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Analysis population / time point                                                                                                                     | ITT population / Week W26 and/or Week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | ITT population / Week W26 and/or Week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | ITT population / Week W26 and/or Week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                      | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | CHF5993 100/6/12.5 (TEST)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | CHF1535 100/6 (COMPARATOR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                              | • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | N=545                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N=539                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Adj. mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.196 (0.165; 0.227)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.158 (0.127; 0.189)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.038 (-0.007; 0.082), p=0.096                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.038 (-0.007; 0.082), p=0.096                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                       | • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | N=575                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N=574                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Responder (N/%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 306 (53.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 278 (48.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Non-responder (N/%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 269 (46.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 296 (51.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Odds ratio (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.213 (0.961; 1.530), p=0.104                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 1.213 (0.961; 1.530), p=0.104                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies) | • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                                                                                                                                                                                                                                                                                                             | • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                                                                                                                                                                                                                                                                                                             | • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | N=1146                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | N=1145                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Probability (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.185 (0.163; 0.209)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.228 (0.204; 0.253)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Hazard ratio (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.788 (0.656, 0.911) p=0.011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.788 (0.656, 0.911) p=0.011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| • ACQ-7 responders at week 26                                                                                                                        | • ACQ-7 responders at week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | • ACQ-7 responders at week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | • ACQ-7 responders at week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | N=575                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N=574                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Responder (N/%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 317 (55.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 291 (50.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Non-responder (N/%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 258 (44.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 283 (49.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Odds ratio (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.199 (0.948;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 1.517), p=0.129                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Analysis description                                        | Key secondary efficacy analysis ( continued )   | Key secondary efficacy analysis ( continued )   | Key secondary efficacy analysis ( continued )   |
|-------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                                             | Treatment group                                 | CHF5993 100/6/12.5 (TEST)                       | CHF1535 100/6 (COMPARATOR)                      |
| • change from baseline in the percentage of asthma week W52 | symptom-free days at                            | symptom-free days at                            | symptom-free days at                            |
| Descriptive statistics and estimate variability;            | Number of subjects                              | N=575                                           | N=574                                           |
|                                                             | Adj. mean (95%CI)                               | 16.847 (14.552; 19.143)                         | 15.916 (13.615; 18.217)                         |
| effect estimate                                             | Adj. mean difference (95% CI), p-value          | 0.931 (-2.320; 4.182), p=0.574                  | 0.931 (-2.320; 4.182), p=0.574                  |

<div style=\"page-break-after: always\"></div>

## Table 23: Summary of efficacy for trial CCD-05993AB2-02 -- TRIGGER

## Title:

A 52 week, randomized, double blind, multinational, multicentre, active controlled, 3-arm parallel grou p trial comparing CHF 5993 200/6/12.5 μg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 200/6 μg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) alone or on top of openlabel tiotropium 2.5 μg Respimat in patients with asthma uncontrolled on high doses of inhaled corticosteroids in combination with longacting β2 -agonists.

| Study identifier   | CCD-05993AB2-02 -- TRIGGER                                                                                                                                                                                                        | CCD-05993AB2-02 -- TRIGGER                                                                                                                                                                                                        |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design             | Randomised, double-blind (main comparison vs active control), additional open-label active control arm, three parallel groups                                                                                                     | Randomised, double-blind (main comparison vs active control), additional open-label active control arm, three parallel groups                                                                                                     |
|                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                    | 52 weeks 2 weeks NA                                                                                                                                                                                                               |
| Hypothesis         | Superiority in terms of efficacy                                                                                                                                                                                                  | Superiority in terms of efficacy                                                                                                                                                                                                  |
| Treatment groups   | CHF 5993 100/6/12.5                                                                                                                                                                                                               | CHF5993 (BDP/FF/GB) 100/6/12.5, two puffs bid for 52 weeks                                                                                                                                                                        |
|                    | CHF 1535 100/6                                                                                                                                                                                                                    | CHF1535 (BDP/FF) 100/6 two puffs bid for 52 weeks                                                                                                                                                                                 |
|                    | CHF 1535 100/6 + tiotropium 2.5                                                                                                                                                                                                   | CHF1535 (BDP/FF) 100/6 two puffs bid plus tiotropium 2.5 two puffs od for for 52 weeks                                                                                                                                            |
| Database lock      | 28SEP2018 (Note : a number of changes from the protocol-defined analyses and also additional efficacy variables were introduced in the final SAP dated 27JUL2018; for details reference is made to the respective section of this | 28SEP2018 (Note : a number of changes from the protocol-defined analyses and also additional efficacy variables were introduced in the final SAP dated 27JUL2018; for details reference is made to the respective section of this |

## Results and Analysis

| Analysis description             | Co-primary analysis (two parameters)   |
|----------------------------------|----------------------------------------|
| Analysis population / time point | ITT population / Week W26              |

<div style=\"page-break-after: always\"></div>

2

5

6

+

m

5

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Adj. mean (95%CI)                               | 0.229 (0.196; 0.263)            | 0.157 (0.123; 0.190)            |
|-------------------------------------------------|---------------------------------|---------------------------------|
| T vs. C1 Adj. mean difference (95% CI), p-value | 0.073 (0.026; 0.120), p=0.003   | 0.073 (0.026; 0.120), p=0.003   |
| T vs. C2 Adj. mean difference (95% CI), p-value | -0.045 (-0.103; 0.013), p=0.125 | -0.045 (-0.103; 0.013), p=0.125 |

<div style=\"page-break-after: always\"></div>

| Analysis description                                                                                                                                                                                                                                                                                                                                                                                                        | Co-primary analysis ( continued )                                                                                                                                                                                                                                                                                                                                                                                           | Co-primary analysis ( continued )                                                                                                                                                                                                                                                                                                                                                                                           | Co-primary analysis ( continued )                                                                                                                                                                                                                                                                                                                                                                                           | Co-primary analysis ( continued )                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population / time point                                                                                                                                                                                                                                                                                                                                                                                            | ITT population / Week W52                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W52                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W52                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population / Week W52                                                                                                                                                                                                                                                                                                                                                                                                   |
| • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                          | • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                          | • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                          | • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                          | • Rate of moderate to severe asthma exacerbations (PEx) at Week 52                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | Number of subjects with PEx / all (%)                                                                                                                                                                                                                                                                                                                                                                                       | N=323/571 (56.6%)                                                                                                                                                                                                                                                                                                                                                                                                           | N=364/571 (63.7%)                                                                                                                                                                                                                                                                                                                                                                                                           | N=162/287 (56.4%)                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | Adj. mean PEx rate (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                  | 1.726 (1.543; 1.932)                                                                                                                                                                                                                                                                                                                                                                                                        | 1.963 (1.757; 2.192)                                                                                                                                                                                                                                                                                                                                                                                                        | 1.613 (1.373; 1.897)                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | T vs. C1 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                             | 0.880 (0.751; 1.030 ), p= 0.110                                                                                                                                                                                                                                                                                                                                                                                             | 0.880 (0.751; 1.030 ), p= 0.110                                                                                                                                                                                                                                                                                                                                                                                             | 0.880 (0.751; 1.030 ), p= 0.110                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | T vs. C2 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                             | 1.070 (0.878; 1.303), p=0.502                                                                                                                                                                                                                                                                                                                                                                                               | 1.070 (0.878; 1.303), p=0.502                                                                                                                                                                                                                                                                                                                                                                                               | 1.070 (0.878; 1.303), p=0.502                                                                                                                                                                                                                                                                                                                                                                                               |
| Notes: For one of the co-primary endpoints (i.e. the rate of moderate to severe asthma exacerbations at week W52) statistical significance was not achieved. Therefore, the pre-defined hierarchical testing strategy was broken early and overall type-I error is not preserved for lower-ranking endpoints. For both co-primary endpoints, the extemporaneous triple combination (CHF1535 200/6 + tiotropium) numerically | Notes: For one of the co-primary endpoints (i.e. the rate of moderate to severe asthma exacerbations at week W52) statistical significance was not achieved. Therefore, the pre-defined hierarchical testing strategy was broken early and overall type-I error is not preserved for lower-ranking endpoints. For both co-primary endpoints, the extemporaneous triple combination (CHF1535 200/6 + tiotropium) numerically | Notes: For one of the co-primary endpoints (i.e. the rate of moderate to severe asthma exacerbations at week W52) statistical significance was not achieved. Therefore, the pre-defined hierarchical testing strategy was broken early and overall type-I error is not preserved for lower-ranking endpoints. For both co-primary endpoints, the extemporaneous triple combination (CHF1535 200/6 + tiotropium) numerically | Notes: For one of the co-primary endpoints (i.e. the rate of moderate to severe asthma exacerbations at week W52) statistical significance was not achieved. Therefore, the pre-defined hierarchical testing strategy was broken early and overall type-I error is not preserved for lower-ranking endpoints. For both co-primary endpoints, the extemporaneous triple combination (CHF1535 200/6 + tiotropium) numerically | Notes: For one of the co-primary endpoints (i.e. the rate of moderate to severe asthma exacerbations at week W52) statistical significance was not achieved. Therefore, the pre-defined hierarchical testing strategy was broken early and overall type-I error is not preserved for lower-ranking endpoints. For both co-primary endpoints, the extemporaneous triple combination (CHF1535 200/6 + tiotropium) numerically |
| Analysis description                                                                                                                                                                                                                                                                                                                                                                                                        | Key secondary efficacy analysis (three parameters)                                                                                                                                                                                                                                                                                                                                                                          | Key secondary efficacy analysis (three parameters)                                                                                                                                                                                                                                                                                                                                                                          | Key secondary efficacy analysis (three parameters)                                                                                                                                                                                                                                                                                                                                                                          | Key secondary efficacy analysis (three parameters)                                                                                                                                                                                                                                                                                                                                                                          |
| Analysis population / time point                                                                                                                                                                                                                                                                                                                                                                                            | ITT population / Week W26 (peak0-3h FEV1 and morning PEF); Week W52 (severe asthma exacerbations [pooled analysis]                                                                                                                                                                                                                                                                                                          | ITT population / Week W26 (peak0-3h FEV1 and morning PEF); Week W52 (severe asthma exacerbations [pooled analysis]                                                                                                                                                                                                                                                                                                          | ITT population / Week W26 (peak0-3h FEV1 and morning PEF); Week W52 (severe asthma exacerbations [pooled analysis]                                                                                                                                                                                                                                                                                                          | ITT population / Week W26 (peak0-3h FEV1 and morning PEF); Week W52 (severe asthma exacerbations [pooled analysis]                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                             | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                             | T CHF5993 100/6/12.5 (TEST)                                                                                                                                                                                                                                                                                                                                                                                                 | C1 CHF1535 100/6 (DOUBLE-BLIND COMPARATOR)                                                                                                                                                                                                                                                                                                                                                                                  | C2 CHF1535 100/6 + tiotropium 2.5 (OPEN-LABEL                                                                                                                                                                                                                                                                                                                                                                               |
| • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                      | • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                      | • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                      | • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                      | • Change from baseline in peak0-3h FEV1 (L) at Week 26                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                          | N=547                                                                                                                                                                                                                                                                                                                                                                                                                       | N=540                                                                                                                                                                                                                                                                                                                                                                                                                       | N=272 0.555                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | Adj. mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                           | 0.522 (0.488; 0.556)                                                                                                                                                                                                                                                                                                                                                                                                        | 0.417 (0.383; 0.451)                                                                                                                                                                                                                                                                                                                                                                                                        | (0.507; 0.603)                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | T vs. C1 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                             | 0.105 (0.057; 0.153), p<0.001                                                                                                                                                                                                                                                                                                                                                                                               | 0.105 (0.057; 0.153), p<0.001                                                                                                                                                                                                                                                                                                                                                                                               | 0.105 (0.057; 0.153), p<0.001                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | T vs. C2 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                             | - 0.033 (-0.092; 0.026), p=0.271                                                                                                                                                                                                                                                                                                                                                                                            | - 0.033 (-0.092; 0.026), p=0.271                                                                                                                                                                                                                                                                                                                                                                                            | - 0.033 (-0.092; 0.026), p=0.271                                                                                                                                                                                                                                                                                                                                                                                            |
| • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                                                                                                                                                                                                                                                                                                 | • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                                                                                                                                                                                                                                                                                                 | • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                                                                                                                                                                                                                                                                                                 | • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                                                                                                                                                                                                                                                                                                 | • change from baseline in the average morning PEF (L/min) over the 26-week treatment period                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                          | N=563                                                                                                                                                                                                                                                                                                                                                                                                                       | N=562                                                                                                                                                                                                                                                                                                                                                                                                                       | N=287                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | Adj. mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                           | 10.102 (6.717; 13.487)                                                                                                                                                                                                                                                                                                                                                                                                      | 2.297 (-1.091; 5.684)                                                                                                                                                                                                                                                                                                                                                                                                       | 10.286 (5.540; 15.032)                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | T vs. C1 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                             | 7.805 (3.016; 12.594), p<0.001                                                                                                                                                                                                                                                                                                                                                                                              | 7.805 (3.016; 12.594), p<0.001                                                                                                                                                                                                                                                                                                                                                                                              | 7.805 (3.016; 12.594), p<0.001                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability; effect estimate                                                                                                                                                                                                                                                                                                                                                            | T vs. C2 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                                                                                                                                                             | -0.184 (-6.013; 5.645), p=0.951                                                                                                                                                                                                                                                                                                                                                                                             | -0.184 (-6.013; 5.645), p=0.951                                                                                                                                                                                                                                                                                                                                                                                             | -0.184 (-6.013; 5.645), p=0.951                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Analysis description                                                                                                                                 | Key secondary efficacy analysis ( continued )                                                                                                                                                                                                                                           | Key secondary efficacy analysis ( continued )                                                                                                                                                                                                                                           | Key secondary efficacy analysis ( continued )                                                                                                                                                                                                                                           | Key secondary efficacy analysis ( continued )                                                                                                                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                      | Treatment group                                                                                                                                                                                                                                                                         | T CHF5993 100/6/12.5 (TEST)                                                                                                                                                                                                                                                             | C1 CHF1535 100/6 (DOUBLE-BLIND COMPARATOR)                                                                                                                                                                                                                                              | C2 CHF1535 100/6 + tiotropium 2.5 (OPEN-LABEL COMPARATOR)                                                                                                                                                                                                                               |
| • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)           | • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                              | • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                              | • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                              | • rate of severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                              |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects with PEx / all (%)                                                                                                                                                                                                                                                   | N=209/1146 (18.2%)                                                                                                                                                                                                                                                                      | N=257/1145 (22.4%)                                                                                                                                                                                                                                                                      | NA                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Adj. mean PEx rate (95%CI)                                                                                                                                                                                                                                                              | 0.239 (0.206; 0.276)                                                                                                                                                                                                                                                                    | 0.310 (0.271; 0.354)                                                                                                                                                                                                                                                                    | NA                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | T vs. C1 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                         | 0.770 (0.636; 0.933), p=0.008                                                                                                                                                                                                                                                           | 0.770 (0.636; 0.933), p=0.008                                                                                                                                                                                                                                                           | 0.770 (0.636; 0.933), p=0.008                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | T vs. C2 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                                                                                      | NA                                                                                                                                                                                                                                                                                      | NA                                                                                                                                                                                                                                                                                      |
| Notes                                                                                                                                                | Due to the broken testing hierarchy at the level of the co-primary endpoint, results for the key secondary endpoints (including the pooled analysis for the rate of severe asthma exacerbations) are not confirmatory and resulting p-values need to be considered nominal values only. | Due to the broken testing hierarchy at the level of the co-primary endpoint, results for the key secondary endpoints (including the pooled analysis for the rate of severe asthma exacerbations) are not confirmatory and resulting p-values need to be considered nominal values only. | Due to the broken testing hierarchy at the level of the co-primary endpoint, results for the key secondary endpoints (including the pooled analysis for the rate of severe asthma exacerbations) are not confirmatory and resulting p-values need to be considered nominal values only. | Due to the broken testing hierarchy at the level of the co-primary endpoint, results for the key secondary endpoints (including the pooled analysis for the rate of severe asthma exacerbations) are not confirmatory and resulting p-values need to be considered nominal values only. |
| Analysis description                                                                                                                                 | Selected secondary efficacy analysis (five parameters)                                                                                                                                                                                                                                  | Selected secondary efficacy analysis (five parameters)                                                                                                                                                                                                                                  | Selected secondary efficacy analysis (five parameters)                                                                                                                                                                                                                                  | Selected secondary efficacy analysis (five parameters)                                                                                                                                                                                                                                  |
| Analysis population / time point                                                                                                                     | ITT population / Week W26 and/or Week W52                                                                                                                                                                                                                                               | ITT population / Week W26 and/or Week W52                                                                                                                                                                                                                                               | ITT population / Week W26 and/or Week W52                                                                                                                                                                                                                                               | ITT population / Week W26 and/or Week W52                                                                                                                                                                                                                                               |
|                                                                                                                                                      | Treatment group                                                                                                                                                                                                                                                                         | T CHF5993 100/6/12.5 (TEST)                                                                                                                                                                                                                                                             | C1 CHF1535 100/6 (DOUBLE-BLIND COMPARATOR)                                                                                                                                                                                                                                              | C2 CHF1535 100/6 + tiotropium 2.5 (OPEN-LABEL COMPARATOR)                                                                                                                                                                                                                               |
| • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                              | • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                                                                                                                                                                 | • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                                                                                                                                                                 | • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                                                                                                                                                                 | • Change from baseline in pre-dose FEV1 (L) at week W52                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects                                                                                                                                                                                                                                                                      | N=534                                                                                                                                                                                                                                                                                   | N=534                                                                                                                                                                                                                                                                                   | N=263                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Probability (95%CI)                                                                                                                                                                                                                                                                     | 0.238 (0.205; 0.272)                                                                                                                                                                                                                                                                    | 0.152 (0.118; 0.186)                                                                                                                                                                                                                                                                    | 0.267 (0.219; 0.314)                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | T vs. C1 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                         | 0.086 (0.038; 0.134), p<0.001                                                                                                                                                                                                                                                           | 0.086 (0.038; 0.134), p<0.001                                                                                                                                                                                                                                                           | 0.086 (0.038; 0.134), p<0.001                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | T vs. C2 Adj. mean difference (95% CI), p-value                                                                                                                                                                                                                                         | -0.028 (-0.087; 0.030), p=0.347                                                                                                                                                                                                                                                         | -0.028 (-0.087; 0.030), p=0.347                                                                                                                                                                                                                                                         | -0.028 (-0.087; 0.030), p=0.347                                                                                                                                                                                                                                                         |
| • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                       | • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                                                                                                                                                          | • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                                                                                                                                                          | • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                                                                                                                                                          | • FEV1 responders at week 52 (change from baseline in pre- dose FEV1 ≥ 100 mL)                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Number of subjects                                                                                                                                                                                                                                                                      | N=571                                                                                                                                                                                                                                                                                   | N=571                                                                                                                                                                                                                                                                                   | N=287                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Responder (N/%)                                                                                                                                                                                                                                                                         | 326 (57.1%)                                                                                                                                                                                                                                                                             | 241 (42.2%)                                                                                                                                                                                                                                                                             | 158 (55.1%)                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | Nonresponder (N/%)                                                                                                                                                                                                                                                                      | 245 (42.9%)                                                                                                                                                                                                                                                                             | 330 (57.8%)                                                                                                                                                                                                                                                                             | 129 (44.9%)                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | T vs. C1 Odds ratio (95% CI), p-value                                                                                                                                                                                                                                                   | 1.831 (1.447, 2.317), p<0.001                                                                                                                                                                                                                                                           | 1.831 (1.447, 2.317), p<0.001                                                                                                                                                                                                                                                           | 1.831 (1.447, 2.317), p<0.001                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability; effect estimate                                                                                     | T vs. C2 Odds ratio (95% CI), p-value                                                                                                                                                                                                                                                   | 1.088 (0.817, 1.449), p=0.562                                                                                                                                                                                                                                                           | 1.088 (0.817, 1.449), p=0.562                                                                                                                                                                                                                                                           | 1.088 (0.817, 1.449), p=0.562                                                                                                                                                                                                                                                           |
| • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies) | • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                    | • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                    | • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                    | • Time to the first severe asthma exacerbations over 52 weeks of treatment (pre-defined pooled analysis of data from both pivotal phase III studies)                                                                                                                                    |
|                                                                                                                                                      | Number of subjects                                                                                                                                                                                                                                                                      | N=1146                                                                                                                                                                                                                                                                                  | N=1145                                                                                                                                                                                                                                                                                  | NA                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                      | Adj. mean (95%CI)                                                                                                                                                                                                                                                                       | 0.185 (0.163; 0.209)                                                                                                                                                                                                                                                                    | 0.228 (0.204; 0.253)                                                                                                                                                                                                                                                                    | NA                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability; effect estimate   | T vs. C1 Hazard ratio (95% CI), p-value T vs. C2   | 0.788 (0.656, 0.911) p=0.011   |
|--------------------------------------------------------------------|----------------------------------------------------|--------------------------------|

<div style=\"page-break-after: always\"></div>

| Analysis description                                                             | Selected secondary efficacy analysis ( continued )                               | Selected secondary efficacy analysis ( continued )                               | Selected secondary efficacy analysis ( continued )                               | Selected secondary efficacy analysis ( continued )                               |
|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|                                                                                  | Treatment group                                                                  | T CHF5993 100/6/12.5 (TEST)                                                      | C1 CHF1535 100/6 (DOUBLE-BLIND COMPARATOR)                                       | C2 CHF1535 100/6 + tiotropium 2.5 (OPEN-LABEL COMPARATOR)                        |
| • ACQ-7 responders at week 26                                                    | • ACQ-7 responders at week 26                                                    | • ACQ-7 responders at week 26                                                    | • ACQ-7 responders at week 26                                                    | • ACQ-7 responders at week 26                                                    |
| Descriptive statistics and estimate variability; effect estimate                 | Number of subjects                                                               | N=571                                                                            | N=571                                                                            | N=287                                                                            |
| Descriptive statistics and estimate variability; effect estimate                 | Responder (N/%)                                                                  | 350 (61.3%)                                                                      | 319 (55.9%)                                                                      | 180 (62.7%)                                                                      |
| Descriptive statistics and estimate variability; effect estimate                 | Nonresponder (N/%)                                                               | 221 (38.7%)                                                                      | 252 (44.1%)                                                                      | 107 (37.3%)                                                                      |
| Descriptive statistics and estimate variability; effect estimate                 | T vs. C1 Odds ratio (95% CI), p-value                                            | 1.233 (0.969, 1.568), p=0.088                                                    | 1.233 (0.969, 1.568), p=0.088                                                    | 1.233 (0.969, 1.568), p=0.088                                                    |
| Descriptive statistics and estimate variability; effect estimate                 | T vs. C2 Odds ratio (95% CI), p-value                                            | 0.913 (0.678, 1.229), p=0.548                                                    | 0.913 (0.678, 1.229), p=0.548                                                    | 0.913 (0.678, 1.229), p=0.548                                                    |
| • change from baseline in the percentage of asthma symptom-free days at week W52 | • change from baseline in the percentage of asthma symptom-free days at week W52 | • change from baseline in the percentage of asthma symptom-free days at week W52 | • change from baseline in the percentage of asthma symptom-free days at week W52 | • change from baseline in the percentage of asthma symptom-free days at week W52 |
| Descriptive statistics and estimate variability; effect estimate                 | Number of subjects                                                               | N=571                                                                            | N=568                                                                            | N=287                                                                            |
| Descriptive statistics and estimate variability; effect estimate                 | Adj. mean (95%CI)                                                                | 16.569 (14.298; 18.840)                                                          | 12.790 (10.513; 15.067)                                                          | 12.725 (9.514; 15.937)                                                           |
| Descriptive statistics and estimate variability; effect estimate                 | T vs. C1 Adj. mean difference (95% CI), p-value                                  | 3.779 (0.563; 6.995), p=0.021                                                    | 3.779 (0.563; 6.995), p=0.021                                                    | 3.779 (0.563; 6.995), p=0.021                                                    |
| Descriptive statistics and estimate variability; effect estimate                 | T vs. C2 Adj. mean difference (95% CI), p-value                                  | 3.843 (-0.090; 7.777), p=0.05                                                    | 3.843 (-0.090; 7.777), p=0.05                                                    | 3.843 (-0.090; 7.777), p=0.05                                                    |

## Analysis performed across trials (pooled analyses and meta-analysis)

Due to the low number of patients enrolled in each of the two pivotal clinical trials, a pooled analysis of TRIMARAN and TRIGGER results was pre-defined in the CTP and SAP in order to evaluate the effect of triple  treatment  with  CHF5993  (both  ICS  dose  strengths  combined)  on  the  rate  of  severe  asthma exacerbations over the entire 52-week treatment period.

This parameter was included as a key secondary efficacy variable. Results of this pre-defined analysis have been presented in the corresponding chapter (' Key secondary variables' ) of the first pivotal study (TRIMARAN).

A number of additional post hoc statistical analyses were performed by the applicant, based on pooled data from TRIMARAN and TRIGGER studies. Results for relevant variables are briefly summarised under the subheading 'Ancillary analyses'.

## Clinical studies in special populations

No efficacy studies involving special populations were performed.

## Supportive study

Not applicable.

## 2.7.3. Discussion on clinical efficacy

Dose-finding studies

<div style=\"page-break-after: always\"></div>

The  MAH  conducted  two  phase  II  studies  (TRISKEL  &amp;  ELITRA)  to  provide  information  on  the  dose response to GB in asthma patients.

The TRISKEL study was a key dose-finding study, which led to selection of the dose of GB for CHF 5993 pMDI. A dose range of 25/50/100 µg GB daily on top of medium-dose Foster has been tested against medium-dose Foster alone for a variety of spirometry outcomes. The selected dose range for GB relies mainly on data obtained during the COPD development programme for Trimbow which is supported. In this study, all doses of GB (25, 50, and 100 μg) in combination with Foster were superior versus Foster alone in terms of the primary efficacy variable, FEV1 AUC0-12h normalised by time after 6 weeks of treatment in adult patients with uncontrolled asthma on medium-dose ICS/LABA, and also for the key secondary efficacy variable change from baseline in peak FEV1 evaluated after 6 weeks of treatment. The two highest doses of GB (50 and 100 μg) generally showed a similar improvement in lung function, which was consistently numerically greater than that observed with the GB 25 μg dose. Overall, there was no effic acy advantage seen with the GB 100 μg dose over the GB 50 μg dose. Thus, the proposed daily dosing for the LAMA component (i.e. 50 µg GB) seems to be the optimal dose when combined with medium-dose BDP and FF in a fixed triple combination. No formal dose finding for the GB component of CHF-5993-HS has been conducted which is considered acceptable by CHMP.

## Pivotal studies

The MAH submitted the results of two pivotal studies, one intended to support the use of the medium dose triple combination (CHF5993 100/6/12.5; TRIMARAN) and the other intended to support the use of the high dose triple combination (CHF5993 200/6/12.5; TRIGGER).

In each of these studies, the triple fixed-dose combination product (CHF 5993) was compared with the dual fixed dose combination product having the same ICS dose strength (100 µg or 200 µg BDP per puff).

With two exceptions, both trials had an identical design, including, but not limited to the following:

- double-blind treatment (for the two confirmatory treatment groups);
- parallel treatment groups;
- though differing in symptoms severity (refer to below) patients enrolled in both studies had uncontrolled asthma on their current dual ICS / LABA treatment and remained at potential risk of  asthma  exacerbations  despite  treatment  with  medi um or high dose ICS plus LABA (≥ 1 documented asthma exacerbation in the year prior to enrolment);
- identical study periods, i.e. a 2-week run-in period to standardise the study population on the same ICS / LABA combination product, followed by a 52-week randomised treatment;
- same methodology to collect daily asthma symptoms and exacerbation data;
- identical co-primary endpoint consisting of a spirometry [change from baseline to week W26 in pre-dose FEV1] and a clinical endpoint [rate of moderate to severe exacerbations at week W52];
- identical key secondary and secondary endpoints;
- identical primary between-group  comparison:  triple combination CHF  5993  versus  the corresponding ICS dose strength of dual fixed-dose treatment (CHF 1535);
- hierarchical testing or ' gatekeeping ' procedure pre-specified in the CTP and applied to the two co-primary and key secondary endpoints in order to preserve overall type I error.

The first exception relates to the dose of ICS which asthma patients were routinely taking in the prestudy period: medium dose ICS / LABA for patients enrolled in TRIMARAN (GINA step 4) and high dose ICS / LABA for those enrolled in TRIGGER (GINA step 5).

Secondly, a further comparator group was included in the TRIGGER study, associating the approved LAMA  tiotropium  to  dual  treatment  with  ICS /  LABA  (extemporaneous  combination  of  CHF  1535 +

<div style=\"page-break-after: always\"></div>

tiotropium) in an open-label fashion. The MAH's original intention to additionally demonstrate on this basis the non-inferiority of CHF5993 vs. the extemporaneous triple combination including tiotropium was abandoned and instead, a purely exploratory approach and sample size was pre-defined in the CTP.

Overall,  the  design  of  the  two  studies  and  their  duration  followed  the  broad  lines  discussed  in  the scientific advice meeting and was suitable to answer the main research question, which was to quantify the contribution of the LAMA glycopyrronium bromide to the observed therapeutic effect of the triple fixed-dose combination.

During  the  2-week  run-in  period,  asthma  maintenance  treatment  of  patients  in  both  trials  was ' standardised ' and/or ' stabilised ' on dual ICS / LABA (either CHF 1535 100/6 in TRIMARAN or CHF 1535 200/6 in TRIGGER).

During  the  52-week  randomised  treatment  period,  in  both  trials,  the  same  dose  of  glycopyrronium bromide (12.5 µg GB) was added as a third controller and compared with the corresponding approved fixed dose dual combination product associating BDP and formoterol. Solely in the second trial in patients with high dose ICS treatment (TRIGGER), another active control group (i.e. the extemporaneous openlabel combination of CHF 1535 + tiotropium) was added for exploratory purposes. The relevant betweengroup comparisons were therefore:

TRIMARAN

CHF5993 100/6/12.5 vs. CHF1535 100/6;

TRIGGER

CHF5993 200/6/12.5 vs. CHF1535 200/6

(for exploratory comparison: CHF1535 200/6 + tiotropium, open-label).

Based on these design aspects, the two pivotal studies produced evidence in support of the add-on indication, but not a general (or specific) switch or substitution indication as initially proposed by the MAH. This was agreed by the MAH in the course of the procedure and thus, the indication was restricted as follows:

## -Medium dose

'Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.'

## -High dose

'Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.'

The patient population was adequately selected and comprised adult asthma patients of both gender (18-75 years of age) who were uncontrolled on their current medium or high dose ICS / LABA treatment regimen (as based on ACQ-7) and had to have a documented history of at least one moderate to severe asthma exacerbation in the year prior to enrolment. Other eligibility criteria were mostly in line with those  defined  in  comparable  asthma  trials.  It  is  noted  that,  reportedly,  the  vast  majority  of  study participants  had  never  smoked.  According  to  the  MAH,  this  criterion  was  introduced  to  avoid  the confounding risk of including patients with COPD. Moreover, the EMA guidance document (CHMP/EWP/2922/01  rev.1)  was  issued  and  became  effective  after  the  initiation  of  TRIMARAN  and TRIGGER studies.

The co-primary endpoint is acceptable as it combined a lung-function (i.e. the change in pre-dose FEV1 at  week 26)  and  a  symptom-related  parameter (i.e.  rate  of  moderate  to  severe  exacerbations  over 52 weeks of treatment). The criteria used to define moderate and severe asthma exacerbation episodes

<div style=\"page-break-after: always\"></div>

were sufficiently detailed to allow their consistent identification in both treatment groups and were also in line with current guidance.

Although the study definition of what is a « severe » asthma exacerbation did not exactly match the one proposed  by  the  CHMP  guideline  on  clinical  trials  in  asthma,  further  analyses  suggested  that  this deviation did have no impact on the overall outcome of the studies.

Relevant data  (e.g.  daily  asthma  symptoms,  compliance  with  IMP)  were  reported  by  patients  in  an eDiary. The MAH explained in a satisfactory manner why problems with capturing or transmitting e-diary data had no impact on the completeness and overall integrity of data.

Statistically significant improvements with CHF 5993 were observed for both co-primary endpoints in the first trial ( TRIMARAN ). At week 26, the adjusted mean change in pre-dose FEV1 was greater with CHF 5993 than with CHF1535 (between-group difference of +57 mL , 95%CI [15 mL; 99 mL]). Moreover, at week 52, treatment with CHF 5993 resulted in a decrease of -15.4% (p=0.03) in the rate of moderate to severe asthma exacerbations .

From a clinical point of view, the benefit of adding a second controller was modest. The improvement in pre-dose FEV1 was small though more or less maintained over the 52-week treatment period. It is noted that  the  adjusted  between-group  difference  in  pre-dose  FEV1  at  week  W52  amounted  to +38 mL [95%CI: -7 mL; 82 mL] only and no longer achieved statistical significance.

The percentage of patients classified as FEV1 responders (i.e. those with a change from baseline in predose FEV1 ≥100 mL) was numerically greater with CHF 5993 than with CHF 1535 (53.7% vs. 44.9% and 53.2% vs. 48.4% at weeks W26 and W52, respectively). The between-group difference achieved statistical significance at week W26, but not at week W52.

CHF 5993 100/6/12.5 resulted in a moderate, but statistically significant reduction in the annual rate of moderate to severe exacerbations at week W52 ( 15.4% reduction based on the adjusted rate ratio, p=0.033).

There was no added benefit on symptomatic asthma control or other patient-reported outcome measures when  a  second  bronchodilator  (glycopyrronium  bromide)  was  added  to  medium  dose  ICS/LABA treatment.

The second pivotal study ( TRIGGER ) failed its primary objective and the hierarchical testing strategy was broken early. Although at week 26, the adjusted mean change in pre-dose FEV1 was greater with CHF 5993 than with CHF 1535 (between-group difference of +73 mL , 95%CI [26 mL; 120 mL]), the decrease in the rate of moderate to severe asthma exacerbations was not statistically significant ( -12.0% , p=0.11 ).

Same as in the TRIMARAN trial, the addition of a second controller resulted in a modest, but sustained bronchodilation. The percentage of patients classified as FEV1 responders (i.e. those with a change from baseline in predose FEV1 ≥100 mL) was greater with CHF 5993 than with CHF 1535 at both weeks W26 and W52 (57.4% vs. 45.0% and 57.1% vs. 42.2%, respectively). The between-group difference achieved statistical significance at both measurement times, with odds ratios of 1.660 (95%CI [1.312;2.099]) and 1.831 (95%CI [1.447; 2.317]), respectively. The percentage of patients classified as FEV1 responders in the two triple treatment groups was comparable at both measurement times with odds ratios around / close to 1.

As  in  the  parallel  trial,  no  added  benefit  on  symptomatic  asthma  control  or  other  patient-reported outcome measures was observed.

In the TRIGGER trial, an open-label, active comparator arm (adding the approved tiotropium to high dose  ICS /  LABA  [CHF1535  200/6])  was  added  for  ' benchmarking '  and  exploratory  purposes  and numerically performed better than CHF 5993 200/6/12.5. This result was consistent across a number of

<div style=\"page-break-after: always\"></div>

parameters and in particular in terms of effect on the rate of severe asthma exacerbations. Since the TRIGGER study was not powered to evaluate the comparative efficacy of CHF 5993 200/6/12.5 and this extemporaneous triple combination product, the observed differences should be interpreted with caution as it is not clear whether those are real or attributed to a random result.

Modest increases in pre-dose FEV1 attributable to the addition of GB to the therapeutic regimen were observed in both trials ( +57 mL and +73 mL by week W26, respectively), remaining markedly below the putative MCID of ≥100 mL.

It is important to note, however, that in both trials, randomised trial medication was given on top of maintenance  therapy  that  had  been  standardised /  stabilised  during  the  two-week  run-in  period. Reportedly, a clinically relevant improvement in pre-dose FEV1 was already achieved during these two weeks.  This  may  explain  why  the  room  for  further  improvement  during  subsequent  randomised treatment period was limited.

Although the asthma populations studied are not comparable, the benefit of adding tiotropium (total daily dose of 5µg) to dual treatment with ICS and LABA in the two PrimoTinA asthma trials was more important than in the present trials (increases in pre-dose FEV1 versus placebo of +88 mL and +111 mL at week W24, respectively).

Similarly, the decrease in the rate of moderate to severe exacerbations in the individual studies was modest ( -15% and -12% by  week W52, respectively). The minimally clinically important difference (MCID) for the reduction of exacerbations in asthma has not been defined. In view of the low background incidence of asthma exacerbations, the between-group difference in absolute terms and resulting effect size is small, meaning that triple treatment would have to be maintained for years to prevent a single episode.

A clinically more relevant result in favour of CHF 5993 was obtained in the pre-defined pooled analysis , where CHF 5993 (medium and high dose ICS) was superior to CHF 1535 (medium and high dose ICS) in terms of the adjusted rate of severe asthma exacerbations (relative reduction in the adjusted rate of such exacerbations of 23.0% , result based on pooled ITT population and week W52).

In this respect, the magnitude of effect was in the range of what was previously reported if tiotropium was  added  to  combined  treatment  with  ICS  and  LABA  (overall  reduction  of  -21%  in  the  risk  of experiencing a severe exacerbation). Due to the chosen hierarchical testing procedure, results of this analysis were no more adjusted for multiplicity and, therefore, could not be considered as confirmatory.

The addition of GB on top of dual ICS / LABA treatment had no discernible effect on various other parameters  of  asthma  control (e.g.  ACQ-7,  use  of  rescue  medication,  asthma  symptoms  scores including chest tightness or breathlessness, percentage of asthma symptom-free days).

A substantial proportion of patients in all treatment groups reported a symptomatic improvement over the  52 weeks  of  randomised  treatment  (which  exceeded  the  generally  accepted  MCID  of ACQ-7 of 0.5 points). However, no relevant additional benefit could be demonstrated when  a second bronchodilator (LAMA) was added to medium or high dose ICS / LABA treatment, and this independent of the type of analysis (ACQ-7 change in score points or responder analysis). Further analyses presented by  the  applicant  suggested  that  ACQ-7  results  were  not  only  driven  by  the  improvement  in  prebronchodilator FEV1% score.

Based on 2019 GINA 2019, its revised severity classification and proposed asthma treatment strategy, the  TRIMARAN  trial  left  one  important  question  unanswered.  Add-on  treatment  with  the  LAMA glycopyrronium bromide resulted in a modest clinical benefit only in this group of step 4 asthma patients uncontrolled  on  medium  dose  ICS /  LABA  treatment.  The  effect  of  the  other  controller  option,  i.e. increasing the dose of the ICS component from medium to high, was not investigated.

<div style=\"page-break-after: always\"></div>

## Exploratory post hoc analyses of efficacy data

Because the TRIGGER trial failed to achieve its primary objective, additional post hoc analyses were carried out by the MAH in order to provide exploratory evidence that adding glycopyrronium bromide to the corresponding strength dual treatment regimen resulted in a clinical benefit in this group of step 5 asthma patients uncontrolled on high dose ICS / LABA treatment.

For  that  purpose,  amongst  other  approaches,  a TRIGGER subpopulation more  closely  resembling patients enrolled in the pivotal PrimoTinA studies for tiotropium was selected (i.e. patients with persistent airflow limitation, PAL). A little less than two thirds of patients in the ITT dataset (62.5% and 60.6% in groups CHF5993 and CHF1535, respectively) met these post hoc selection criteria.

For  several  exacerbation endpoints,  the  effect  sizes  of  CHF  5993  200/6/12.5  in  this  subgroup  were higher, with p-values achieving nominal statistical significance versus dual therapy.

Overall, the primary efficacy results and exploratory post hoc analyses presented by the MAH for the high  ICS  dose  strength  product  (CHF5993  200/6/12.5)  were  considered  by  CHMP  to  be  robust  and compelling enough to endorse the approval of the high strength.

It should be highlighted that there is no data on the effect of stepping down from the high strength (Trimbow 172/5/9 micrograms) to the medium strength beclometasone diproprionate medicinal product (Trimbow 87/5/9 micrograms). Patients should nevertheless be regularly reassessed by a doctor so that their  doses  of  beclometasone/formoterol/glycopyrronium  remain  optimal  and  are  only  changed  on medical advice. In addition, the doses should be titrated to the lowest doses at which effective control of asthma symptoms is maintained. This information has been adequately reflected in sections 4.2 and 4.4. of the SmPC.

## 2.7.4. Conclusions on the clinical efficacy

Moderate, but statistically significant effects on the co-primary variable (change from baseline in predose FEV1 and the annualised rate of moderate to severe asthma exacerbations) were observed in the TRIMARAN study if glycopyrronium bromide (GB) was added to medium ICS dose CHF 1535 100/6.

The high ICS dose treatment (CHF 5993 200/6/12.5) failed to achieve one of the co-primary objective in  the  TRIGGER  study.  The  clinical  benefit  of  adding  GB  to  high  dose  CHF  1535  200/6  was  not demonstrated in a confirmatory manner as the effect on the rate of moderate to severe exacerbations did not reach statistical significance. Thus, from a formal point of view, the requirements defined in the ' Guideline on clinical development of fixed combination medicinal products ' (EMA/CHMP/158268/2017) were not met.

Since a hierarchical testing or 'gatekeeping' procedure was pre-defined by the MAH, no confirmatory claims could be based on the results of efficacy variables. This was particularly true for the pre-defined pooled analysis of severe asthma exacerbations where treatment with CHF 5993 (medium and high dose ICS pooled) resulted in a 23% decrease when compared with CHF 1535 (data on medium and high dose ICS pooled).

In exploratory post hoc analyses, mainly involving a sub-population of asthma patients with persistent airflow limitation (about  2 /3 of patients included in the ITT dataset), supporting evidence was produced to  suggest  that  the  addition  of  GB  to  CHF  1535  200/6  had  a  beneficial  effect  on  the  exacerbation endpoint.

Overall, the CHMP considered that both strengths (medium and high) are approvable since a beneficial effect could be demonstrated in the asthma adult patients.

<div style=\"page-break-after: always\"></div>

## 2.8. Clinical safety

Trimbow is a fixed dose combination of the three known substances Beclometasone diproprionate (BDP), formoterol fumarate (FF) and glycopyrronium bromide (GB) and has already a marketing authorisation for the indication chronic obstructive pulmonary disease (COPD) for the medium strength 100/6/12,5 µg since 2017.

Foster is the FDC of BDP and FF and is approved for the treatment of asthma in both strengths 100/6 µg and 200/6 µg since 2006 and 2015. Given that Trimbow can be regarded as a FDC of Foster with one additional  known  active  substance  (GB),  reference  was  also  made  to  the  known  safety  database  of Foster.

Safety data has been presented from the six completed PK/efficacy/safety studies (Dose Proportionality study, Spacer study, TRISKEL, ELITRA, TRIMARAN and TRIGGER), which were performed during the development programme. As throughout Phase I only single dose application and throughout Phase II different freely combined doses of the single substances were studied, the primary safety assessment will be based on the two pivotal long-term Phase III trials (TRIMARAN and TRIGGER) performed with Trimbow.

## Patient exposure

A total of 1147 patients with asthma were exposed to at least 1 dose of Trimbow in the two completed Phase III studies. 576 received the lower dose (100/6/12,5 µg) and 571 the higher dose (200/6/12,5 µg). The mean treatment duration was 354.6 (±51.2) days (range 1 - 398) for the lower and 354.2 (±53.9) days (range 9 - 400) for the higher dose with 73.6% and 72.2% of patients completing at least 52 weeks of treatment. The exposure was 559.2 and 553.7 patient years in the TRIMARAN and TRIGGER study.

Table 24 : Duration of exposure -TRIMARAN and TRIGGER studies

|                                         | TRIMARAN study        | TRIMARAN study         | TRIGGER study         | TRIGGER study         | TRIGGER study          |
|-----------------------------------------|-----------------------|------------------------|-----------------------|-----------------------|------------------------|
|                                         | BDP/FF/GB 100/6/12,5  | BDP/FF 100/6           | BDP/FF/GB 200/6/12,5  | BDP/FF 200/6          | BDP/FF +Tiotropium 2.5 |
| Number of patients in safety population | 576                   | 574                    | 571                   | 573                   | 287                    |
| Days Mean (SD) range                    | 354.6 (±51.2) 1 - 398 | 352.8 (±57.4) 20 - 401 | 354.2 (±53.9) 9 - 400 | 351.1 (±61.5) 1 - 391 | 348 (±65.7) 1 - 394    |

Table 25: Duration of exposure -TRIMARAN and TRIGGER studies

|                | TRIMARAN study       | TRIMARAN study   | TRIGGER study        | TRIGGER study   | TRIGGER study          |
|----------------|----------------------|------------------|----------------------|-----------------|------------------------|
| Exposure n (%) | BDP/FF/GB 100/6/12,5 | BDP/FF 100/6     | BDP/FF/GB 200/6/12,5 | BDP/FF 200/6    | BDP/FF +Tiotropium 2.5 |
| 48-52 weeks    | 122 (21.2)           | 132 (23.0)       | 128 (22.4)           | 130 (22.7)      | 47 (16.4)              |
| ≥52 weeks      | 424 (73.6)           | 408 (71.1)       | 412 (72.2)           | 406 (70.9)      | 217 (75.6)             |

<div style=\"page-break-after: always\"></div>

Baseline demographic patient characteristics were balanced between groups. Cardiovascular risk factors were present in 58.4% and 57.1% of patients in the TRIMARAN and TRIGGER study.

## Adverse events

## Integrated analysis of TRIMARAN and TRIGGER studies

The percentage of patients treated with BDP/FF/GB who had at least 1 TEAE was 73.3%, while 78.3% of patients treated with BDP/FF had at least 1 TEAE. The integrated treatment groups presented with similar percentages of patients with treatment-emergent ADRs (4.4% and 3.7% with BDP/FF/GB and BDP/FF) and serious TEAEs (4.9% and 4.8%). Fewer patients experienced severe TEAEs with BDP/FF/GB than with BDP/FF (6.0% and 8.1%). Serious ADRs, TEAEs leading to study medication discontinuation and TEAEs leading to death were reported at low and similar percentages of patients in both integrated treatment groups. The majority of TEAEs were mild or moderate in intensity and resolved by the end of the study.

Table 26: Summary of TEAEs, Safety population - TRIMARAN and TRIGGER studies (integrated analysis)

|                                                   | BDP/FF/GB (100/6/12.5 and 200/6/12.5) N=1147   | BDP/FF/GB (100/6/12.5 and 200/6/12.5) N=1147   | BDP/FF (100/6 and 200/6) N=1147   | BDP/FF (100/6 and 200/6) N=1147   |
|---------------------------------------------------|------------------------------------------------|------------------------------------------------|-----------------------------------|-----------------------------------|
|                                                   | Number of events                               | Number of patients (%)                         | Number' of events                 | Number of patients (%)            |
| TEAEs                                             | 3471                                           | 841 (73.3)                                     | 3772                              | 898 (78.3)                        |
| Treatment-emergent ADRs                           | 64                                             | 50 (4.4)                                       | 59                                | 43 (3.7)                          |
| Serious TEAEs                                     | 67                                             | 56 (4.9)                                       | 67                                | 55 (4.8)                          |
| Serious treatment-emergent ADRs                   | 2                                              | 2 (0.2)                                        | 2                                 | 2 (0.2)                           |
| TEAEs leading to study medication discontinuation | 9                                              | 8 (0.7)                                        | 15                                | 13 (1.1)                          |
| Severe TEAEs                                      | 89                                             | 69 (6.0)                                       | 112                               | 93 (8.1)                          |
| TEAEs leading to death                            | 5                                              | 4 (0.3)                                        | 1                                 | 1 (0.1)                           |

## Treatment-emergent adverse events

The most common TEAEs by PT reported with either treatment (i.e. TEAEs reported in ≥ 3% of patients), in decreasing order of overall frequency were:

|                                   | BDP/FF/GB %of patients   | BDP/FF %of patients   |
|-----------------------------------|--------------------------|-----------------------|
| Asthma exacerbation               | 57.5%                    | 64.8%                 |
| Nasopharyngitis                   | 10.2%                    | 12.4%                 |
| Headache                          | 5.5%                     | 6.4%                  |
| Respiratory tract infection viral | 2.8%                     | 4.7%                  |
| Bronchitis                        | 3.1%                     | 3.5%                  |

The most common TEAE of asthma exacerbation was reported in a lower percentage of patients with BDP/FF/GB than with BDP/FF (57.5% and 64.8%, respectively). Nasopharyngitis was also reported in a lower percentage of patients with BDP/FF/GB than with BDP/FF (10.2% and 12.4%, respectively).

All other common TEAEs were reported in a similar percentage of patients in both integrated treatment groups, with ≤ 2% between -treatment differences.

<div style=\"page-break-after: always\"></div>

Nasopharyngitis was reported in a higher percentage of patients with BDP/FF/GB 100/6/12.5 than with BDP/FF/GB 200/6/12.5 (12.3% and 8.1%, respectively). All other common TEAEs were reported in a closely comparable percentage of patients with both strengths.

## Treatment-emergent adverse drug reactions

The  most  common  treatment-emergent  ADRs  reported  with  either  integrated  treatment  (i.e.  ADRs reported in ≥ 1% of patients) were from the SOCs Respiratory, Thoracic and Mediastinal Disorders and Infections and Infestations. The 3 most common treatment-emergent ADRs were:

|                  | BDP/FF/GB %of patients   | BDP/FF %of patients   |
|------------------|--------------------------|-----------------------|
| Dysphonia        | 1.7%                     | 0.8%                  |
| Oral candidiasis | 0.3%                     | 0.6%                  |
| Dry mouth        | 0.6%                     | 0.1%                  |

Additional common treatment-emergent ADRs (i.e. ADRs reported in &gt; 2 patients with either integrated treatment) were oropharyngeal candidiasis, electrocardiogram QT prolonged, muscle spasms, tremor and headache.

Muscle spasms were observed only in 3 patients treated with BDP/FF/GB 200/6/12.5, all other common ADRs were reported in a similar percentage of patients with BDP/FF/GB 100/6/12.5 and BDP/FF/GB 200/6/12.5.

Aproximately half of the ADRs occurred within the first 3 months of study treatment and a drop in ADR reports in the last 6 months of the one-year study.

## Serious adverse event/deaths/other significant events

## Serious adverse events

Overall,  the  incidence  of  serious  adverse  events  in  the  two  strengths  of  BDP/FF/GB  was  low  and comparable between the TRIMARAN and the TRIGGER trials (both 4.9%), while patients treated with the higher strength of BDP/FF reported more serious TEAEs than with the lower strength (5.8 vs 3.8%).

The most common serious TEAEs by PT (i.e. TEAEs reported in ≥ 2 patients with ei ther strength of BDP/FF/GB) in decreasing order of frequency were Asthma exacerbation, Pneumonia, Atrial fibrillation and Pancreatitis acute.

All  common serious TEAEs were reported in a similar percentage of patients with both strengths of BDP/FF/GB.

Table 27: Serious TEAEs reported in TRIMARAN and TRIGGER trials

| Study    | Medication                    |   Serious TEAEs |   Patients [n] |   Patients [%] | Related to study medication   |                                  |
|----------|-------------------------------|-----------------|----------------|----------------|-------------------------------|----------------------------------|
| TRIMARAN | BDP/FF/GB 100/6/12.5          |              34 |             28 |            4.9 | 1                             | Atrial fibrillation              |
| TRIMARAN | BDP/FF 100/6                  |              26 |             22 |            3.8 | -                             | -                                |
| TRIGGER  | BDP/FF/GB 200/6/12.5          |              33 |             28 |            4.9 | 1                             | Oesophageal candidiasis          |
| TRIGGER  | BDP/FF 200/6                  |              41 |             33 |            5.8 | 2                             | Pneumonia Angle closure glaucoma |
| TRIGGER  | BDP/FF 200/6 + Tiotropium 2.5 |              17 |             15 |            5.2 | -                             | -                                |

<div style=\"page-break-after: always\"></div>

Atrial fibrillation, oesophageal candidiasis, pneumonia and angle closure glaucoma were attributed to the study  medication.  Several  reported  cardiac,  vascular  and  nervous  system  disorders  such  as  atrial fibrillation, acute cardiac failure, coronary artery disease, left ventricular failure, myocardial ischaemia, aortic  aneurysm  rupture,  cerebral  haemorrage  and  hypertensive  crisis  were  not  attributed  to  study medication, despite the known ADR profile of Trimbow.

None of the serious asthma exacerbations (8/4 in the TRIMARAN BDP/FF/GB and BDP/FF groups, 12/11/6 events in the TRIGGER, BDP/FF/GB, BDP/FF and BDP/FF/Tiotropium groups) was considered to be related to treatment. The most frequently reported possible causes for the exacerbations were the underlying disease  or  respiratory  infections.  None  of  these  serious  asthma  exacerbations  caused  permanent withdrawal of study drug (only one case in the triple arm in the TRIMARAN study led to temporarily interruption). All but one of these serious asthma exacerbations led to hospitalisation, none to intubation.

All serious TEAEs classified as related to study medication were moderate in intensity and none of them led to study medication discontinuation. All but one serious TEAEs resolved by the end of the studies. The reported angle closure glaucoma was considered as related to study medication and did not resolve, but study medication was not stopped.

## Deaths

A total of 5 deaths was observed throughout the 6 presented trials, all were reported in the Phase III trials. Four of the deaths occurred in patients treated with Trimbow. All patients with fatal outcome had relevant concomitant cardiovascular diseases.

A dose relationship is not apparent.

Table 28 : Deaths reported in TRIMARAN and TRIGGER trials

| Study    | Medication                    |                                      | Patients with TEAE leading to death [n]   | TEAE leading to death [%]   | Related to study medication   |
|----------|-------------------------------|--------------------------------------|-------------------------------------------|-----------------------------|-------------------------------|
| TRIMARAN | BDP/FF/GB 100/6/12.5          | Left ventricular failure*            | 1                                         | 0.2                         | no                            |
| TRIMARAN |                               | Acute Pancreatitis                   | 1                                         | 0.2                         | no                            |
| TRIMARAN |                               | Acute cardiac failure/gastric cancer | 1                                         | 0.2                         | no                            |
| TRIMARAN | BDP/FF 100/6                  |                                      | -                                         | -                           | -                             |
| TRIGGER  | BDP/FF/GB 200/6/12.5          | Cerebral haemorrage*                 | 1                                         | 0.2                         | no                            |
| TRIGGER  | BDP/FF 200/6                  | Sudden cardiac death*                | 1                                         | 0.2                         | no                            |
| TRIGGER  | BDP/FF 200/6 + Tiotropium 2.5 |                                      | -                                         | -                           | -                             |

* Event classified as MACE (major adverse cardiovascular event)

None of the deaths was considered to be related to study medication.

## Other significant adverse events

ICS class effects (Comparative safety analysis of BDP/FF/GB 100/6/12.5 vs BDP/FF/GB 200/6/12.5) Lower respiratory tract infections (LRTI)

<div style=\"page-break-after: always\"></div>

The most common LRTIs in both treatment groups were bronchitis and viral respiratory tract infections which were observed in approximately 3% of patients each. Low numbers of patients (1.2% and 0.3% with BDP/FF/GB 200/6/12 and 100/6/12.5) presented with pneumonia. Frequencies of LRTIs were similar to the comparative BDP/FF treatments, none was assessed to be treatment related and none led to study medication discontinuation.

## Oropharyngeal candidiasis

Low numbers of patients (1.6% and 0.9% with BDP/FF/GB 200/6/12 and 100/6/12.5) presented with oropharyngeal  candidiasis,  assessed  as  treatment  related  in  1.4%  and  0.5%.  Frequencies  of oropharyngeal fungal infections were similar to the comparative BDP/FF treatments, none led to study medication discontinuation.

## Ocular effects

One patient (0.2%) treated with BDP/FF/GB 100/6/12 presented with cataract and blurred vision. The event was not considered treatment related and did not lead to treatment discontinuation.

## LABA and LAMA class effects (Integrated analysis of BDP/FF/GB [both strengths] vs BDP/FF [both strengths])

## Cardiovascular events including Major cardiovascular events (MACEs)

Vascular disorders were observed in 5.4% vs. 3.7% and cardiac disorders in 4.8% vs. 3.6% of patients treated with BDP/FF/GB compared to BDP/FF. None of the vascular events and few of the cardiac events were  considered  treatment-related  (0.5%  and  0.6%  with  BDP/FF/GB  and  BDP/FF,  respectively). Cardiovascular disorders led to study medication discontinuation in a low percentage of patients (vascular disorders:  0.1%  vs.  0.1%,  BDP/FF/GB  vs.  BDP/FF  respectively;  cardiac  disorders:  0.4%  vs.  0.1%, respectively).

## Major adverse cardiovascular events (MACEs)

Low numbers of patients (0.6% and 0.3% with BDP/FF/GB and BDP/FF) presented with MACE of which none was assessed as related to the study medication. No dose-relationship is obvious.

A total of 7 MACEs (acute myocardial infarction (3), atrial fibrillation, cardiovascular death due to heart failure, ischaemic stroke, death due to haemorrhagic stroke) were reported for the BDP/FF/GB groups (both strengths).

A  total  of  3  fatal  outcomes  were  reported:  'cardiovascular  death  due  to  heart  failure'  (BDP/FF/GB 100/6/12.5), 'death due to haemorrhagic stroke' (BDP/FF/GB 200/6/12.5) and 'sudden cardiac death' with BDP/FF 200/6).

The MACE rate per 1,000 patients per year was 6.3 with BDP/FF/GB and 3.6 with BDP/FF (calculated on a total of 11 events).

Table 29: MACEs reported in TRIMARAN and TRIGGER trials

| Study    | Medication           | Number of MACE, Number and %of Patients   | Number of MACE, Number and %of Patients   | Related to study medication   | Resolved/resolving by end of study   | Death   |
|----------|----------------------|-------------------------------------------|-------------------------------------------|-------------------------------|--------------------------------------|---------|
|          |                      | [n]                                       | [%]                                       |                               |                                      |         |
| TRIMARAN | BDP/FF/GB 100/6/12.5 | 4                                         | 0.7                                       | -                             | 3                                    | 1       |
| TRIMARAN | BDP/FF 100/6         | 1                                         | 0.2                                       | -                             | 1                                    | -       |

<div style=\"page-break-after: always\"></div>

| TRIGGER   | BDP/FF/GB 200/6/12.5          | 3   | 0.5   | -   | 2   | 1   |
|-----------|-------------------------------|-----|-------|-----|-----|-----|
| TRIGGER   | BDP/FF 200/6                  | 3   | 0.5   | -   | 2   | 1   |
| TRIGGER   | BDP/FF 200/6 + Tiotropium 2.5 | -   | -     | -   | -   | -   |

## Effects on glucose

Treatment-emergent events related to effects on glucose tolerance (Diabetes mellitus, hyperglycaemia, impaired fasting glucose, impaired glucose etc.) were observed in a similar percentage of patients with BDP/FF/GB and BDP/FF (1.3% vs. 1.0%). None of the events were considered treatment-related and none led to study medication discontinuation.

## Urinary retention

Urinary  retention  and  associated  events  were  observed  in  a  similar  percentage  of  patients  with BDP/FF/GB and BDP/FF (0.9% vs. 0.6%, respectively). None of these events were considered treatmentrelated. 1 event of stress urinary incontinence led to study medication discontinuation with BDP/FF.

## Muscle spasms

Muscle spasms were observed in a similar percentage of patients with BDP/FF/GB and BDP/FF (0.8% vs. 0.6%,  respectively).  A  similar  percentage  of  patients  experienced  an  event  which  was  considered treatment-related with BDP/FF/GB and BDP/FF (0.3% vs. 0.3%, respectively). None of the events led to study medication discontinuation.

## Dry mouth/dry throat

Dry mouth/dry throat was observed in a slightly higher percentage of patients with BDP/FF/GB compared to  BDP/FF  (0.9%  vs.  0.2%,  respectively).  This  was  considered  treatment-related  with  BDP/FF/GB 200/6/12.5 and with BDP/FF/GB 100/6/12.5 in 0.6% vs. 0.1%, respectively. One event of dry throat led to study medication discontinuation with BDP/FF.

## Tremor

Tremor was observed in a similar percentage of patients with BDP/FF/GB and BDP/FF (0.5% vs. 0.3%, respectively). Of these events, 0.3% and 0.2% were considered treatment-related with BDP/FF/GB and BDP/FF, respectively. None led to study medication discontinuation.

## Effects on potassium

Treatment-emergent events related to effects on potassium (hyper- or hypokalemia) were observed in a similar percentage of patients with BDP/FF/GB and BDP/FF (0.2% vs. 0.3%, respectively). None of the events were considered treatment-related and none led to study medication discontinuation.

## Ocular effects

Treatment-emergent ocular effects were observed in a similar percentage of patients with BDP/FF/GB and BDP/FF (0.1% vs. 0.3%, respectively). Events of angle closure glaucoma and visual acuity reduced (each  in  1  patient  with  BDP/FF)  were  considered  treatment-related.  None  led  to  study  medication discontinuation.

## Constipation

Constipation and associated events were observed in a similar percentage of patients with BDP/FF/GB and BDP/FF (0.1% vs. 0.2%, respectively). None of these events were considered treatment-related and none led to study medication discontinuation.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Haematology and Blood chemistry

Haematology and Blood chemistry tests were performed at screening, week 26 and week 52 in the TRIMARAN and TRIGGER studies.

For all haematology parameters, the majority of patients presented normal or not significantly abnormal values at all time points. A low number of patients (≤ 1%) showed clinically significant abno rmal values. Three clinically significant abnormalities in haematology parameters were associated with serious TEAEs (squamous cell carcinoma of the cervix, mantle cell lymphoma stage IV, pulmonary tuberculosis and anaemia due to vitamin B12 deficiency). None of these serious TEAEs were considered related to study medication.

For all biochemistry parameters, the majority of patients presented normal or not significantly abnormal values at screening, Week 26 and Week 52. A low number of patients (≤ 1.6 %) showed clinically significant abnormal values. None of these abnormalities in biochemistry parameters were reported as serious TEAEs or associated with serious TEAEs.

## Vital signs

Vital signs included HR, SBP and DBP and were assessed at screening, at pre-dose and 45 minutes postdose at all visits from Week 0 (V2) to Week 52 (V7) in the TRIMARAN and TRIGGER studies. The mean changes from baseline were minimal and similar across time points and with either treatment. 1 serious TEAE of  'hypertensive  crisis'  was  reported  with  BDP/FF/GB  200/6/12.5  and 1  with  BDP/FF  100/6,  1 serious TEAE of 'worsening of hypertension' was reported in 1 patient with BDP/FF 200/6; all patients were  already  suffering  from  hypertension  at  study  entry.  Neither  of  these  TEAEs  was  considered treatment-related, all were moderate in severity and had resolved by the end of the study without any change to study medication.

## ECG

The adjusted mean changes in HR from baseline / pre dose to 45 minutes post-dose were minimal and generally similar across time points with all treatments in the TRIMARAN and TRIGGER studies.

The adjusted mean changes in QTcF from baseline / pre dose to 45 minutes post-dose were minimal and generally similar across time points and treatments (BDP/FF/GB and BDP/FF) in the TRIMARAN and TRIGGER study. 1 (0.2%) patient with BDP/FF/GB 100/6/12.5 and 3 (0.5%) patients with BDP/FF 100/6 each had 1 non-serious TEAE (PT: electrocardiogram QT prolonged) associated with clinically significant 12-lead ECG abnormalities in HR. All 4 TEAEs were considered related to the study medication, were mild in intensity and had resolved by the end of the study.

## Safety in special populations

## Paediatric population

Children were not included in the studies.

## Pregnancy and Lactation

3  pregnancies  (withdrawn from TRIGGER study) and 2 cases of pregnancy in the partners of study patients were reported. No issues related to either mothers or the babies were reported, 2 cases were lost to follow up.

## Subgroup analysis

<div style=\"page-break-after: always\"></div>

The safety population wa s stratified by Age (&lt; 65 years, ≥ 65 years), BMI at screening (&lt; 25, ≥ 25 to &lt; 30, ≥ 30 kg/m 2 ),  use  of  spacer  during  the  study  (yes/no)  and  Presence  of  relevant  concomitant cardiovascular diseases.

In the elderly patients (≥ 65 years) more TEAEs in the cardiac, vascular, cerebrovascular and anticholinergic disorders were seen in either treatment group compared to younger patients.

Table 30 : TEAEs stratified by age group - TRIMARAN and TRIGGER studies (safety population)

|                                                                                       | Age < 65 year's                           | Age < 65 year's              | Age≥65year's                              | Age≥65year's                 |
|---------------------------------------------------------------------------------------|-------------------------------------------|------------------------------|-------------------------------------------|------------------------------|
|                                                                                       | BDP/FF/GB 100/6/12.5 and 200/6/12.5 N=943 | BDP/FF 100/6 and 200/6 N=926 | BDP/FF/GB 100/6/12.5 and 200/6/12.5 N=204 | BDP/FF 100/6 and 200/6 N=221 |
| Total AEs                                                                             | 691 (73.3)                                | 722 (78.0)                   | 150 (73.5)                                | 176 (79.6)                   |
| Serious AEs - Total                                                                   | 45 (4.8)                                  | 31 (3.3)                     | 11 (5.4)                                  | 24 (10.9)                    |
| -Fatal                                                                                | 2 (0.2)                                   | 0                            | 2 (1.0)                                   | 1 (0.5)                      |
| -Hospitalization/prolongexistinghospitalization                                       | 42 (4.5)                                  | 31 (3.3)                     | 10 (4.9)                                  | 23 (10.4)                    |
| - Life-threatening                                                                    | 2 (0.2)                                   | 2 (0.2)                      | 2 (1)                                     | 2 (0.9)                      |
| - Disability/incapacity                                                               | 2 (0.2)                                   | 0                            | 0                                         | 0                            |
| - Other (medically significant)                                                       | 6 (0.6)                                   | 8 (0.9)                      | 3 (1.5)                                   | 3 (1.4)                      |
| AEs leading to drop-out                                                               | 6 (0.6)                                   | 9 (1.0)                      | 2 (1.0)                                   | 4 (1.8)                      |
| Psychiatric disorders                                                                 | 5 (0.5)                                   | 1 (0.1)                      | 1 (0.5)                                   | 2 (0.9)                      |
| Nervous system disorders                                                              | 68 (7.2)                                  | 72 (7.8)                     | 14 (6.9)                                  | 20 (9.0)                     |
| Accidents and injuries                                                                | 16 (1.7)                                  | 23 (2.5)                     | 7 (3.4)                                   | 4 (1.8)                      |
| Cardiac disorders                                                                     | 34 (3.6)                                  | 24 (2.6)                     | 18 (8.8)                                  | 11 (5.0)                     |
| Vascular disorders                                                                    | 32 (3.4)                                  | 19 (2.1)                     | 10 (4.9)                                  | 6 (2.7)                      |
| Cerebrovascular disorders                                                             | 5 (0.5)                                   | 2 (0.2)                      | 2 (1.0)                                   | 3 (1.4)                      |
| Infections and infestations                                                           | 252 (26.7)                                | 297 (32.1)                   | 56 (27.5)                                 | 74 (33.5)                    |
| Anticholinergic syndrome                                                              | 15 (1.6)                                  | 11 (1.2)                     | 6 (2.9)                                   | 1 (0.5)                      |
| Quality of life decreased                                                             | 48 (5.1)                                  | 48 (5.2)                     | 12 (5.9)                                  | 13 (5.9)                     |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 14 (1.5)                                  | 18 (1.9)                     | 4 (2.0)                                   | 2 (0.9)                      |

Source: CSR study TRIMARAN, Listing 16.2.7.2; CSR study TRIGGER, Listing 16.2.7.2

Number and percentage of patients with at least one TEAE are presented

N=Number of patients in the safety population in the subgroup

In  the  group  with  concomitant  CVD  for  both  BDP/FF/GB  and  BDP/FF,  the  proportion  of  patients experiencing at least one TEAE, one SAE, and an AE leading to drop out was higher compared to the group without concomitant CVD.

No relevant  trends  were  observed  in  the  other  analysed  subgroups  compared  to  the  overall  Safety population in terms of TEAEs, ADRs, TEAEs leading to death and TEAEs leading to study medication discontinuation.

## Immunological events

N/A

## Safety related to drug-drug interactions and other interactions

No specific analysis of safety was performed of drug interactions.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Table 31: Discontinuations from study medication

| Study   | Medication                    |   TEAEs leading to discontinuation |   Patients [n] |   Patients [%] | Related to study medication   | TEAE                         | Resolved by end of study   |
|---------|-------------------------------|------------------------------------|----------------|----------------|-------------------------------|------------------------------|----------------------------|
| TRIMRAN | BDP/FF/GB 100/6/12.5          |                                  5 |              4 |            0.7 |                               |                              |                            |
| TRIMRAN | BDP/FF 100/6                  |                                  7 |              5 |            0.9 | 2                             | Rhinitis, Oral candidiasis   | No Yes                     |
| TRIGGER | BDP/FF/GB 200/6/12.5          |                                  4 |              4 |            0.7 | 1                             | Palpitations                 | Yes                        |
| TRIGGER | BDP/FF 200/6                  |                                  8 |              8 |            1.4 | 2                             | Dry throat, Oral candidiasis | Yes                        |
| TRIGGER | BDP/FF 200/6 + Tiotropium 2.5 |                                  2 |              2 |            0.7 | 1                             | Arthralgia                   | Yes                        |

The overall rate of discontinuation of study medication was low.

The ADRs leading to discontinuations were mild to moderate in intensity and resolved mostly by the end of the trial. Across treatment groups only few TEAEs leading to discontinuation were attributed to study medication (rhinitis, oral candidiasis, dry throat, palpitation and arthralgia).

## Post marketing experience

No post-marketing data are available concerning the use of BDP/FF/GB 100/6/12.5 and 200/6/12.5 in patients with asthma.

Post-marketing data are available for the use of BDP/FF/GB 100/6/12.5 in patients with COPD for the period from 31 July 2017 to 16 July 2019. No signals were identified. The safety profile and the benefitrisk balance remained unchanged (PSUSA/00010617/201907).

## 2.8.1. Discussion on clinical safety

Trimbow  100/6/12,5  has  already  a  marketing  authorisation  for  the  indication  chronic  obstructive pulmonary disease (COPD) since 2017. Thus, the safety profile has already been established for the lower strength in a patient population, which is generally older and has more co-morbidities than the asthma patient population under review in this application. The new higher strength under review applies to the ICS component only (800 μg total daily dose or 200 μg per met ered dose) and is intended only for the use in the asthma indication.

The FDC double inhaler (BD/FF 100/6 and 200/6) is already approved in patients with asthma since 2006 with a well-established safety profile in this population. However, glycopyrronium has not been approved for patients with asthma to date. Tiotropium is currently the only approved LAMA for the treatment of asthma.

A total of 1147 patients with asthma were exposed to at least 1 dose of Trimbow (both strengths) in the two completed Phase III studies with a mean treatment duration of 354 days (range 1 - 400). 836

<div style=\"page-break-after: always\"></div>

patients (&gt;70%) were treated for at least 12 months, which is in line with ICH E1. Exposure expressed in patient-years was 559.2 and 553.7 patient years in the TRIMARAN and the TRIGGER study.

The majority of patients included in the Phase III trials were non-smoking female Caucasians and had been diagnosed with asthma for an average of approximately 25 years. Demographic characteristics and cardiovascular risk factors were balanced between groups.

The  most  common  TEAEs  reported  with  BDP/FF/GB  (both  strengths)  were  Asthma  exacerbation, Nasopharyngitis, Headache, viral Respiratory tract infection and Bronchitis. The incidence of TEAEs in patients  treated  with  BDP/FF/GB  was  slightly  lower  than  in  patients  treated  with  BDP/FF  plausibly explained with a lower incidence of asthma exacerbations. The majority of TEAEs were mild or moderate in intensity and resolved by the end of the study.

Overall, treatment-emergent ADRs were reported at low frequencies. The most common ADRs were dysphonia, oral candidiasis, dry mouth, oropharyngeal candidiasis, prolonged QT, muscle spasms, tremor and headache, which are in line with the already known safety profile of Trimbow and with expected ICS, LABA and LAMA class effects. ICS ADRs such as oral candidiasis were observed slightly more often in the higher BDP/FF/GB 200/6/12.5 strength compared to the lower 100/6/12.5 strength. For other ADRs no dose relationship was apparent.

TEAEs  were  evaluated  by  the  investigators,  who  assessed  causality  considering  factors  like  time relationship between study drug intake and event's onset, dechallenge and rechallenge, class effects, medical history and concomitant medications, lack of efficacy/worsening of existing condition, protocol procedures. TEAEs were defined as ADRs if there was a reasonable causal relationship with study drug, i.e. facts (evidence) or arguments suggesting the causal relationship. A number of TEAEs (especially MACE and CV disorders) which were considered as not related to study medication although being already labelled as ADR in the SmPC or being ICS, LAMA or LABA class effects was explained in detail according to patients narrative.

The process to calculate the frequencies of ADRs to be outlined in the SmPC was described as based on the overall safety population of patients with asthma treated in the TRIGGER and TRIMARAN trials as well  as  on  the  156  asthma  patients  treated  with  free  combination  of  BD/FF  400/12  +  GB  50  daily (TRISKEL),  although  application  and  length  of  treatment  differed.  The  TRISKEL  design  included  an investigational phase of 21 weeks and comprised 3 cross-over treatment periods (different GB strengths) of 6 weeks separated by an open-label wash-out period on BD/FF 100/6. In addition, in line with the application in COPD, also ADRs reported in the BDP/FF pMDI 200/6 SmPC were taken into consideration to cover the high dosage of BDP. In line with the reactions observed in the above-mentioned studies, the MAH proposed to add the ADRs 'fungal (oro)pharyngitis' with a frequency 'uncommon'; and to add 'exacerbation  of  asthma'  and  'supraventricular  extrasystoles'  with  a  frequency  'rare'.  Those  are consistent with the known effects of the individual components of the triple fixed dose combination and thus their inclusion to SmPC section 4.8 was endorsed by CHMP. Some ADRs reported in the TRIMARAN and TRIGGER studies were not considered for the proposed SmPC due to the very low incidence (single instances) or due to lack of evidence from post-marketing data: glossitis, glossodynia, laryngitis, alanine aminotransferase  increased,  gamma-glutamyl  transferase  increased  and  atrioventricular  block  first degree. These ADRs will be monitored in the post-marketing setting through routine pharmacovigilance activities. This was supported by CHMP. Furthermore, the frequency of the ADR 'pharyngeal erythema' has been changed from 'rare' to 'uncommon' and the ADR 'asthmatic crisis' added with a frequency 'uncommon' according to the BDP/FF SmPC. A footnote is included to the table in section 4.8 of the SmPC to clarify which ADRs were reported in the SmPCs of the single components, but not during the clinical development of CHF 5993 pMDI.

<div style=\"page-break-after: always\"></div>

Aproximately half of the ADRs occurred within the first 3 months of study treatment and a drop in ADR reports in the last 6 months of the one-year study. This information has been adequately reflected in the summary of the safety profile in section 4.8 of the Trimbow SmPC.

The  proportion  of  cardiac  disorder  ADRs  was  equally  distributed  between  groups  with  and  without cardiovascular risk factors.

The two pivotal studies excluded patients who had clinically significant CV conditions including CHF, IHD, arrhythmias and QTcF prolongation. This is adequately described in the SmPC section 4.4. The MAH has identified prolonged QT interval as an ADR, based on a low numbers of events, 3 events occurred in the double inhaler compared to 1 event in the triple inhaler. QT prolongation has previously been captured in the RMP as an important identified risk.

In patients with cardiovascular co-morbidities or risk factors the proportion of ADRs was higher with BDP/FF/GB (both strengths) and BDP/FF (both stregths), but mainly driven by Infections and Infestations and Respiratory, thoracic and mediastinal disorders ADRs.

The incidence of serious adverse events was low and similar between BDP/FF/GB strengths (both 4.9%) and comparable to treatment with BDP/FF. The most common serious TEAEs (in ≥ 2 patients) were Asthma exacerbation, Pneumonia, Atrial fibrillation and acute Pancreatitis. Atrial fibrillation, oesophageal candidiasis, pneumonia and angle closure glaucoma were attributed to the study medication and are known class effects.

The frequency of MACE and the observed difference between the treatment groups is very low (0.6% vs. 0.3% with BDP/FF/GB [both strengths] and BDP/FF [both strengths] respectively). In the TRIMARAN study more events have been observed in the BDP/FF/GB arm compared to the BDP/FF arm (4 events vs 1 event) while in the TRIGGER study the distribution was equal between groups (3 events each). No MACEs were reported in the BDP/FF 200/6 + Tiotropium 2.5 arm, most likely confounded by the smaller sample size randomized to that treatment arm. Incidences, however, seem to be too small to conclude a trend or a new concern. No MACE was considered related to study medication.

Deaths were reported in a total of 5 patients with a higher occurrence (4 vs 1 patient) in the BDP/FF/GB groups compared with BDP/FF. The imbalance is apparent only in the TRIMARAN study (3 vs 0). In the TRIGGER study one fatal outcome was observed in both of the treatment groups. Considering the overall low incidence and the assessment of all fatal outcomes not to be treatment related to study treatment, no safety concern can be derived from these findings.

Clinically  significant  changes  in  haematology  parameters  were  reported  in  less  than  1%  of  the participants, this accounts also for most of the blood chemistry parameters. As local laboratories were used to assess the samples, reference normal ranges were not directly comparable between patients. Abnormal laboratory values occurred either in association with relevant underlying medical conditions (e.g. liver disease, hypercholesterolemia, obesity, diabetes, etc.) or were associated to a TEAE. No trends related  to  changes  in  laboratory  parameters  in  association  with  either  BDP/FF/GB  (100/6/12.5  or 200/6/12.5) or BFD/FF (100/6 or 200/6) could be identified.

The  observations  in  ECG  abnormalities  including  QTcF  changes  were  overall  comparable  between treatment groups and in line with the already known safety profile.

None of the performed subgroup analyses (BMI, spacer use and cardiovascular diseases) highlighted relevant differences in the safety profiles.

In terms of TEAE analyses stratified by age there was no discernible trend to suggest that patients ≥ 65 years experienced more adverse events in the triple inhaler arm compared to younger patients. In fact, elderly patients appeared to have less events (67.3% v 72.7%) in the higher dose triple inhaler however elderly patients represented only 17% of the population (n=98 in that triple inhaler arm of the total 571

<div style=\"page-break-after: always\"></div>

patients). The observed findings, that in the elderly patients (≥ 65 years) more TEAEs in the cardiac, vascular,  cerebrovascular and anti-cholinergic  disorders as  well  as  in accidents  and  injuries  and anticholingergic syndrome were seen with BDP/FF/GB and BD/FF (both strengths) compared to younger patients is not unexpected according to the usual age distribution of these observed disorders. For LABA and LAMAclass TEAEs, there was a higher occurrence in the ≥ 65 years age category with BDP/FF/GB, mainly  driven  by vascular  disorders  (hypertension,  blood  pressure  increased)  and  cardiac  disorders TEAEs with the LAMA component being likely to be the contributor to this increase in TEAEs in this age group. Considering however the low number and proportion of patients experiencing a LABA or LAMAclass ADR no new safety concern can be derived from this data. No age-related trend between medium and high- ICS dose BDP/FF/GB could be observed. This is adequately reflected in section 4.2 of the SmPC.

The interaction potential of Trimbow is already established.

The overall rate of discontinuation of study medication was low. The ADRs leading to discontinuations were mild to moderate in intensity and resolved mostly by the end of the trial. Across treatment groups only few TEAEs leading to discontinuation were attributed to study medication (rhinitis, oral candidiasis, dry throat, palpitations and arthralgia.

## 2.8.2. Conclusions on the clinical safety

From  the  safety  data  presented  in  this  application,  there  were  no  particular  signals  that  suggest  a different  safety  profile  of  Trimbow  in  the  new  asthma  indication  or  for  the  newly  introduced  higher strength  BDP/FF/GB  200/6/12.5.  The  main  ADRs  that  have  been  observed,  i.e.  dysphonia,  oral candidiasis, dry mouth, oropharyngeal candidiasis, prolonged QT, muscle spasms, tremor and headache are in accordance with the known ICS, LAMA and LABA class effects.

The clinical safety sections of the SmPC do sufficiently reflect the available safety data.

## 2.9. Risk Management Plan

## Safety concerns

| Important Identified risks:   | None                               |
|-------------------------------|------------------------------------|
| Important Potential risks:    | Cardio- and cerebrovascular events |
| Missing information:          | None                               |

## Pharmacovigilance plan

No other routine PhV activities beyond adverse reactions reporting, signal detection and routine PSUR/PBRER in order to further characterize the potential risk.

| Safety concern: Important Potential risk - Cardio- and cerebrovascular events   | Safety concern: Important Potential risk - Cardio- and cerebrovascular events   | Safety concern: Important Potential risk - Cardio- and cerebrovascular events   |
|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Areas requiring confirmation or further investigation                           | Proposed routine PhV activities                                                 | Objectives                                                                      |

<div style=\"page-break-after: always\"></div>

| Safety concern: Important Potential risk - Cardio- and cerebrovascular events   | Safety concern: Important Potential risk - Cardio- and cerebrovascular events                                                                                                                                                     | Safety concern: Important Potential risk - Cardio- and cerebrovascular events   |
|---------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Cardio-and cerebrovascular events                                               | All ADRs of cardio- and cerebrovascular events will be reviewed regularly during the signal detection activity. Cumulative data will be discussed in aggregate reports such as PSURs/PBRERs according to regulatory requirements. | On-going characterisation of risk in the post marketing setting.                |

No additional PhV activities are planned for Trimbow pMDI.

## Risk minimisation measures

| Safety concern                     | Routine risk minimisation measures                                                                                     | Pharmacovigilance activities   |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| Cardio- and cerebrovascular events | - Statement in section 4.4 and labelled in section 4.8 of the SmPC - Statement in section 2 and in section 4 of the PL | Routine PhV activities         |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 6.5 is acceptable.

## 2.10. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.11. Product information

## 2.11.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

This consultation procedure was already successfully completed for the medium ICS dose strength of Trimbow pressurised inhalation solution package during the initial marketing authorisation procedure in the  COPD  indication  and  in  the  procedure  extending  its  indication  (EMEA/H/C/004257/II/0002). Furthermore, the posology and instructions for use remain valid for the new indication (asthma) and new

<div style=\"page-break-after: always\"></div>

ICS  dose  strength,  and  the  new  indication  targets  a  comparable  and  potentially  younger  patient population, therefore the CHMP considered  that the proposed package leaflet changes do not affect the results of the original user consultation.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The GINA 2019 updated report defines asthma as an heterogenous disease, usually characterised by chronic airway inflammation and hyper-responsiveness. The main consequences are recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. Exacerbation events are a significant burden for patients and the community, and in severe cases may be life-threatening.

## 3.1.2. Available therapies and unmet medical need

The long-term goals of asthma management are therefore control of disease-related symptoms and reduction in the risk of further airway damage and asthma exacerbations, while keeping the potential for adverse drug reactions as low as possible.

Persistent asthma requires long-term, daily treatment with « controller » medications which in accordance with GINA are adjusted in a stepwise escalating manner. Daily administration of ICS constitutes the backbone for GINA step 2 to 5 patients. With increasing disease severity, long-action ß-agonists (LABA) are  added  to  the  therapeutic  regimen.  However,  a  relevant  percentage  of  asthma  patients  remains inadequately controlled in spite of treatment with medium to high dose ICS/LABA treatment.

Until recently, the only available step-up options for patients who were inadequately controlled by high doses of ICS/LABA was the addition of drugs such as theophylline, injectable anti-immunoglobulins and oral corticosteroids.

The first LAMA (tiotropium, Spiriva Respimat inhalation solution) as an add-on to ICS/LABA received regulatory clearance in the asthma indication in Europe in September 2014. In two pivotal trials, modest but sustained (up to 24 hours) bronchodilation was reported after adding once daily treatment with tiotropium to an ICS/LABA controller regimen in patients with uncontrolled asthma. In the two trial, the mean increase from baseline in pre-dose FEV1 were in the order of +86 mL and +154 mL , respectively. Step-up treatment with tiotropium also reduced the episodes of asthma worsening and in particular the risk of severe asthma exacerbations (overall reduction of -21% ; hazard ratio 0.79, p=0.03).

Nevertheless, an unmet medical need remains for patients at the more severe end of the asthma disease spectrum.

Actual treatment guidance (GINA 2019) recommends the following preferred step-up options:

- GINA step 4: increase ICS from medium to high;
- GINA step 5: limited options, add-on tiotropium or biologic therapy (e.g. anti-IgE, anti-IL5/5R or anti-IL4R), add-on low dose oral corticosteroids.

## 3.1.3. Main clinical studies

The MAH has performed two pivotal phase III (TRIMARAN and TRIGGER), randomised, double-blind, active-controlled clinical trials of 52 weeks duration in order to investigate the long-term efficacy and safety of CHF 5993 in patients whose asthma was uncontrolled on ICS/LABA treatment and who remained

<div style=\"page-break-after: always\"></div>

at  risk  of  experiencing  asthma  exacerbations  (inclusion  criterion:  at  least  one  severe  asthma exacerbation in the year prior to study enrolment).

The main objective of these trials was to demonstrate the incremental clinical effect attributable to the addition of GB to the dual fixed-dose combination treatment. For that purpose, the superiority of the triple fixed-dose treatment with CHF 5993 (incl. GB) over the dual fixed-dose combination ICS/LABA (CHF 1535) in terms of a co-primary endpoint (pre-dose FEV1 at week W26 and rate of moderate to severe exacerbations at week W52) was to be demonstrated in a parallel group design.

Both trials had essentially the same design and methodology, but enrolled patients with different degrees of disease severity (according to GINA 2019). As a result, two different ICS dose strengths of CHF 5993 were investigated (Trimbow, CHF 5993 100/6/12.5 and CHF 5993 200/6/12.5):

- TRIMARAN (N=1155 randomised patients):

GINA step 4 patients uncontrolled on medium dose ICS / LABA;

- TRIGGER (N=1437 randomised patients)

GINA step 5 patients uncontrolled on high dose ICS / LABA.

## 3.2. Favourable effects

In  the  first  of  the  pivotal  studies  ( TRIMARAN ),  the  triple  medium  ICS  dose  regimen  (CHF  5993 100/6/12.5) was found to be superior to the corresponding dual treatment regimen (CHF 1535 100/6) in GINA 2019 step 4 patients in terms of the co-primary endpoint and two out of three key secondary endpoints.

The  second  confirmatory  trial  ( TRIGGER )  involving  the  triple  high  ICS  dose  regimen  (CHF  5993 200/6/12.5) failed to achieve its primary objective in GINA 2019 step 5 patients. While the change from baseline in pre-dose FEV1 was statistically significant, the reduction in the rate of moderate to severe exacerbations was not. Therefore, the pre-defined hierarchical testing strategy was broken early and the overall type-1 error for the lower ranking endpoints not preserved.

In both pivotal studies, the incremental effect of adding GB to dual treatment with ICS/LABA on the primary lung function endpoint (change from baseline of pre-dose FEV1 at week W26) was statistically significant, but modest from a clinical point of view (additional bronchodilation +57 mL and +73 mL , respectively).  This  effect  was  more  or  less  maintained  over  the  entire  treatment  period  (adjusted between-group difference of +38 mL and +86 mL at week W52); this result was no more statistically significant in the TRIMARAN study.

The  minimal  clinically  important  difference  (MCID)  in  FEV1  has  not  been  rigorously  established  for asthma,  but  it  is  likely  that  changes  of  100-200  mL  in  FEV1  are  clinically  important.  The  reported improvements in lung function was not large, but on balance and in comparison to the results reported for other medicinal products could be considered as borderline clinically relevant.

The beneficial effect of CHF 5993 on the reduction of moderate to severe exacerbations was modest. The -15% decrease in the TRIMARAN trial was statistically significant, while the -12% decrease in the TRIGGER trial was not, thereby breaking the pre-defined statistical testing hierarchy.

Therefore, the reduction by -23% (adjusted hazard ratio 0.077, 95%CI [0.636; 0,933], p=0.008) in the rate of severe asthma exacerbations in the pre-defined pooled analysis - though considered important was not confirmatory and the resulting p-value needed to be considered a nominal value only.

In  an exploratory post  hoc analysis of  TRIGGER  data,  a  risk  reduction  of -25.9% in  terms  of moderate to severe exacerbations was observed (result nominally statistically significant; p=0.002), if the  analysis  was  limited  to  a patient  subpopulation representing  approx. two  thirds of  the  ITT

<div style=\"page-break-after: always\"></div>

population (i.e. patients with persistent airflow limitation, PAL ). In the PAL subset, a marked effect was also demonstrated on the rate of severe exacerbation (risk reduction of -31.8% , nominal p=0.019).

This subpopulation was believed by the MAH to more closely resemble the patient population enrolled in the pivotal and replicate PrimoTinA trials, leading to regulatory approval of add-on treatment with the LAMA tiotropium in asthma in 2014. These effect sizes of CHF 5993 200/6/12.5 reported in this patient subpopulation exceeded those reported for tiotropium in the PrimoTinA studies (pooled results).

The percentage of patients classified as FEV1 responders (i.e. those with a change from baseline in predose FEV1 ≥100 mL) was numerically greater with CHF 5993 than with CHF 1535 at both weeks W26 and W52, but this did not consistently achieve statistical significance (TRIMARAN: 53.7% vs. 44.9% and 53.2% vs. 48.4% at weeks W26 and W52, respectively; TRIGGER: 57.4% vs. 45.0% and 57.1% vs. 42.2%, respectively).

In both trials, a substantial proportion of patients in all treatment arms reported better symptomatic asthma control and an improvement in other measures of patient-reported outcome over the 52 weeks of randomised treatment. However, the improvement was comparable in the two treatment arms (CHF 5993 and CHF 1535), so that no added benefit was observed when a second bronchodilator (glycopyrronium bromide) was added to medium or high dose ICS/LABA treatment.

## 3.3. Uncertainties and limitations about favourable effects

This  was  a  fixed-dose  combination  application  and  therefore  -  as  required  by  the  respective  CHMP guidance - the clinical benefit of adding GB to the dual fixed dose combination needed to be shown.

In both studies, statistically significant, but clinically moderate improvements in lung function were observed at week W26 (co-primary variable: change from baseline in pre-dose FEV1 at week W26). It is noted that in the trial with less severely affected patients (TRIMARAN), the treatment effect was not consistently maintained over the 52-week treatment period (adjusted mean difference of +37 mL by week W52 and no more statistically significant).

However, when assessing these values, it needs  to  be  taken  into  consideration,  that  in  both  trials, relevant improvements in pre-dose FEV1 of &gt;100 mL were already reported during the two-week run-in period in both treatment groups. During the subsequent randomised treatment period, further increases in pre-dose FEV1 of clinical relevance have been rapidly observed with both dual and triple treatment and were more or less maintained over the remainder of the 52-week treatment period. Taken together, this may explain why the room for a more marked improvement by the addition of GB to the ICS/LABA regimen and incremental effect over CHF 1535 was small and may have been limited by a ceiling effect.

In both trials, the effect of CHF 5993 on the other co-primary endpoint (i.e., the rate of moderate to severe asthma exacerbations ) in absolute terms was small, and not statistically significant in the second trial (TRIGGER study), thereby failing to achieve the study's primary objective.

<div style=\"page-break-after: always\"></div>

In view of the broken statistical testing hierarchy, the reduction in the rate of severe asthma exacerbations in the pre-defined, pooled analysis across the two pivotal studies achieved a clinically relevant order of magnitude (risk reduction of minus 23%) but could not be considered confirmatory evidence.

A  limitation  of  the  TRIMARAN  study  assessing  the  lower  ICS  dose  strength  product  (CHF  5993 100/6/12.5) in asthma step 4 patients is the fact that the preferred step-up option of GINA 2019 was not included in the trial design. It remains therefore unanswered  a) what the corresponding effect size would have been in this group of patients uncontrolled on medium dose ICS/LABA, if the ICS dose was increased rather than adding a LAMA;  and b) whether phenotype subgroups could be identified liable to benefit more from one or the other step-up option.

In view of the fact that the TRIGGER trial, assessing the higher ICS dose strength product (CHF5993 200/6/12.5) in asthma step 5 patients, failed to achieve its primary objective, a limitation of this trial is the fact that the open-label tiotropium arm was included by the MAH for ' benchmarking ' purposes and an exploratory comparison only. No formal non-inferiority hypothesis was formulated.

## Exploratory post hoc analyses

Exploratory post  hoc analyses  presented  by  the  MAH  (among  them  the  analysis  in  the patient subpopulation with persistent airflow limitation, PAL ) suggest a marked treatment effect of CHF 5993 200/6/12.5 on the exacerbation endpoint. The subgroup of patients with persistent airflow limitation in TRIGGER  may  in  fact  more  closely  correspond  to  the  patient  population  included  in  the  replicate PrimoTinA studies with tiotropium than the full ITT population of TRIGGER. There remain, however, other important differences  between  TRIGGER  and  PrimoTinA  studies,  making  such  a cross-study comparison difficult (i.e. patients enrolled in PrimoTinA studies continued to take their individual pretrial maintenance / background asthma therapy with no standardisation or optimisation; the definition of what represents a severe asthma exacerbation significantly differed from the one used in the TRIGGER study).

As the TRIGGER study was not powered to confirm the non-inferiority of CHF 5993 200/6/12 versus the open-label,  active  comparator,  any within-study  comparison of  these  two  treatments  options  is afflicted  with  a  relevant  degree  of  uncertainty.  It  was  however  a  consistent  observation  that  the extemporaneous triple combination product including tiotropium was numerically superior to CHF 5993 200/6/12.5, in particular in terms on the effect on the rate of severe asthma exacerbations. The adjusted rate ratios vs CHF 1535 200/6 and corresponding 95%CI in ( post hoc ) analyses were:

| • CHF 5993 (pre-defined pooled analysis)       | 0.770 [0.636;0.933], p=0.008   |
|------------------------------------------------|--------------------------------|
| • CHF 5993 200/6/12.5 (ITT dataset)            | 0.797 [0.619;1.027], p=0.079   |
| • CHF 5993 200/6/12.5 (post hoc PAL subgroup)  | 0.682 [0.494;0.940], p=0.019   |
| • CHF 1535 200/6 plus tiotropium (ITT dataset) | 0.640 [0.458;0.895], p=0.009   |

However, it needs to be reminded that with the exception of the pre-defined pooled analysis, all others were exploratory and data-driven so that their robustness and validity is subject to a relevant degree of uncertainty.

## 3.4. Unfavourable effects

Cardio- and cerebro-vascular AEs are considered key unfavourable effects, due to the concomitant administration of a LABA and a LAMA. Long-acting anti-cholinergics act as parasympatholytics whereas LABAs act as sympathomimetics, both associated with increased risk of tachyarrhythmias, myocardial ischaemia, stroke and death.

<div style=\"page-break-after: always\"></div>

The cardiovascular safety profile was assessed in the long-term pivotal studies, changes in HR, QTcF were minimal and comparable between both dose strengths of BDP/FF/GB vs. all other treatments. Additionally, MACEs were recorded, the number of events was low (0.6% and 0.3% with BDP/FF/GB and BDP/FF) and generally similar among treatments. None of the events has been attributed to study treatment. The MACE rate per 1,000 patients per year was 6.3 with BDP/FF/GB and 3.6 with BDP/FF (calculated on a total of 11 events).

The following ADRs were added to section 4.8 of the SmPC: 'fungal (oro)pharyngitis' with a frequency 'uncommon', 'asthmatic crisis' with a frequency 'uncommon', 'exacerbation of asthma' with a frequency 'rare' and 'supraventricular extrasystoles' with a frequency 'rare'. In addition, the frequency of the ADR 'pharyngeal erythema' has been changed from 'rare' to 'uncommon'.

## 3.5. Uncertainties and limitations about unfavourable effects

The two pivotal studies excluded patients who had clinically significant CV conditions including CHF, IHD, arrhythmias and QTcF prolongation. Although adequately addressed in SmPC section 4.4 that no data in these patients has been generated and therefore treatment should be performed with caution, the uncertainty remains on how the safety profile presents in these patients.

## 3.6. Effects Table

Table 32: Effects Table for CHF 5993 100/6/12.6 (TRIMARAN study) and CHF 5993 200/6/12.6 (TRIGGER study)

| Effect                                        | Short Descrip tion                            | Unit                                          | Treatment (T) CHF5993                              | Control 1 (C1) CHF1535                             | Control 2 (C2) CHF1535 + tiotropium           | Uncertainties/ Strength of evidence               | References                                    |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------|---------------------------------------------------|-----------------------------------------------|
| Favourable Effects (pivotal phase III trials) | Favourable Effects (pivotal phase III trials) | Favourable Effects (pivotal phase III trials) | Favourable Effects (pivotal phase III trials)      | Favourable Effects (pivotal phase III trials)      | Favourable Effects (pivotal phase III trials) | Favourable Effects (pivotal phase III trials)     | Favourable Effects (pivotal phase III trials) |
| Co-primary endpoint                           | Co-primary endpoint                           | Co-primary endpoint                           | Co-primary endpoint                                | Co-primary endpoint                                | Co-primary endpoint                           | Co-primary endpoint                               | Co-primary endpoint                           |
| trough FEV1 at week W26                       | adj. mean change from baseline (95%CI)        | mL                                            | 185 (155; 214)                                     | 127 (98; 157)                                      | --                                            | modest effect of adding GB                        | TRIMARAN                                      |
| trough FEV1 at week W26                       | adj. mean change from baseline (95%CI)        | mL                                            | adj. between group difference 57 (15; 99)          | adj. between group difference 57 (15; 99)          | --                                            | modest effect of adding GB                        | TRIMARAN                                      |
| trough FEV1 at week W26                       | adj. mean change from baseline (95%CI)        | mL                                            | 229 (196; 263)                                     | 157 (123; 190)                                     | 274 (227; 321)                                | modest effect of adding GB vs. CHF1535            | TRIGGER                                       |
| trough FEV1 at week W26                       | adj. mean change from baseline (95%CI)        | mL                                            | adj. between group difference 73 (26; 120)         | adj. between group difference 73 (26; 120)         | --                                            | modest effect of adding GB vs. CHF1535            | TRIGGER                                       |
| trough FEV1 at week W26                       | adj. mean change from baseline (95%CI)        | mL                                            |  ________ -45 (-103; 13) __________              |  ________ -45 (-103; 13) __________              |  ________ -45 (-103; 13) __________         | CHF5993 inferior to CHF1535 + tiotropium          | TRIGGER                                       |
| trough FEV1 at week W26                       | adj. mean change from baseline (95%CI)        | mL                                            |  _____ not calculated ______                     |  _____ not calculated ______                     |  _____ not calculated ______                |  _____ not calculated ______                    | TRIGGER                                       |
| asthma exacer- bations at week W52            | adj. mean rate and hazard ratios (HR) (95%CI) | rate / HR                                     | 1.825 (1.634; 2.037)                               | 2.157 (1.937; 2.402)                               | --                                            | modest effect of adding GB (-15%)                 | TRIMARAN                                      |
| asthma exacer- bations at week W52            | adj. mean rate and hazard ratios (HR) (95%CI) | rate / HR                                     | adj. between group difference 0.846 (0.725; 0.987) | adj. between group difference 0.846 (0.725; 0.987) | --                                            | modest effect of adding GB (-15%)                 | TRIMARAN                                      |
| asthma exacer- bations at week W52            | adj. mean rate and hazard ratios (HR) (95%CI) | rate / HR                                     | 1.726 (1.543; 1.932)                               | 1.963 (1.757; 2.192)                               | 1.613 (1.373; 1.897)                          | low background incidence; modest and statist. not | TRIGGER                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect                                                                  | Short Descrip tion                             | Unit                                           | Treatment (T) CHF5993                               | Control 1 (C1) CHF1535                              | Control 2 (C2) CHF1535 + tiotropium            | Uncertainties/ Strength of evidence                                                                               | References                                     |
|-------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
|                                                                         |                                                |                                                | adj. between group difference 0.880 (0.751; 1.030 ) | adj. between group difference 0.880 (0.751; 1.030 ) | --                                             | signif. effect of adding GB vs. CHF1535 (-12%)                                                                    |                                                |
|                                                                         |                                                |                                                |  _____ 1.070 (0.878; 1.303) ________              |  _____ 1.070 (0.878; 1.303) ________              |  _____ 1.070 (0.878; 1.303) ________         | CHF1535 + tiotropium numerically superior                                                                         |                                                |
|                                                                         |                                                |                                                |  ____ not calculated _____                        |  ____ not calculated _____                        |  ____ not calculated _____                   |                                                                                                                   |                                                |
| Key secondary endpoints (severe exacerbations)                          | Key secondary endpoints (severe exacerbations) | Key secondary endpoints (severe exacerbations) | Key secondary endpoints (severe exacerbations)      | Key secondary endpoints (severe exacerbations)      | Key secondary endpoints (severe exacerbations) | Key secondary endpoints (severe exacerbations)                                                                    | Key secondary endpoints (severe exacerbations) |
| severe asthma exacer- bations at week W52 (pre-defined pooled analysis) | adj. mean rate and hazard ratios (HR) (95%CI)  | rate / HR                                      | 0.239 (0.206; 0.276)                                | 0.310 (0.271; 0.354)                                | not calculated                                 | low background incidence; rate reduction relevant (-23%); result not confirmatory due to broken testing hierarchy | TRIMARAN and TRIGGER (pooled results)          |
| severe asthma exacer- bations at week W52 (pre-defined pooled analysis) | adj. mean rate and hazard ratios (HR) (95%CI)  | rate / HR                                      | adj. between group difference 0.770 (0.636; 0.933)  | adj. between group difference 0.770 (0.636; 0.933)  | --                                             | low background incidence; rate reduction relevant (-23%); result not confirmatory due to broken testing hierarchy | TRIMARAN and TRIGGER (pooled results)          |
| severe asthma exacer- bations at week W52 (pre-defined pooled analysis) | adj. mean rate and hazard ratios (HR) (95%CI)  | rate / HR                                      |  ________ not calculated __________               |  ________ not calculated __________               |  ________ not calculated __________          |                                                                                                                   | TRIMARAN and TRIGGER (pooled results)          |
| severe asthma exacer- bations at week W52 (pre-defined pooled analysis) | adj. mean rate and hazard ratios (HR) (95%CI)  | rate / HR                                      |  ____ not calculated _____                        |  ____ not calculated _____                        |  ____ not calculated _____                   | CHF1535 + tiotropium numerically superior based on unadj. results                                                 | TRIMARAN and TRIGGER (pooled results)          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect                                         | Short Descrip tion                             | Unit                                           | Treatment (T) CHF5993                               | Control 1 (C1) CHF1535                              | Control 2 (C2) CHF1535 + tiotropium            | Uncertainties/ Strength of evidence                                 | References                                     |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------|
| Favourable Effects (pivotal phase III trials)  | Favourable Effects (pivotal phase III trials)  | Favourable Effects (pivotal phase III trials)  | Favourable Effects (pivotal phase III trials)       | Favourable Effects (pivotal phase III trials)       | Favourable Effects (pivotal phase III trials)  | Favourable Effects (pivotal phase III trials)                       | Favourable Effects (pivotal phase III trials)  |
| Key secondary endpoints (spirometry variables) | Key secondary endpoints (spirometry variables) | Key secondary endpoints (spirometry variables) | Key secondary endpoints (spirometry variables)      | Key secondary endpoints (spirometry variables)      | Key secondary endpoints (spirometry variables) | Key secondary endpoints (spirometry variables)                      | Key secondary endpoints (spirometry variables) |
| peak(0-3h) FEV1 at week W26                    | adj. mean change from baseline (95%CI)         | mL                                             | 485 (453; 516)                                      | 401 (369; 432)                                      | --                                             | modest effect of adding GB                                          | TRIMARAN                                       |
| peak(0-3h) FEV1 at week W26                    | adj. mean change from baseline (95%CI)         | mL                                             | adj. between group difference 84 (40; 129)          | adj. between group difference 84 (40; 129)          | --                                             | modest effect of adding GB                                          | TRIMARAN                                       |
| peak(0-3h) FEV1 at week W26                    | adj. mean change from baseline (95%CI)         | mL                                             | 0.522 (0.488; 0.556)                                | 0.417 (0.383; 0.451)                                | 0.555 (0.507; 0.603)                           | modest effect of adding GB vs. CHF1535                              | TRIGGER                                        |
| peak(0-3h) FEV1 at week W26                    | adj. mean change from baseline (95%CI)         | mL                                             | adj. between group difference 0.105 (0.057; 0.153)  | adj. between group difference 0.105 (0.057; 0.153)  | --                                             | modest effect of adding GB vs. CHF1535                              | TRIGGER                                        |
| peak(0-3h) FEV1 at week W26                    | adj. mean change from baseline (95%CI)         | mL                                             |  _____ - 0.033 (-0.092; 0.026) ________           |  _____ - 0.033 (-0.092; 0.026) ________           |  _____ - 0.033 (-0.092; 0.026) ________      | CHF1535 + tiotropium numerically superior                           | TRIGGER                                        |
| peak(0-3h) FEV1 at week W26                    | adj. mean change from baseline (95%CI)         | mL                                             |  ____ not calculated _____                        |  ____ not calculated _____                        |  ____ not calculated _____                   | CHF1535 + tiotropium numerically superior                           | TRIGGER                                        |
| average morning PEF at week W26                | adj. mean change from baseline (95%CI)         | L                                              | 5.325 (1.921; 8.729)                                | -3.131 (-6.533; 0.271)                              | --                                             | modest and clinically insignificant effect of adding GB             | TRIMARAN                                       |
| average morning PEF at week W26                | adj. mean change from baseline (95%CI)         | L                                              | adj. between group difference 8.456 (3.643; 13.269) | adj. between group difference 8.456 (3.643; 13.269) | --                                             | modest and clinically insignificant effect of adding GB             | TRIMARAN                                       |
| average morning PEF at week W26                | adj. mean change from baseline (95%CI)         | L                                              | 10.102 (6.717; 13.487)                              | 2.297 (-1.091; 5.684)                               | 10.286 (5.540; 15.032)                         | modest and clinically insignificant effect of adding GB vs. CHF1535 | TRIGGER                                        |
| average morning PEF at week W26                | adj. mean change from baseline (95%CI)         | L                                              | adj. between group difference 7.805 (3.016; 12.594) | adj. between group difference 7.805 (3.016; 12.594) | --                                             | modest and clinically insignificant effect of adding GB vs. CHF1535 | TRIGGER                                        |
| average morning PEF at week W26                | adj. mean change from baseline (95%CI)         | L                                              |  _____ -0.184 (-6.013; 5.645) ________            |  _____ -0.184 (-6.013; 5.645) ________            |  _____ -0.184 (-6.013; 5.645) ________       | modest and clinically insignificant effect of adding GB vs. CHF1535 | TRIGGER                                        |
| average morning PEF at week W26                | adj. mean change from baseline (95%CI)         | L                                              |  ____ not calculated _____                        |  ____ not calculated _____                        |  ____ not calculated _____                   |                                                                     | TRIGGER                                        |

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The two pivotal trials assessing triple fixed-dose treatment with CHF 5993 100/6/12.5 and CHF 5993 200/6/12.5 µg (two puffs bid) were targeting patients uncontrolled on medium or high dose ICS/LABA treatment (uncontrolled status defined as ACQ-7 score ≥ 1.5). These patients correspond to GINA 2019 step 4 and step 5 patients, respectively.

The primary objective of these pivotal studies conducted in support of this application was to demonstrate the incremental clinical benefit of adding glycopyrronium bromide to fixed-dose dual treatment with ICS/LABA. Thereby, superiority of CHF 5993 over the corresponding ICS strengths of CHF 1535 in terms of the co-primary endpoint (pre-dose FEV1 and rate of moderate to severe asthma exacerbations) was to be demonstrated.

The first trial (TRIMARAN) assessing the effects of the medium ICS fixed-dose triple combination (CHF 5993 100/6/12.5) met its primary objective. At week 26, the adjusted mean change in pre-dose FEV1 was greater with CHF 5993 than with CHF 1535 (between-group difference of +57 mL , 95%CI [15 mL; 99 mL], p=0.008). Moreover, at week 52, treatment with CHF 5993 resulted in a statistically significant decrease of -15.4% (p=0.03) in the rate of moderate to severe asthma exacerbations . The second trial  (TRIGGER)  assessing  the  effects  of  the  high  ICS  fixed-dose  triple  combination  (CHF  5993 200/6/12.5) failed to achieve its primary objective. Though at week 26, the adjusted mean change in pre-dose FEV1 was greater with CHF 5993 than with CHF 1535 (between-group difference of +73 mL , 95%CI  [26 mL;  120 mL],  p=0.003),  the  decrease  in  the  rate  of moderate  to  severe  asthma exacerbations failed  to  achieve  statistical  significance  ( -12.0% , p=0.11 ),  thereby  prematurely breaking the pre-defined statistical testing hierarchy.

Exploratory post  hoc analyses  of  the  TRIGGER  data  (among  them  the  analysis  in  the patient subpopulation with persistent airflow limitation, PAL ) presented by the MAH in addition to the predefined pooled analysis of severe exacerbations suggested a more or less consistent treatment effect of CHF  5993  200/6/12.5  on  the  exacerbation  endpoint.  A  statistically significant difference  was demonstrated on time to exacerbation for the high ICS fixed dose triple combination. Although the data from these exploratory post hoc analyses were obtained in a patient subset (approximately two third of the ITT population), it was considered that the consistency of effects across parameters and analyses as well as the generally clinically meaningful effect sizes were overall sufficient to support a regulatory approval of the high ICS strength product (CHF 5993 200/6/12.5).

From a safety point of view, no particular concerns arose. The overall safety profile of the medium ICS dose strength product (CHF 5993 100/6/12.5) in the asthma population investigated was comparable to the one previously established in COPD patients. Moreover, data presented for the newly introduced higher ICS dose strength product (CHF 5993 200/6/12.5) are not suggestive of relevant dose-related effects. Overall, the main ADRs that have been observed (i.e. dysphonia, oral candidiasis, dry mouth) are known class effects of inhaled products including ICS, LABA and LAMA.

Cardio-  and  cerebrovascular  events  are  considered  important  potential  risks  for  BDP/FF/GB.  Clinical features may be atrial fibrillation, QT prolongation, palpitations, tachy- or bradycardia, tachyarrhythmia, VES, SVES, angina pectoris and hypertension. Thus, BDP/FF/GB should be used with caution in patients with respective co-morbidities and/or co-medication.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

The primary efficacy results and exploratory post hoc analyses presented by the MAH for the high ICS dose strength product (CHF5993 200/6/12.5) are robust and compelling enough to endorse the approval of the high strength.

Overall, the CHMP considered that both dose strength products in the targeted asthma population (CHF 5993 100/6/12.5 and CHF 5993 200/6/12.5) are approvable based on the evidence provided.

The  benefit-risk  balance  of  the  two  strengths  in  the  proposed  adult  asthma  population  is  therefore considered positive.

The CHMP agreed that the following indication wording is approvable which no longer includes a reference to the degree(s) of severity of the previous exacerbation(s):

- Trimbow medium dose (CHF 5993 100/6/12.5)

'Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.'

-Trimbow high dose (CHF 5993 200/6/12.5)

'Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.'

## 3.8. Conclusions

The overall B/R of Trimbow is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of, Trimbow new strength (172 μg / 5 μg / 9 μg) is favourable in the following indication:

Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

The CHMP therefore recommends the extensions of the marketing authorisation for Trimbow subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out

<div style=\"page-break-after: always\"></div>

in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

In addition, CHMP recommend the variations to the terms of the marketing authorisation, concerning the following changes:

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of indication to add 'Maintenance treatment of asthma, in adults not adequately controlled with  a  maintenance  combination  of  a  long-acting  beta2-agonist  and  medium  dose  of  inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year' for Trimbow 87μg/5μg/9μg . As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and labelling are updated in accordance.

In addition, the MAH took the opportunity to revise the product information in line with the EC guideline on excipients. Furthermore, the PI is brought in line with the latest QRD template version 10.1.

The risk management plan version 6.5 is acceptable.